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Summary - Zusammenfassung
Transmissible spongiform encephalopathies (TSEs), also termed prion diseases, are
lethal neurodegenerative diseases of humans and animals including bovine spongiform
encephalopathy (BSE) in cattle, scrapie in sheep, chronic wasting disease (CWD) in
deer and elk and Creutzfeldt-Jakob disease (CJD) in humans. Prion disease in humans
(and animals) can occur by peripheral infection of the host (e.g. via an oral route of
infection or iatrogenic transmission). According to the “protein-only” hypothesis the
major component of the prion agent is an abnormal variant of the cellular prion protein
(PrPC), termed PrPSc. Intensive studies of prion pathogenesis suggest that the immnune
system is a catalyst of prion replication/propagation long before the pathological agent
finds its way into the brain.
In the first part of this thesis I will discuss the establishment of a “humanized mouse
model” for prion diseases using human umbilical cord blood transplanted immunodeficient
mice. This model might be employed to address many open questions in peripheral prion
biology and would serve as an efficient in vivo test system for preclinical studies and
diagnostic procedures. We were able to replicate a current model based on a publication
of Traggiai et al. [119] and to induce a human adaptive immune system in BALB/c
Rag2-Il2rg−/− mice. We therefore set out to modify this model by a complex strategy
to generate “humanized mice” devoid of endogenous murine PrPC and, in a later stage
of the project, have re-inserted a human PrP transgenically to mimic further stages of
disease progression beyond the immune system.
Interestingly, we did not succeed in engrafting immunodeficient mice devoid of PrPC
even though we employed a microsatellite based monitoring and backcrossing strategy to
strongly control for the genetic background of the grafted recipient mice because currently
unknown genetic factors modulate the innate response to xenografting. Littermates
carrying at least one allele of Prnp were successfully engrafted whereas reconstitutability
was abrogated in mice devoid of PrPC . We show that PrPC is highly expressed in homing
compartments of the engrafted cells, especially in bone marrow macrophages and B-cell
precursors indicating a possible function of Prnp in modulating xenogeneic stem cell
engraftment. However, this phenomenon could not be rescued by mice expressing a human
PrP transgene on a mouse PrP deficient background and exhibiting an equivalent STR
marker profile as compared to reconstitutable mice, implicating that other genetic factors
in the region of Prnp might be modulating the engraftment behaviour of xenogeneic
cells. A more detailed STR analysis in the region around Prnp indicated that around 9
megabases of the Prnp- chromosome were still present in most of our backcrossed recipient
mice. A recent publication of a polymorphic gene coding for signal regulatory protein
alpha (Sirpa), very closely linked to Prnp, explained our observations to a great extent.
A meiotic recombination screen finally led to a Prnp−/− mouse that is reconstitutable
with human stem cells and serves as an ideal model since human PRNP expression is
7
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restricted to the grafted cells.
The second part of this thesis describes a screen for genes that are differentially
regulated upon prion infection in cell culture models of prion infection. A comparative
transcriptional analysis revealed transcriptional stability of cultured neuroblastoma
cells upon prion infection. Although highly infected, cells did not display consistent
changes in transcriptional profiles as a response to prion infection. Several transcripts
previously reported by others to be differentially expressed in prion-infected cells could
not be confirmed in our assays. Most likely these discrepancies can be attributed to the
technical stringency of the current study which was performed under conditions designed
to minimize potential genetic drift. Therefore, it is concluded there are no universal
transcriptional changes induced by prion infection of neuronal cells in vitro.
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Zusammenfassung
Prionenerkrankungen sind obligat to¨dlich endende Erkrankungen des zentralen Ner-
vensystems, welche bei Menschen und Tieren vorkommen. Die wichtigsten Entita¨ten
sind die Creutzfeldt-Jacob Erkrankung (CJD) bei Menschen, die bovine spongiforme
Enzephalopathie (BSE) bei Rindern, Scrapie bei Schafen und die Chronic Wasting Disease
(CWD) bei Elchen. Prionenerkrankungen ko¨nnen durch Inokulation des Erregers in
periphere Organe oder Organe des zentralen Nervensystems u¨bertragen werden, z.B.
peroral oder iatrogen. Gema¨ss der “protein-only” Hypothese besteht das pathogene
Agens, PrPSc, hauptsa¨chlich aus einer anders konformierten Variante eines zellsta¨ndigen
Proteins (PrPC), welches sowohl im Immunsystem als auch im Nervensystem vorkommt.
Zahlreiche Arbeiten u¨ber die Pathogenese von Prionenerkrankungen belegen, dass das
Immunsystem ein Katalysator der Replikation von PrPSc darstellt, lange bevor das
infektio¨se Agens in das Nervensystem gelangt.
Im ersten Teil dieser Arbeit stelle ich die Etablierung eines“humanisierten Mausmodells”
fu¨r Prionenerkrankungen vor. Hierbei benutzten wir haematopoietische Stammzellen aus
Nabelschnurblut, welches wir in immundefiziente, neugeborene Ma¨use transplantierten.
Dieses Modell ko¨nnte sowohl fu¨r diagnostische Tests und praeklinische Studien als
auch fu¨r grundlegende Fragen in der Prionenbiologie angewendet werden. Zuna¨chst
gelang es uns, ein bestehendes Modell, basierend auf der Methode von Traggiai et al.
[119] zu reproduzieren, indem wir ein humanes adaptives Immunsystem in BALB/c
Rag2−/−Il2rg−/− Ma¨usen induzieren konnten. Wir entschlossen uns daher, dieses Modell
dahingehend zu modifizieren, dass wir das endogene Maus-PrPC mit einer komplexten
Zuchtstrategie auf genetischem Wege entfernten und, in einer spa¨teren Phase, ein humanes
PrP-Transgen hineinkreuzten, um spa¨tere Krankheitsstadien (Neuroinvasion) zu unter-
suchen. Jedoch gelang es uns nicht, Prnp-defiziente Ma¨use mit humanen Stammzellen
zu transplantieren, obwohl wir eine aufwa¨ndige, Mikrosatelliten-basierte U¨berwachung
des genetischen Hintergrunds der Akzeptorma¨use durchfu¨hrten. Es ist bekannt, dass
der genetische Hintergrund eine wesentliche Rolle bei immunologischen Experimenten
spielt, jedoch schien in unserem Fall die Rekonstituierbarkeit in genetisch beinahen iden-
tischen Tieren Prnp-abha¨ngig zu sein. Wir zeigen, dass PrP im Knochenmark, speziell
in Makrophagen und B-Zell Vorla¨ufern hoch exprimiert ist und daher evtl. eine mod-
ulierende Funktion auf das Anwachsen xenogener Stammzellen ausu¨ben ko¨nnte. Jedoch
konnten wir diesen Effekt mittels Re-Expression eines humanen PRNP -Transgens und in
Absenz von Maus-Prnp nicht komplementieren, obwohl auch diese Tiere eine beinahe
identische genetische Konstellation aufwiesen. Eine na¨here Analyse in der Region um
Prnp auf Maus Chromosom 2 zeigte, dass trotz zahlreichen Ru¨ckkreuzungen eine Region
von ca. 9Mb die urspru¨ngliche Konstellation des Prnp−/− Chromosoms besass und somit
auch andere genetische Faktoren diesen Effekt ausu¨ben ko¨nnten. Tatsa¨chlich hat vor
9
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kurzem eine Gruppe ein polymorphes Gen, welches fu¨r das “Signal regulatory protein
alpha” kodiert (Sirpa), publiziert, welches ganz nahe bei Prnp gelegen ist und aufgrund
seiner Eigenschaften die Nicht-Rekonstituierbarkeit der Prnp−/− Ma¨use erkla¨rt [116].
Mittels eines meiotischen Rekombinationsscreens konnten wir schlussendlich eine mit
menschlichen Stammzellen rekonstituierbare Prnp−/− Maus herstellen, welche ein ide-
ales Modell fu¨r die periphere Replikation von Prionenerkrankungen im Menschen darstellt.
Der zweite Teil dieser Arbeit beschreibt die Suche nach differentiell exprimierten Genen
nach subakuter Infektion mit Prionen in einem Zellkultur-Modell mittels Microarray und
Taqman-Technologie. U¨berraschenderweise scheinen verschiedene neuronale Zelllinien
keine nennenswerte Modulation ihres transkribierten Genoms aufzuweisen, obwohl alle
untersuchten Zelllinien im Vergleich zu den Kontrollen zu beinahe 100% mit PrPSc
infiziert waren. Diese Resultate widersprechen anderen Studien, welche einige hoch-
oder herunterregulierte Gene identifiziert haben. Wir denken jedoch, dass unsere Re-
sultate aufgrund des experimentellen Designs, welches die Entwicklung von genetisch
unterschiedlichen Zellinienklonen verhindert, ein realistischeres Bild der Ereignisse bei Pri-
oneninfektion in vitro widerspiegelt, und die zellula¨re Antwort auf eine Prioneninfektion
eher in posttranslationellen Modifikationen zu suchen ist.
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Establishing a Humanized Mouse Model to Study
Prions
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1. Introduction
1.1. Prion diseases in humans, mice and cattle
Prion diseases are a large but clinically homogenous group of lethal neurodegenerative
disorders affecting both humans and animals. They are also called “Transmissible Spongi-
form Encephalopathies” (TSEs) because of the neuropathological picture of spongiform
vacuolation classically seen in affected individuals and because of the transmissibility of
this disease. Animal TSEs include sheep and goat scrapie, the prototypic animal TSE
that was recognized more than 200 years ago, but also transmissible mink encephalopathy
[50], chronic wasting disease of mule deer, antelope and elk (CWD) [127] and bovine
spongiform encephalopathy (BSE) [124]. Human TSEs include familial, sporadic and
variant Creutztfeldt-Jakob diseases (CJD), fatal familial insomnia (FFI), Gerstmann-
Stra¨ussler-Scheinker syndrome (GSS) and kuru. TSEs are either dominantly inherited,
transmitted by infection or classified as sporadic if a known genetic or infectious trans-
mission can be excluded. All TSE can be experimentally transmitted and can therefore
be categorized as infectious diseases. However, the unusually long incubation time and
the resistance to common means of sterilization such as high temperatures, formaldehyde
treatment or UV light irradiation distinguish the prion from conventional bacterial or
viral infectious agents. The Prion agent (from “ infectious only”) seems to be devoid
of any informational nucleic acids, and prion infectivity is associated with PrP-scrapie
(PrPSc), an “infectious” and proteinase resistant isoform of a physiological protein called
PrPC (cellular prion protein) [95].
1.1.1. Historical perspective
The first description of what would later be understood as a prion disease dates back to
the 18th century and concerns scrapie, a natural neurological illness that occurs in sheep
and goats. It was also called “tremblante” in French because of the tremor syndrome
affecting these animals. Yet it was only in the 1930s that the transmissible nature of
scrapie was demonstrated by transmission between sheep [21]. Scrapie was at that time
considered to be a viral disease.
Spielmeyer introduced the term “Creutzfeldt-Jakob disease” in 1922 on the basis of cases
described by Creutzfeldt and Jakob. Families with high incidences of CJD (familial CJD
or fCJD) have been documented.
In the 1950s a great deal of attention was given to an epidemic of a neurodegenerative
disease called Kuru among indigenous populations in the highlands of Papua New Guinea.
It was soon suggested that Kuru was transmitted by ingestion of brain tissue during
anthropophagic rituals. Transmission of human Kuru to chimpanzees by intracerebral
inoculation of brain homogenates by Gajdusek during his expeditions to Papua New
Guinea [34], [35] followed by transmission of CJD [37] and GSS [77] helped to categorize
13
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these diseases as “transmissible dementias”. In 1974, the first case of iatrogenic CJD
(iCJD) was described in a 55-year-old woman whose symptoms began 18 months after
corneal implant surgery - the donor had died of CJD [25]. Since then, other mechanisms
of iatrogenic transmission have been identified including neurosurgical instruments, depth
electrodes [14], human pituitary hormones [62] and human dura mater grafts [51]. To
date, iCJD has developed in over 160 human growth hormone (hGH) recipients in a
number of countries, mainly the US, the UK and France. All of these CJD transmissions
have involved cross-contamination with material in or adjacent to the brain where the
expected levels of prion accumulation would be highest. The route of inoculation has
been parenteral, either by surgery or by intramuscular injection. Therefore, biosafety
measures have been implemented including avoidance of cadaveric hGH and lyophilized
dura and special sterilization methods for neurosurgical instruments since the infectious
agent seems to be resistant to most of the common sterilisation methods [36]. A major
impact on daily life came along in the UK in the late 1990s with the outbreak of “mad
cow disease”, bovine spongiform encephalopathy, and the suspected link to a CJD-like
syndrome called variant CDJ (vCJD) in teenagers and much younger patients than usually
affected [125]. To date, about 207 patients have succumbed to this type of prion disease,
almost exclusively in the UK [126], http://www.cjd.ed.ac.uk/vcjdworld.htm. There is
quite a body of evidence that vCJD might be caused by consumption of mainly neural
bovine tissues from BSE-affected cattle, yet this has still to be proved. Human-to-human
prion transmission of vCJD via blood transfusions has been reported and this has alerted
health authorities worldwide to tighten the quality control of blood and blood products
[68]. Thus, prion diseases still present a major challenge and danger to society.
1.1.2. Clinical phenomenology and course of sCDJ, diagnostics, neuropathology,
treatment options
A common denominator of all these described entities is a quick and invariably fatal
neurodegeneration which I would like to highlight by describing the clinical course and
the most common diagnostic and pathological changes in CJD. The vast majority of
CJD cases are sporadic (85 to 95 percent), while 5 to 15 percent are due to fCJD; iCJD
generally accounts for fewer than 1 percent. Approximately one case of sporadic CJD
occurs per 1,000,000 population per year with a worldwide distribution. In Switzerland,
a recent rise in sCJD cases has been reported, likely because of better surveillance [40].
The mean age for the onset of disease is between 57 and 62 years, although rare cases
in young adults and persons over 80 years of age have been described. The incidence of
CJD is increased 30 to 100-fold in certain geographic regions including areas of North
Africa, Israel, Italy, and Slovakia, mainly because of clusters of fCJD.
Clinical features
Rapidly progressive mental deterioration and myoclonus are the two cardinal clinical
manifestations of sCJD. However, a number of variants or subtypes of disease have
14
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been defined based upon focal neurologic findings reflecting predominant involvement of
individual brain regions. Examples of these include forms with mainly visual, cerebellar,
thalamic, and striatal features. Variants of sCJD have also been classified according
to the genotype of the prion protein gene (PRNP) and the molecular properties of the
pathological prion protein (PrPSc). Mental deterioration may be manifest as dementia,
behavioral abnormalities, and deficits of higher cortical function. Concentration, memory,
and judgment difficulties are frequent early signs. Mood changes such as apathy and
depression are common; euphoria, emotional lability, and anxiety occur less frequently.
Sleep disturbances, particularly hypersomnia, but also insomnia, are common and may
be a presenting sign [40,41]. With disease progression, dementia becomes dominant in
most patients and can advance rapidly. Death usually occurs within one year. Myoclonus,
especially provoked by startle, is present in more than 90 percent of patients at some
point during the illness but may be absent at presentation, even when dementia is
profound. Extrapyramidal signs such as hypokinesia and cerebellar manifestations,
including nystagmus and ataxia, occur in approximately two-thirds of patients and are
the presenting symptoms in 20 to 40 percent [39]. Signs of corticospinal tract involvement
develop in 40 to 80 percent of patients, including such findings as hyperreflexia, extensor
plantar responses (Babinski sign), and spasticity.
Diagnostic procedures
Brain biopsy remains the gold standard diagnostic test for CJD. However, a number of
tests can be helpful in providing clinical support for the diagnosis.
Neuroimaging : MRI is the imaging method of choice for diagnosing CJD. Abnormally
increased T2 and FLAIR signal intensity in the putamen and head of the caudate nucleus
is the most common finding on conventional MRI sequences in patients with CJD. Less
commonly, areas of T2 and FLAIR signal hyperintensity are seen in the globus pallidus,
thalamus, cerebral and cerebellar cortex and white matter. Laminar lesions in the cerebral
cortex and cerebellum may be observed.
An electroencephalogram (EEG) can provide supportive but not definitive evidence for
CJD. A characteristic EEG pattern of periodic synchronous bi- or triphasic sharp wave
complexes (PSWC) is observed in 67 to 95 percent of patients with sCJD at some time
during the course of the illness.
CSF biomarkers: A protein that is secreted into the CSF, the 14-3-3 protein, has been
claimed to be a sensitive and specific diagnostic test for sCJD. In one study, a modified
western blot technique for CSF 14-3-3 protein had a positive predictive value of 95 and
93 percent, respectively, for patients with definite and probable sCJD [52], but these
results were challenged by other groups [38]. A variety of other CSF diagnostic tests
have been reported in small series, including the S100 protein, neuron specific enolase,
and tau protein, which are of unproven diagnostic utility at present. Therefore, the quest
for good and non-invasive diagnostic markers is still ongoing.
Detection of extraneural PrPSc: Establishing the diagnosis of prion diseases by detecting
abnormal prions outside the CNS remains a major research goal. Although a number of
methods have been reported, none have been validated as diagnostic tests in human prion
15
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diseases. One study in our lab by Glatzel [39] revealed extraneural PrPSc in skeletal
muscle and spleen, and currently more sensitive assays are under development to detect
minute levels of PrPSc.
Neuropathology
On macroscopic examination, most brains show some atrophy, which may include the
deep gray structures such as the caudate nucleus, putamen, and thalamus. In contrast to
Alzheimer’s disease, the hippocampus is spared whereas the cerebellum may also show
atrophy of the folia, usually due to loss of gray matter. The main histologic features of
prion disease are spongiform change, neuronal loss (particularly of cortical layers III-V)
without inflammation, gliosis and accumulation of the abnormal prion protein that is
usually detectable by antibodies specific for PrP (Figure 1.1) and, most recently, with
conjugated polyelectrolyte probes that distinguish between various molecular substrains
of PrPSc on the basis of their biophysical properties [111].
A B
C D
Figure 1.1.: Histologic features of prion diseases.
Central nervous system parenchyma of sporadic Creutzfeldt-Jakob disease (A
and B) and variant Creutzfeldt-Jakob disease (C and D) showing astrogliosis
and widespread spongiform changes. The protease-resistant forms of host-
derived prion protein deposition are synaptic (A and B) and in the form
of florid plaques (asterisk, C and D). A and C, hematoxylin-eosin, original
magnification x400. B and D, immunohistochemical stainings for prion protein,
original magnification x400. Scale bar = 50 µm. Adapted from Glatzel [41].
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Post-mortem molecular typing
Varying clinical phenotypes of sporadic CJD have been associated with molecular subtypes
determined by the PRNP gene codon 129 genotype and PrPSc type. The PRNP genotype
is homozygous or heterozygous for methionine (M) or valine (V) at codon 129. The
PrPSc type is determined by western blot analysis and classified in the Parchi/Gambetti
nomenclature as type 1 or type 2 depending on the size and electrophoretic mobility of
the protease resistant core fragment (PrPres) [88], [89], but this classification is currently
widely debated [91].
Therapeutical strategies?
Despite the recent advances in research and the understanding of pathogenesis of prion
diseases, no successful therapeutical strategies have been developed to date. Upon clinical
manifestation, the destruction of the brain is already too far advanced to interfere with
and therefore major efforts regarding diagnosis (i.e. development of early sensitive/specific
markers) and peripheral pathogenetic mechanisms will be needed in the future.
1.2. PrPSc - the destructive agent and the discovery of its underlying gene
Prnp
To date, compelling evidence speaks in favor of the protein-only hypothesis formulated
by Prusiner [95] which represented a major new paradigm in infectious diseases. A
possible viral nature of the “infectious” agent responsible for transmissible spongiform
encephalopathies was questioned because of the absence of direct evidence of such a
virus and the lack of a detectable immune response to the infectious agent, although
some voices still claim a viral nature of this agent [75], [76]. Nevertheless, the resistance
of the transmissible agent to procedures that inactivate nucleic acids (UV irradiation
and nuclease treatment) suggested that the “infectious” agent was devoid of information-
bearing nucleic acids [5] and led Griffith to define the “protein only hypothesis” in 1967
stating that the agent could well be a protein [43]. This hypothesis gained general
acceptance after Stanley Prusiner purified the protease-resistant infectious protein, which
he called PrPSc (scrapie-associated prion protein) in 1982 [95].
A very strong argument for the protein only hypothesis was the discovery of a gene
coding for PrPC (PRNP in humans, Prnp in mice) and subsequent gene-knockout studies.
Prnp was cloned by Basler and Weissmann [10] based on partial sequencing of PrPSc
and identification of a cDNA leading to a chromosomal gene encoding for a physiological
protein. PrPC is a highly conserved protein in mammals and paralogues, present in
turtle [112], fish [101] and even amphibians [114]. The murine Prnp gene encoding
the cellular isoform of the prion protein is located on chromosome 2 and the mature
form of murine PrPC consists of 210 amino acids [10]. The broad, diverse expression
pattern of PrPC with expression in skeletal muscle, kidney, heart, pancreas, secondary
lymphoid organs and the CNS presumably points to a general, conserved function ([31];
[3]). PrPC is a glycosyl phosphatidyl inositol (GPI)-linked glycoprotein, and can be
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either un-, mono- or diglycosylated. After passing through the Golgi apparatus PrP is
trafficked mainly to the cell surface, where its GPI anchor allows it to enter lipid raft
domains preferentially. Pulse-chase labeling experiments have shown that the half-life
of PrPC in murine splenocytes is similar to that in neurons; about 1.5 to 2 h [20]. The
three dimensional structure of mature PrPC from mouse, humans, cattle and Syrian
hamster shares common features e.g. a long, flexible N-terminal tail (residue 23-121),
three α-helices, and a two-stranded anti-parallel β-sheet that flanks the first α-helix. The
C-terminus is stabilized by a disulfide bond linking α-helices 2 and 3 [98]. PrPC and PrPSc
have the same amino acid sequence yet unlike PrPSc, PrPC is protease sensitive and it is
now known that PrPSc is a conformational variant derived from PrPC . The mechanism
of conversion from PrPC to the much more aggregation-prone PrPSc is still a matter of
intense debate. It is believed that PrPC acts as a substrate for the conversion process
of the abnormally folded PrPSc. The conversion from PrPC to PrPSc is thought to rely
on a physical interaction between host-encoded PrPC and exogenous or spontaneously
generated PrPSc as a template, resulting in the PrPSc conformation being imposed on
PrPC (“template-directed refolding model”). Another model suggests that PrPC and
PrPSc are in a constant equilibrium strongly favoring PrPC , while stabilization of PrPSc
due to unknown mechanisms and subsequent seed formation results in a cascade of
infectious amyloid formation and fragmentation (“seeding model”) as depicted in Figure
1.2. How PrPC is turned into PrPSc remains elusive, but it can be stated nearly with
certainty that genetic deficiency of a PrPC will result in the inability of PrPSc-generation
due to the lack of the appropriate template. Therefore, organisms that lack PrPC will
never develop disease [12].
1.3. Assigned functions to PrPC
To date, the physiological function of PrPC remains unknown. However, based on in
vitro and in vivo studies, several possible though highly controversial “functions” have
been assigned to it. These include regulation of the immune system, signal transduction,
copper binding, being an antioxidant, synaptic transmission, inducing apoptosis or
being anti-apoptotic or inducing circadian rhythms [18]. Furthermore, PrPC positively
regulates neural precursor proliferation during neurogenesis [113], but postnatal depletion
of PrPC in neurons does not result in neurodegeneration [73]. Interestingly, studies
performed in PrPC deficient mice have not elucidated a real phenotype associated with
the deficiency of the protein, but mice expressing various PrPC-deletion mutants show
severe neurodegenerative and myelinotoxic phenotypes that are rescued with re-expression
of a full-length Prnp wildtype copy as described by Shmerling and Baumann [107], [11].
In old age, however, Zrch1-Prnp−/− mice can develop a demyelinating phenotype as
well, even in “near-normal” Zrch1-Prnp−/− mice. Frank Baumann claims that PrPC
might interact with a yet unknown receptor which exerts myelin survival signals. In the
total absence of PrPC , residual activity of the putative receptor might still be present
whereas in case of deletion of certain domains of the protein it might be stabilized in
a dominant-negative conformation and therefore lose its signaling to maintain myelin
integrity [11]. The quest for possible PrPC-interaction partners or for the composition of
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Figure 1.2.: Hypothetical models of conversion from PrPC to PrPSc.
Schematic of the refolding or template-directed assistance model (A) and the
seeding or nucleation-polymerization model (B); adapted from [4].
a putative PrPC-complex is ongoing and might soon shed light on a function of PrPC in
the nervous system and elsewhere.
1.4. Functions of PrPC related to the peripheral immune system in
physiological and pathological conditions
The relationship between PrPC , PrPSc and the immune system is complex in both
physiological and diseased states. The absence of a measurable adaptive immune response
in prion disease is assumed to be due to tolerance to PrPSc. Further, the immune system
contributes to peripheral pathogenesis by replicating or accumulating prions in lymphoid
compartments before the infectious agent finds its way into the brain.
1.4.1. Proposed functions of PrPC in immune regulation and hematopoiesis
Although studies in Prnp−/− mice were not very enlightening at first about the functions
of PrpC in the immune system, very recent analyses of hematopoietic development
and the immune system in Prnp−/− mice have revealed fine tuned regulations. Steele
et al. report that PrPC is expressed on the surface of long-term (LT) hematopoietic
stem cells (HSC) and HSC from Prnp−/− mice exhibited impaired self-renewal in serial
transplantation of lethally irradiated mouse recipients in both the presence and the
absence of competitors. Furthermore, when treated with a cell cycle-specific myelotoxic
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agent, the animals reconstituted with Prnp−/− HSC exhibited increased sensitivity to
hematopoietic cell depletion [130].
Comparison of lectin induced mitogenesis and selected cell signaling pathways in
splenocytes from wild-type BALB/c and Zrch1-Prnp−/− mice has revealed that activation
was significantly reduced in Prnp−/− splenocytes, most prominently early in activation
[78].
Other groups compared the phagocytic activity of Prnp−/− macrophages to that of
their wildtype counterparts and found a downregulation of macrophage activity in case
of Prnp-deficiency [22]. Additionally, PrPC seems to be involved in the phagocytic
machinery used by Brucella abortus to invade macrophages [122], although this finding
has been challenged [30].
Clues to the function of PrPC may be gained by examination of cell-specific expression
patterns. CD34+ hematopoietic stem cells express PrPC , but, although lymphocytes
and monocytes at least maintain PrPC expression throughout their differentiation, PrPC
is downregulated upon differentiation along the granulocyte lineage [23]. In contrast,
maturation of monocytes and dendritic cells leads to PrPC up-regulation [16]. Dendritic
cells (DC) display the highest expression levels of PrPC , in both humans and mice [16].
PrPC was found to be present on murine epidermis Langerhans cells [115], on DC in
extrafollicular areas, including T cell zones, of the gut mucosa [31], and DC of the splenic
white pulp [16]. PrPC was also found on the surface of bone marrow derived human
and mouse DC generated in vitro in the presence of GMCSF, at levels that increased
with LPS stimulation and were correlated with that of MHC II and the costimulatory
molecule CD86 [16]. In lymph nodes, the highest PrPC level was observed in the CD8int
subset, which are strong stimulators of Ag-dependent delayed-type hypersensitivity. This
was interpreted as a possible involvement of PrPC in T cell activation leading to Th1
responses [8]. Studies in mice show a trend towards downregulation of PrPC during
B and T cell maturation, and mature T lymphocyte expression during quiescence is
low, yet, high expression of PrPC is seen in erythroid cells and maturing granulocytes.
Approximately 50% of the cells in the region of small lymphocytes and progenitor cells
also express PrPC . Most of these PrPC+ cells are CD43(+), but B220(-), surface IgM(-)
(sIgM(-)), and IL-7R(-), a phenotype that belongs to cells not yet committed to the
B cell lineage. [66]. However, there are significant species differences in the reported
expression profile on immune cells: in humans and sheep PrPC expression on mature
blood and lymphoid cells remains high [65], with levels increasing further with ageing
[90]. In various non-human primates, the expression level of PrPC is reported to be very
variable: all examined species displayed PrPC on white blood cells (WBCs), with the
highest levels found on human cells. Only humans, chimpanzees, and to a lesser degree
rhesus macaques expressed PrPC on platelets [49]. In the hamster, however, PrPC has
been observed in very weak quantities on various peripheral blood cell sub-populations
[48]. This expression and subtype discrepancy among mice, humans and other species
suggests that any reported functional properties of PrPC , mostly investigated in mice,
should be interpreted cautiously.
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1.4.2. Peripheral immune organs function as prion replication machinery prior to
neuroinvasion
Experiments in mice have shown that after oral or intraperitoneal inoculation with PrPSc,
prion accumulation/replication occurs in many sites of the immune system, including
the spleen, lymph nodes, Peyer’s patches and tonsils. After peripheral prion inoculation
of wildtype mice with RML, PrPSc load increases in the spleen and lymph nodes at
approximately 30 to 50 days post inoculation (dpi), reaching a plateau after 6 to 9 weeks.
However, brain PrPSc accumulation is only detected 4 to 5 months after inoculation.
Even after intracerebral inoculation with the RML strain, PrPSc accumulation is found
in spleens of wild-type mice at 4 dpi. High PrPSc titres in lymphoid organs are not
accompanied by significant histoarchitectural changes; this rules out a damaging effect of
PrPSc in peripheral lymphatic organs.
Splenectomy prior to peripheral prion challenge prolongs the lifespan of scrapie-infected
mice whereas thymectomy or athymia has no effect. However, the tropism to peripheral
lymphatic organs is species- and prion-strain specific. Splenic prion replication does not
occur in all rodent TSE models: analysis of Syrian hamsters that were splenectomized
and subsequently infected with the 236K strain showed that neuroinvasion occurred
without substantial prion replication in the lymphoreticular system [59]. Additionally,
splenectomy had no influence on incubation times after infection with a mouse-adapted
CJD prion strain [83], [118].
Separation of splenic pulp from the stroma revealed that approximately ten times more
infectivity was present in the stroma than in the pulp fraction. Moreover, infectivity
in the stromal fraction was directly correlated with both whole spleen weight and the
weight of the stroma [2]. It was concluded that the stromal compartment is the site of
replication of the scrapie agent [20], and that the cells involved in scrapie replication are
not mitotically active [32]. Accordingly, sublethal irradiation, which preferentially targets
mitotically active cells, failed to alter the incubation period of the disease [33].
PrpC itself is involved in transporting prion infectivity from peripheral sites to the
CNS. Adoptive transfer of wild-type bone marrow into Prnp−/− mice reconstitutes the
ability of the spleen to accumulate high titres of prion infectivity up to 300 dpi [58],
[15]. However, this process was insufficient to restore prion neuroinvasion. Therefore,
hematopoietic cells (for example, B and T cells, macrophages and dendritic cells) facilitate
the transport of prions from the peripheral entry site to secondary lymphoid organs,
where prions can accumulate and/or replicate. However, the primary cellular reservoir for
prion neuroinvasion seems to be non-hematopoietic, because this phenotype cannot be
restored by bone marrow reconstitution [58], [15], [60]. Nevertheless, other publications
speak against the hypothesis of an exclusively stromal prion replication competence
and claim that neuroinvasion is not dependent on a stromal reservoir such as follicular
dendritic cells [106]. Inducing ectopic chronic inflammation in organs that normally do
not possess lymphoid follicles restores prion replication in these organs and impressively
highlights the importance of lymphoid organs in prion pathogenesis [45].
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1.5. Modeling a human adaptive immune system in mice for studying prion
diseases
1.5.1. Historical overview and perspectives
“Humanized mouse models” for studying infectious and immunological phenomena in
a more realistic manner have been developed and steadily improved over the last few
decades. The main applications for modeling the human immune system in a small
animal environment include
1. testing of virulence/pathogenicity of various pathogens in a near-real human-like
environment
2. determination of genetic susceptibility variations of donor-specific immune reactions
3. replacement of current animal models previously used in the pharmaceutical industry
in preclinical trials
4. diagnostic assay development tool, e.g. blood tests
5. circumvention of ethical limitations in clinical research
Most, if not all, of the models currently available are based on the observation that
hematopoietic stem cells can differentiate in vivo into different lineage committed cells in
the presence of a permissive microenvironment. The term “humanized mouse” therefore
stands mainly for a “humanization” of the immune system, and a considerable proportion
of mouse organs and most cellular populations of innate immune cells still originate
from the mouse. Advances in the ability to generate humanized mice have depended
on a systematic progression of genetic modifications to develop immunodeficient host
mice. Three major breakthroughs have occurred in this field as depicted in the timeline
established by Shultz et al (Figure 1.3).
First, the discovery of the Prkdcscid mutation (protein kinase, DNA activated, catalytic
polypeptide; severe combined immunodeficiency, abbreviated scid) in CB17 mice was
soon followed by the observation that human PBMCs [85], fetal haematopoietic tissues
[79] and HSCs [64] could engraft in these mice. However, engraftment occurred at only
a very low level, and the engrafted human cells failed to generate a functional human
immune system.
The second breakthrough was the development of immunodeficient non-obese diabetic
(NOD)-scid mice [108]. Crossing the scid mutation onto different strain backgrounds led
to the observation that NOD-scid mice supported higher levels of engraftment with human
PBMCs than did any of the other strains that were tested, including C3H/HeJ-scid and
C57BL/6-scid mice [46]. Furthermore, it was observed that NK-cell activity, which is one
of the main impediments to the engraftment of human hematopoietic cells [19], was lower
in NOD-scid mice than in CB17-scid mice [108]. NOD-scid mice also have additional
defects in innate immunity [108] that allow higher levels of human PBMC [46] and HSC
[69], engraftment.
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Figure 1.3.: History of humanized mice.
The timeline depicts the most prominent steps in the development of “human-
ized mice”. The lower chart shows current mouse strains and their genetic
modifications utilized for “humanization”. Adapted from Shultz [109]
The third breakthrough was the humanization of immunodeficient mice homozygous
for targeted mutations at the interleukin-2 receptor (IL-2R) gamma-chain locus (Il2rg ;
also known as the common cytokine-receptor gamma-chain, γc) [56], [119], [110], [55].
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These mice support greatly increased engraftment of human tissue, HSCs and PBMCs
compared with all previously developed immunodeficient humanized mouse models.
1.5.2. Generation of a humanized mouse model suitable to study prions
We therefore decided to design a humanized mouse model to study prions because of
the evidence that acquired prion diseases, at least in a majority of cases, start their
way to the brain long before in the peripheral immune system. In order to make the
model really “human compatible” and because of the fact that the cellular components
responsible for prion replication are yet to be defined, we also wanted the model to
contain no endogenous murine PrpC . Having this model in our hands, we would be able
to test various pathogenic prion species for their ability to replicate in a human immune
system. Further, this model would enable us to do genetic susceptibility testing of the
engrafted cells as soon as PrPSc accumulation within the humanized compartments could
be identified. The whole repertoire of prion replicating cells in this mouse would be of
human origin since absence of murine PrpC expression renders the mouse cells incapable
of de novo generation of any kind of prion (a mouse is capable of replicating all kinds of
pathogenic prions, including CJD-prions, if PrpC is present). A further step in our plan
to achieve an optimal model for prion-humanization was to re-express a human sequence
on most of the remaining mouse-cells to study neuroinvasion and not only peripheral
prion replication.
Exploiting the historical advances in the development of humanized mouse models,
we decided to implement a modified version of the model published by E. Traggiai et
al, based on “humanization” of newborn BALB/c Rag2−/−Il2rg−/− mice with CD34(+)
selected pluripotent stem cells from fresh human cord blood [119]. Modification means
introducing a Prnp−/− allele into this mouse and, in a later phase, complementing this
via expression of a human PRNP transgene. However, this modification approach is
combined with genetic background effects that are likely to affect the outcome of our
“humanization” protocol since it is known that xenografting can only be performed in a
distinct genetic environment (see also section 1.5.1).
1.6. Influence of genetic background effects on mouse experimentation and
experimental outcome
Since we knew that the genetic background issue might be of major impact to our strategy,
some introductory words need to be said in order to explain background effects in mouse
genetics.
More than 100 different inbred mouse strains are commercially available, each of which
has distinct physiological and behavioral hallmarks. There are vast differences in the
reaction or resistance of those strains to pathogens, in hematological, biochemical and
serological parameters as well as in transplantation issues.
The process of backcrossing a genetically modified genomic region from knockout or
transgenic strain onto a different inbred strain is complicated by the problem that linked
genetic material from the original strain accompanies the manipulated genomic region.
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The amount of this genetic material can be dozens of megabases and can be minimized
only by monitoring and selection of the random meiotic recombination events that occur
in the DNA flanking the targeted gene. Even eight to ten generations of backcrossing is
no guarantee that the flanking region will be substantially reduced [97]. An illustrative
example to this represents a study where CD38 in 129Sv/J mice was “knocked out” and
the knockout mice were backcrossed ten generations onto the C57Bl/6 strain. Even after
ten generations of backcrossing, at least 20 centimorgans (cM) of linked 129-derived
DNA remained associated with the disrupted CD38 allele. On average, 1 cM corresponds
to approximately 2 Mb of DNA, and the average gene density in mice is ten genes per
megabase; therefore, an additional 400 genes may have been carried along with the
mutated CD38 allele [29].
These considerations had to be taken seriously into account when planning immunolog-
ical and xenografting experiments, and a large part of my thesis is therefore committed
to apply tools for controlling and describing the genetic background of our acceptor mice.
1.7. Experimental plan and outline of the work
A simplified scetch of the experimental setup that serves as a project outline is depicted
in Figure 1.4.
• First, we wanted to reproduce published data by Traggiai et. al. [119].
• Second, we wanted to establish humanized mice devoid of Prnp and therefore only
expressing human PrP on the repertoire of the differentiated human immune cells,
i.e. exhibiting all genetic cofactors involved in pathogenesis.
• Third, stromal expression of a human PRNP transgene on a Prnp−/− background
should reinstall neuroinvasion and serve as a complete model for human-like prion
pathogenesis.
All our reconstituted animals are intended to serve as “bioreactors” that possibly may
replicate prions of different species such as CJD, CWD, BSE and scrapie exclusively in
their human cells. Accumulation of the pathological PrPSc would later be assessed and
novel diagnostic tests and correlation studies to the genetic variability of the human
donor could be developed.
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Rag2-/-Il2rg-/-Prnp-/-
PRNP+Rag2-/-Il2rg-/-Prnp-/-
Figure 1.4.: Experimental plan.
Humanized mice will be generated according to the protocol of Traggiai et
al. [119] with the difference that our mice lack endogenous Prnp and might
express transgenic PRNP. 6 to 8 weeks after intrahepatical transplantation
of sorted stem cells from cord blood, the efficiency of engraftment will be
assessed. Successfully reconstituted mice and controls will be challenged with
prion inocula from various species including CJD, BSE, CWD and Scrapie.
Peripheral organs and blood of these mice serve as a diagnostic surrogate for
prion replication.
26
2. Material and Methods
2.1. Genetically modified mice, breeding strategy
Mice were housed in an SPF facility of the Institute for Laboratory Animals of the
University of Zurich according to the guidelines of the cantonal veterinary office of Zurich
(Kantonales Veterina¨ramt). All our immunodeficient mouse strains were accommodated
in cages with filter covers and received autoclaved drinking water and food pellets.
Rag1−/− Prnp−/− mice on a mixed C57Bl/6-Sv129 background were available in house
[60]. Rag2−/− Il2rg−/− mice on a BALB/c background were kindly provided by Dr.
Markus Manz. Mice carrying transgenically the sequence of the human prion protein
in its 129M-form (TgPRNP129M mice) were kindly provided by Prof. John Collinge
[6]. Mice harboring the Prnp−/− allele on a BALB/c background (10 times backcrossed
to BALB/c) were also obtained from John Collinge. The structure and function of the
modified/deleted genes as well as the targeting constructs with the respective references
and possible genotyping outcomes are depicted in Fig. 2.2.
2.1.1. Rag1−/− and Rag2−/− mice
Rag1−/− and Rag2−/− mice were described by Mombaerts [84] and Shinkai [105]. They
lack functional B- and T- cells because of a deficiency in the generation of functional
immunoglobulin and T-cell receptor structure which is mediated by genomic V(D)J
recombination through Rag1 and Rag2 enzymes in a coordinated way (Figure 2.2). There-
fore, only precursor B-cells and T-cells can be seen in these mice, the splenic architecture
is highly disturbed and an adaptive immune response is impossible. However, these
mice can be kept at an SPF-facility with no further impact on their lifespan and do not
suffer from major infectious complications. The Rag1 and Rag2 genes are both closely
linked at the same locus on chromosome 2 at 56 cM (genetic map) or in the region of
101439121-101450340 bp(-strand) and 101425557-101433367 bp(+strand) according to
the VEGA annotation of NCBI Build 36 (http://www.vega.sanger.ac.uk).
2.1.2. “Zurich1”-Prnp−/− mice
“Zurich1”-Prnp−/− mice were constructed by Bu¨eler and Weissmann [13] in the early 90s
and have since been a very important tool in prion disease research. Mice devoid of PrPC
are resistant to scrapie and other pathogenic prion strains but seem not to exhibit other
strong or uncontested phenotypes (refer also to the introduction of this part). Like most
of the knockout mice available, these mice were initially designed in 129Sv ES cells and
the genetically modified offsprings were mainly maintained on a 129Sv-C57Bl/6 mixed
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background or further backcrossed to BALB/c or C57Bl/6. The gene for Prnp is located
on mouse chromosome 2 at 75 cM (genetic map) or 131601369-131629870 bp (+ strand)
according to the VEGA annotation of NCBI Build 36 (http://www.vega.sanger.ac.uk).
2.1.3. Il2rg−/−-mice
Il2rg−/−-mice were implemented by Ohbo et al. [86] and carry a truncated version of
the common gamma chain of the interleukin receptor 2. A sequence fragment contain-
ing portions of exon 7 and 8 was replaced with a neo cassette inserted by homologous
recombination. The deleted region encoded the majority of the SH2-like domain which
abrogates the cytoplasmic signalling part of the protein (see also Figure 2.2). The
interleukin-2 (IL-2) receptor gamma chain is indispensable for IL-2-, IL-4-, IL-7-, IL-9-,
and IL-15-mediated signaling. Mice carrying the truncated gamma-chain mutant show
a decrease in the number of lymphocytes and an increase in monocytes; the number of
T and B cells is profoundly reduced and no natural killer cells are detected. Further,
Peyers’s patches cannot be found in these mice. The gene for the common gamma
chain is located X-chromosomally at 38 cM (genetic map), 97467097-97470925 (- strand)
respectively according to the VEGA annotation. Il2rg−/−-mice will develop an autoim-
mune/lymphoproliferative disease and are not viable for more than 3 months because
of a deregulation of regulatory T-cells. In combination with a deletion of Rag (Rag1 or
Rag2), the induction of autoimmunity does not occur and Il2rg−/−-Rag−/− mice have
a near-normal lifespan despite their profound adaptive immunodeficiency with a total
abscence of functional B-/T- and Nk-cells.
2.1.4. TgPRNP129M mice
Transgenic mice harbouring multiple copies of a human PRNP transgene were constructed
in the lab of John Collinge [6]. We utilized mice expressing the 129M variant of the
human sequence on a mouse Prnp−/− background and crossed them further to the specific
immunodeficient background (see also “breeding strategy”). These mice, when inoculated
with either bovine spongiform encephalopathy (BSE) or variant CJD prions, may develop
the neuropathological and molecular phenotype of vCJD. These findings are consistent
with the hypothesis that these diseases are caused by the same prion strain.
2.1.5. Breeding strategy
Our complex breeding strategy to yield reconstitutable mice either deficient for the mouse
prion protein or - alternatively - expressing the human prion proten transgenically on a
mouse Prnp-deficient and additionally reconstitutable background is depicted in Figures
3.1 (primary strategy) and 3.2 (alternative strategy) and is described in more detail in
the Results section of my thesis.
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2.2. Genotyping of genetically modified mice
After weaning, mouse tail biopsies were taken and tails were incubated for 5 to 16 hours at
55◦C under constant agitation in lysis buffer (10mM TRIS/HCl pH 9.0; 50mM KCl; 0.45%
NP-40; 0.45% Tween 20 and 0.1 mg/mL proteinase K). Proteinase K was inactivated by
incubation at 95◦C for 10 min. After short centrifugation, the lysate was used for PCR
or stored at 4◦C.
1µL crude tail lysate was added to a PCR mastermix containing 10µL 2x Gotaq green
mastermix (Promega), 0.1µL of the respective desalted primers to yield a final concentra-
tion of 1µM per oligonucleotide (desalted, genomics scale, all synthesised at Microsynth,
Switzerland) and varying amounts of nuclease free water. Normally, DNA isolated as
described above resulted in good PCR results. In case of poor DNA quality, samples were
purified using standard ethanol/chloroform precipitation or an EZ1-tissue kit (Qiagen).
For the various wildtype and knock-out alleles we utilized the primers listed in table 2.1.
PCR cycling was performed on Perkin Elmer and Biolabo thermal cyclers using the
following setups per run: Prnp: 5 min 95◦C, 35 cycles (45 s 95◦C, 45 s at 62◦C, 1 min
72◦C) followed by 7 min 72◦C. Rag2 (previous method with large amplicons): 5 min
94◦C, 32 cycles (1 min 94◦C, 1 min 30 s 60◦C, 2 min 72◦C) followed by 7 min 72◦C.Rag2
(actual methods with smaller amplicons): 5 min 94◦C, 35 cylces (45 s 94◦C, 45 s 55◦C,
45 s 72◦C) followed by 7 min 94◦C. Il2rg : 5 min 94◦C, 35 cylces (45 s 94◦C, 45 s 55◦C,
45 s 72◦C) followed by 7 min 94◦C.
Subsequently, amplicons were loaded on a 2% agarose gel containing 5µL ethidium
bromide per 500mL of agarose and electrophoresed at 120V for about 1 h. Images of
the gel were taken under UV-illumination and results registered in our mouse database
(http://irats.unizh.ch).
2.3. Microsatellite mapping
Whole genome microsatellite mapping was performed with fluorescently labeled oligonu-
cleotides specific for defined informative, strain-specific short-tandem repeat regions
scattered over the whole mouse genome (see table 2.2). For the first set of experiments,
we used commercially available mouse mapping primers (Applied Biosystems, Rotkreuz,
Switzerland) and performed PCR amplification of genomic DNA from various mouse
strains to calibrate our system. To this purpose, genomic DNA was extracted from tail
biopsies as described above, but the resulting lysate was routinely subjected to DNA
purification using a Qiagen biorobot EZ1-tissue kit (Qiagen, USA). DNA amount and
quality was checked with a nanodrop spectrophotometer. For a single PCR reaction, 1-5
ng of gDNA served as a template. PCR-procedure was performed in a either simplex,
duplex or triplex 96-well assay setup per mouse. Per well of a 96 reaction plate, 1-5 ng of
template DNA, 7.5µL of 2x PCR colorless Taq-mastermix (Promega, USA), 1.5µL of
fluorescently labeled primer mix (FAM, VIC, NED, all from Applied Biosystems) and a
variable amount of PCR-grade water to result in a total reaction volume of 15µL was
calculated to be an effective way for medium-throughput assay setup. After setting up
the reaction plate, PCR amplification was performed with Perkin-Elmer thermocyclers
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Gene ID Primer ID Sequence and amplicon info
Prnp P3 5’ATTCGCAGCGCATCGCCTTCTATCGCC
P10 5’GTACCCATAATCAGTGGAACAAGCCCAGC
3’NC 5’CCCTCCCCCAGCCTAGACCACGA
362bp (mutant allele)
546 bp (wildtype allele)
Rag2, old Neo 5’CCAACGCTATGTCCTGATAGCGGT
RAG2-1 5’TTAATTCAACCAGGCTTCTCACT
RAG2-3 5’GCCTGCTTATTGTCTCCTGGTATG
1107 bp (mutant allele)
973 bp wildtype allele)
Rag2, new Rag1 5’GGGAGGACACTCACTTGCCAGTA
Rag2 5’AGTCAGGAGTCTCCATCTCACTGA
Ragneo 5’CGGCCGGAGAACCTGCGTGCAA
350 bp (mutant allele)
263 bp (wildtype allele)
Il2rg P5 5’CTGCTCAGAATGCCTCCAATTCC
P7 5’GATCCAGATTGCCAAGGTGAGTAG
pNeo 5’CCTGCGTGCAATCCATCTTGTTCAAT
350 bp (mutant allele)
660 bp (wildtype allele)
Rag1 Rag 1 Sense 5’TACCCTGAGCTTCAGTTC
Rag 1 antisense 5’CAACATCTGCCTTCACGTC
Rag1 nI 5’CTTGGGTGGAGAGGCTATTC
280 bp (mutant allele)
500 bp (wildtype allele)
TgPRNP129M 129fw 5’CAGTCATTATGGCGAACCTT
129rev 5’GACCTTCCTCATCCCACT
972 bp (presence of transgene)
Table 2.1.: Genotyping PCR primers
(Perkin-Elmer, USA) and the following cycling conditions: 95◦ 5min, 30 repetitions of
95◦C for 30s, 60◦C for 30s and 72◦ for 30s, finally 72◦ for 7min. PCR reactions were
diluted 1:100 in deionized water. Subsequently, 2µL of the diluted reactions were added to
10µL of Hi-Di Formamide (Applied Biosystems) containing 0.04µL GeneScan 600LIZ size
standard (Applied Biosystems) per well. The resulting plate was heated at 94◦C for 2 min
in a Perkin-Elmer thermocycler to denature the DNA and quickly centrifuged (1000 rpm
for 1 min). A sequencer assay file was created and the plate was subjected to capillary
electrophoresis. This procedure was performed on a in-house 16-capillary sequencer
3130xl (Applied Biosystems) or an 48-capillary sequencer 3730 (Applied Biosystems) at
the Institute of Molecular Biology at the University of Zurich. Using the 3130xl-device,
two 96well plates could be analysed within 7hrs. The 3730-device was able to handle
30
2.3. Microsatellite mapping
12 plates over night. Data acquisition protocols and instrument control were defined in
the data collection software of Applied Biosystems. Analysis, allele-calling, binning and
calibration of various mouse strains was implemented manually using GeneMapper Soft-
ware (Applied Biosystems). Alleles were defined to be either non-informative, BALB/c,
C57Bl/6, 129Sv or other (table 3.1). We allowed only two alleles per marker. In total,
292 Markers could be checked in one run. In a further set of studies, we designed our
own STR-primer library, based on UniSTS (http://www.ncbi.nlm.nih.gov/sites/entrez)
ePCR. The respective forward oligonucleotides were either labelled with Yakima Yellow,
FAM or ATTO550 and HPLC purified (Microsynth, Balgach, Switzerland), whereas the
reverse primers remained unlabeled. Two master plates with 96 primer pairs at 10 µM
concentration each were designed that could be multiplexed together to result in one
96well-PCR assay setup per mouse (see table with oligonucleotide sequences and master
plate design).
Table 2.2.: Primer sequences for STR analysis (based on UniSTS)
Marker 5’Label fw Primer rev Primer
D1Mit132.1 ATTO TATTGTTTATGGAAATTGGACCC CATCTCTGAAGGAAAAAGTGCA
D1Mit159.1 FAM TCTGGGGCCACTATGAGATC TCACAATCAGAAAATATTATGAGACTC
D1Mit169.1 ATTO CGCTGACTGCTACTTTATTATATTCC TCTGATTTACTGTCAATCAAGAGACC
D1Mit17.1 FAM GTGTCTGCCTTTGCACCTTT CTGCTGTCTTTCCATCCACA
D1Mit206.1 ATTO TGAGGCACCTTTGTATTCAGC CCAGATGTCTTTGAACATTCTCC
D1Mit21.2 FAM CGCTGGACAATCTTATAATTGCA TCGAATCCCAACAACCACAT
D1Mit215.1 FAM GGAGCAGAGTGTGAGAAGGG CCAGTGTGAGCCCATTCC
D1Mit292.1 FAM GAACTGGAGGTTTGCTACTGC GGACATTGTTATCTCAGTTTTCTTC
D1Mit308.1 FAM GAGGCTATGAGTCAAATGGACC TTTATGAGGTGCTGAGATGCA
D1Mit411.1 YYE GGAAACTGGAAAAGGGGGTA TAGCATTGCTCTTTGGTTTCTG
D1Mit430.1 YYE TATTAATGTTGAAGCCAGAAGCC CTTTAATCATCTCTGTGGCAAGG
D1Mit495.1 YYE CCACCTTGCTCCAAAAGAAA TCTGAGAGGCTGCCACAATA
D1Mit60.1 ATTO GGTTTCTGCACTCAGATTTGC TGCTCTCCTTTCTTCAAAGAAG
D2Mit1.1 YYE CTTTTTCGTATGTGGTGGGG AACATTGGGCCTCTATGCAC
D2Mit100.1 YYE GTGTTCCTAAGGTTGTATTTTGGC GAAATTTGACAATTGCTAGGTGC
D2Mit113.1 ATTO CTCACGTGAGGGTCATGAGA CTTCTCTACCTTCCTCAGAAGCC
D2Mit148.1 YYE GTTCTCTGATCTACGGGCATG TTCACTTCTACAAGTTCTACAAGTTCC
D2Mit285.1 ATTO TCAATCCCTGTCTGTGGTAGG TATGACACTTACAAGGTTTTTGGTG
D2Mit327.1 ATTO TAGGGGATCTGATGCCTCTG GCCCATTGAGCACTTTTGAT
D2Mit365.1 YYE GAGATCCCACTGATGATACAAGC AGATGTGCCCAAGGGTCC
D2Mit395.1 ATTO AGGTCAGCCTGGACTATATGG AGCATCCATGGGATAATGGT
D2Mit404.1 FAM GATGGTGATGATGATGATGATG GACGCGCACAGGAAATAGAT
D2Mit411.1 YYE ACACTCACAACTACGAGATAAAGCC AGGTCATTAGGGCTGTCTTCC
D2Mit61.1 ATTO AAAGTCAACTGCTTTCAGTTACCC CACAGAAGTGCCCTTGCATA
D3Mit147.1 ATTO TCTGCCTCTGTTAGATAGATATCCG TTGTTCATCTATCCTCTGAAGTTCC
D3Mit200.1 ATTO CAACTTCAGTTTCTCATTTGAATTG GCAAATGGAAGAGGTTTCTCC
D3Mit203.1 FAM CTGAATCCTTATGTCCACTGAGG GGGCACCTGCATTCATGT
D3Mit256.1 ATTO TACATTGCTTTTTGCTTTGAGTG GTCGAATGTTATCAGAATTTGCA
D3Mit311.1 YYE CGCCTGGTGGTAGTGGTG CAGTGACTTAAGTACCCTTGACTCC
D3Mit320.1 YYE AATGAAATCTCACGAGAGGCA AAGCCAGGAGCAGAGTCAAG
D3Mit352.1 YYE CGCAAAAGGCAGAGGTAAGT TGCTTGCCTCTCTCCACC
D3Mit51.1 FAM GGCACTGATAGCAGGCCTAG TCTCTTCTGGTATTTCCTTCCG248
D3Mit57.1 FAM TCCAGTTACTTGGTGAACTCCA ATATGTGTACATGTTCATGGTGTG
D4Mit17.1 ATTO TGGCCAACCTCTGTGCTTCC ACAGTTGTCCTCTGACATCC
D4Mit170.1 YYE TTCCATCGAGTGACTTGATCC CAGAGTGGCTGTCATCTGGA
D4Mit18.1 FAM AATTAGCCCGGAGCTTGATT GCTTCCATACATTTGCTTTTCC
D4Mit196.1 FAM TTGACTGGTCTTATATATCTCTATCCC TATATTAAATGCTAACTGCTAAGCACA
D4Mit203.1 YYE GAATTCTTCCTGGGCCTTTC CAAGAGCCCAGGTGTGGTAT
D4Mit251.1 YYE AAAAATCGTTCTTTGACTTCTACATG TTTAAAAGGGTTTCTTTATCCTGTG
D4Mit256.1 ATTO CTGGAGAGTTAGAATGGGGTACC CAACAGAGGCGCTTCCTAAC
D4Mit268.1 ATTO TAATCTGATCCAAACACTAAATCAGA GCAGCCTTATGGAAACTTTCA
D4Mit308.1 YYE TATGGATCCACTCTCCAGAAA CAAAGTCTCCTCCAAGGCTG
D4Mit348.1 FAM ACCAAACTTGAGTTCTATGTAAGAACA TGCTTACATATCAAAACAATACAGACA
D5Mit10.1 FAM CGAGAAGTTGGAAAGACCCA GGCACCCATGCCTCTATG
D5Mit146.1 ATTO TTAAATCTGAAGGTGTGGCTATAGC GAGATTGCAAGTAAAGTGAGAGAGG
D5Mit158.1 FAM AAAGACGCTGAGGAGTCACTG CAGGAGACCTTGTAATAAAGGAAA
D5Mit201.1 YYE GAGGACTCCTTCGATTTCCC TTCCTAAGCAGGAACTGACCA
D5Mit309.1 YYE TAGAGCCTATTTCAAACCCCC GTTGCATCCATAGCAAGCAA
D5Mit352.1 YYE CCCAGAGCCCACATCAAG TAGGTGGGTGTGTCTCTCCC
D5Mit425.1 ATTO TCGCCTTTCTTTCCCTCC AAAATTACATTTGCATCTGGGG
D5Mit95.1 YYE TGTTCTTGTCCATGTCTGATCC AACCAAAGCATGAAACAGCC
D5Mit98.1 FAM TCCTTCATTTTATCTTCTGCCC TGAATTCACTCTCGCACCTG
D6Mit100.1 YYE CTTGAGTAGGTCTCAGTGCGG CACATGCACACACAGAAGCA
continued on next page
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Table 2.2 – continued from previous page
Marker 5’Label fw Primer rev Primer
D6Mit116.1 YYE ACATTTCTTTGTGAGGTTCCTTG CAGGTTTTTTGAAAGACACTCTTG
D6Mit123.1 YYE GGAAGGAGCAGGTCCAATAC CTCCCAACCACCAAGACCTA
D6Mit138.1 ATTO GCTCTTATTAATGAAGAAGAAGGAGG CAAAGAAAGCATTTCAAGACTGC
D6Mit14.1 FAM ATGCAGAAACATGAGTGGGG CACAAGGCCTGATGACCTCT
D6Mit209.1 ATTO CTCCCCCTCTGTGTGATTGT TTATTACACCAGACCCATGTGG
D6Mit284.1 ATTO GGCTGCTGAGAAACAACCTC TGAGTATTGAGCCAAATCCTCC
D6Mit36.1 FAM ACCATCTGCATGGACTCACA GTTGAAGAGGACGACCAAGTG
D6Mit374.1 FAM TTCTGGCTCTTAACAGTCTGTCC TACATATGCCAATGATATTCTCCC
D6Mit86.1 ATTO GACCAAACCAGAAGCCCCT GGAATGTAGCCCTAAGTTGGA
D7Mit101.1 YYE TACAGTGTGAACATGTAGGGGTG TCCCAACATGGATGTGCTAA
D7Mit109.1 YYE TCAACACCAGGAAGTCTCTTCA CCTCCATCTCCCATCCAATA
D7Mit21.1 ATTO GGGTTGAACCTTACAGGGGT ATCAAACCAGCCCAAGTGAC
D7Mit223.1 YYE ATGCACATGAGTGTGTGTATGC TCCTGTGTCTGACGCTCATC
D7Mit228.1 ATTO ATTCTTGGCCTTTTCTTGTAACA AAACCTCCACACTGACTTCCA
D7Mit248.1 YYE AATCAGGCAACTCAGGCACT TCCTTAGGTCTCCAGTGAAAGC
D7Mit259.1 ATTO CCCCTCCTCCTGACCTCTT GTCTCCATGGGAACCACACT
D7Mit294.1 YYE TAGTGGGAAAGAGAGAAACAATCC TAATGTTTAATCTTGTCGTCTTAGTGG
D7Mit323.1 YYE TTTCACCTTCTAATCCTACTTCCTG TGTCCAGAACAGGAAATAGAGTACC
D7Mit350.1 YYE TCTGCATCTCACTGTCCCAG ATCTACAAATGAGTTTCTAAGGACTGC
D7Mit83.1 FAM GGGAGTTGTCATGGGCAG TAACCAAAAACCTATGCTATCAGA
D7Mit98.1 FAM CGCCATAGAACAGATTTGATACC ATGGGTCTCAGATATCCCACC
D8Mit112.1 YYE ATATCAGGCATGCATTATGATCC TCTCTCTAGTGGGATTATCAACACA
D8Mit124.1 ATTO CAACTGTGTATCATAAACTGGGAA GAAGAATCACTCAGCAGTGTATGG
D8Mit155.1 FAM TTGGACAGGGAAAATTCTGC TGAGGACTTGCTTTAAGAGTACTCC
D8Mit178.1 ATTO AAAATCAACTGTTTACATTTGAGCC AGAGCACGCAGTGTGTATGC
D8Mit211.1 FAM CAGAACACTGTCCTGAAAAGTCC TACCCACAAACCTGTATTTAAATTAA
D8Mit289.1 FAM AAAAAGAAAAGAAGGCTTAGTAATGTG CTTGCTATTCATTGCAAAATTCC
D8Mit292.1 YYE AGTCAAGGCATTTAAAATTAACTGG CTGGGTTTGCTAGTGAAAGATG
D8Mit339.2 YYE ACCTATGGTACACACACATCGC CAAACATTTTTAGGCATTTAGATCC
D8Mit45.1 YYE GAACAGGACCAATAAAATGAAAGC CTACCTTACCAAACTTCCCGG
D8Mit46.2 FAM GCCTGGGCTACATGAGACTC GGGAATTCCAATACACTAAAGGG
D8Mit47.1 FAM AAGATGTGCTTACTCTGACTTCCC GGATCTATCCACATGTGGTGC
D8Mit49.1 FAM TCTGTGCATGGCTGTGTATG TGGTGTGCTGCTGATGCT
D8Mit63.1 FAM TCTGGAACACAGTCCAATTCC ATATGTGTGAGGGTTTTACCGG
D8Mit92.1 FAM CTCAGGCTATCTTGGACATGC TGGCTCACATCTGTGCTTTC
D9Mit129.1 ATTO TTGTCTTTTAACCTCCTGGAGC TCCCATCTTTCTCCTTGTGG
D9Mit151.1 YYE TGGTCAAGGTGTGGTATCGA AAAACTCAGCATCCAATGGG
D9Mit2.1 FAM GTGGTCTGCCCTCTTCACAT CAAAGCCAGTCCAACTCCAA
D9Mit201.1 YYE CCTGCAAGCCAACTACATGA GCAAAAATGAAGTTCAAAAGGG
D9Mit250.1 YYE CCCAAAAACCTATTTGCAGTG GTGACATGATTCCTTCAGTCTTACC
D9Mit285.1 ATTO CAAATACATTGCTGATTATATCAGAGA GGACTCTAGATCTCATCAGGGA
D9Mit336.1 YYE AAGTGGTTCACAGAAATGTATACAGG TTTTCTTTCTGTGGTAAAGGGG
D9Mit347.1 YYE CCTCCACATGTGCACTGCT CTGTCCATCTATCATCTATCTGTCTG
D9Mit355.1 YYE CTCATTCACTTCCTGGTCCTG GAAGGAAAGCCCACACTTTG
D9Mit90.1 ATTO AGGAGTCTCCCTGTACCTACACC AAGTAGAGGGGAGGAATGAACC
D9Mit97.1 FAM TCTCACTACTGCCTGCCAGA TAGATTTCTCAGGCAAGGAAGC
D10Mit103.1 ATTO TATGCCGACAATATTTCATTGC GCCTCTGCATACATACCAATACC
D10Mit14.1 ATTO AGAGGGGACAAGGAGAGACC AAGGTTTGGGTTCAGTTCCC
D10Mit20.1 ATTO CACCCTCACACAGATATGCG GCATTGGGAAGTCCATGAGT
D10Mit207.1 ATTO TTTAAGCAAAACACCCATACACA TCTGAGGGTACCTGTAGTCATGC
D10Mit213.1 ATTO CTCCTCCTACTGATTGTCCCC GGGACAAACTTTTAAAAATTGCA
D10Mit230.1 FAM AGATAGCCTAGGGGGTGCAT ATCAGTTTCCAATCGCTGCT
D10Mit233.1 ATTO GTGCTTTATATTGGAGATCATCACA GTCCCGAATTTCACATACATAGC
D10Mit31.1 ATTO CATAAGGAGCACAGGCATGA CCCTCTACGTGCATGCTGTA
D10Mit38.1 ATTO CGATGAGCCCTAACACCAAT CCTGTTACAAACTAAACCAAACCC
D10Mit86.1 ATTO TTTGCCTGTAACAAGCCAGA TTGAGGCTATCAGTTTAAAATCCC
D10Mit95.1 ATTO CCAGCCTAGAAAACCAAGCA ACAGTGCTTCCGGAAAAATG
D11Mit143.1 YYE TTTATATTTTCAGGCTGTTCAGAGG AACCTCTTTGCACACAAGAACA
D11Mit186.1 ATTO AAAACACATTTACATGCATGGTG TGTGTGCACTTAAGCCCTGA
D11Mit189.1 ATTO ACCATGTAATCCGATGCCAT AGATGAATGTAATTGACCTACTTCCA
D11Mit2.1 YYE TCCCAGAGGTCTCCAAGACA CCACAGTGTGTGATGTCTTC
D11Mit285.1 YYE CATGAATCCATCACCAGCAG TTTTTCAGTCATGCAGGCAG
D11Mit326.1 YYE CTATGGCAGGCACATGACTG TTAAAAGTGGTTTCAGGTGTGTATG
D11Mit333.1 ATTO CATGTGGTTATTTTCTAGCCCC AGGCATCAATAACTATTTTTCAGTG
D11Mit4.1 ATTO CAGTGGGTCATCAGTACAGCA AAGCCAGCCCAGTCTTCATA
D11Mit54.1 ATTO AGGCTGGTGGCTAGTGTCC AAGTCTTGCGCTGCATCTTT
D11Mit71.1 FAM GCCATACCTGGTAGCGTGTT AATTTTCAGATGTAGCCATAAGCC
D11Mit86.1 YYE TTGACATTGTGACAAAGACTTTCA AAGGCATCATGAGGTTTTTAGTG
D12Mit11.1 YYE TATTAAAAGGCAATGGGAGGG TTGACTTCAGAGTGATTTCCAGG
D12Mit143.1 ATTO CCCTATGCATGTACATTGTGAA CGTGGGCATTTATCTTTCCT
D12Mit158.1 FAM CATTGGGCAATGGAATTTG ATGAGAGAAAACCAGAAACAAAGG
D12Mit182.1 ATTO GTACATACAATACATCACACAAACGG GGCAAGAAAACAGACCAATAGG
D12Mit285.2 ATTO GCCTCTTTCTAAATTTTTATGTTGTT GTCTGTCTGTCTGTCTTTTTCACA
D12Mit59.1 FAM AGTGAAATTCAGAGCACAAAAGC ACCCTATATCTCCATGGTACGTG
D12Mit7.1 YYE CCGGGGATCTAAAACTACAT TCTAATCTCAGCCCAATGGT
D12Mit91.1 FAM GATTCAAGACAAGACTCCTGCA CGCCCCCTCATGTTTTATC
D13Mit151.1 YYE ACAAATTAAAGACAAAATGTCTGCA TGTGCACACCAGCATACAAA
D13Mit19.1 FAM GGTGAGTTGTGTAATGATGGACA AGCAACAGGGCTACTAAACACA
D13Mit213.1 ATTO GCCTGAAACTCTACATAAAATACATCC AGTTTCATTGCTTTAGTTACATTTTCA
D13Mit275.1 YYE TTAGCAAGGGAACAGAGAGAGG CAATCAAGGTATCCCTGTCTCC
D13Mit56.1 FAM CCTGTAACTCCAGATCCTGAGG CAGTTGACCGAAATAGTCATTCC
D13Mit78.1 FAM ACAGCACGGGTTTATCATCC TATGCCTGCCAGGCTTCTAT
continued on next page
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Table 2.2 – continued from previous page
Marker 5’Label fw Primer rev Primer
D13Mit88.1 FAM ACTGATGGCTCATGAGACCC AAAATTAATAGGAACTGCAAGGG
D14Mit126.1 ATTO CCTGTCCCACAACACCTTTT TATACATATGGGTAGCACTGAGTGG
D14Mit127.1 FAM AAACTTTACCTACCAGTGTCAAGTTAG GTGTTGAACAACTCTATGTCTGTCTG
D14Mit170.1 ATTO TGTGTATGATTGTGTGGGGG AGAAAGCAAACTTGCAAATATTCA
D14Mit174.1 ATTO ACTGCAGAGTCCACACAAGTG TCTGAGCCACTATGCCTGG
D14Mit263.1 YYE TGAGCACAGAGCCTATGTGG ACAGAGAAATACCATGAAAACACC
D14Mit40.2 FAM TCCCGGGGATCAGTAAAATAT CAAGGTGGCCTCTGACTTTC
D14Mit44.1 FAM AGTCACACCTGTAGAGTAAGCACA GCTACTGCCTCGGTTTGTG
D14Mit48.1 YYE TTTCTAGCCCTGACCCCC TCTGTTCACTCTGTGTAATTCTCC
D14Mit5.1 FAM CACATGAACAGAGGGGCAG GTCATGAAGTGCCCACCTTT
D14Mit60.1 ATTO AGGCTGCCCATAAAAGGG GTTTGTGCTAATGTTCTCATCTGG
D15Mit107.1 FAM CAACACTTATACACTTGTGTCAGGG TCATGGTTGGAACAGCAGAC
D15Mit159.1 ATTO CACAGGCATACATAGAAATGTGC CAACTTGTCAGGGTCTACTGAGG
D15Mit242.1 YYE GGTATACACACACACAATTTCAAGG GAAAATAGTACCACAGAAGTTTGGG
D15Mit252.1 YYE CTTCAAACATGTTATCATTGTCACA CTTCTGTATTCACAGGTGCTCG
D15Mit262.1 YYE TTTATTAAAGCCAAACAGAGATTGC AACATTGTATTTGGGTCATTGTG
D15Mit67.1 FAM AGCTTCAACAGTGAAACATAGCC CTGCTGTGTGCACTTATGCA
D15Mit70.1 FAM CATTGAGGGTTTGTAGGTTGG ACCCCTGCAAGTTGTCTTTG
D15Mit80.1 FAM TGAAGTCATCTTTCAATTTTCTCC CGAAGATGCCTGCCAAATAT
D16Mit101.2 FAM TTATGAAATGTTTTATCTTTTGGGG CTCCAGATGTAGAAATTAAAATCTTGG
D16Mit131.1 ATTO TGGTGGTGGTGTTGATGGTA AAGACCATTTCTAATAAACAACACCC
D16Mit153.1 FAM CCTTCCAGGACCACAAAGAA GAAAGAACTAGGAATGGAGAAAAGG
D16Mit189.1 FAM ACAGTGTTTGTTTGTTTGTTTGTG CAGTACAGGAAGTCTTTGCATCC
D16Mit52.1 YYE ACACATGTGCAAGCCTAACC TTATCCCTGGAATCTGGGG
D16Mit60.1 FAM AAATGGTCAGCCCTGAAGC TGCCTCACCCTTTGAAGTGT
D16Mit86.2 ATTO TAATGTGGCAAGCAACCAAA GCATGTTTCCATGTGTCTGG
D17Mit1.1 FAM TGCTTGAAATCCTGGGTTCA TGCAAAAATGTATGTGCCTG
D17Mit143.2 YYE GCTTTCTTGAAGACGTGGGA CACAGGATGCTTGTAAGCACA
D17Mit180.1 ATTO AGACACTGTCTAAAAACACAAGATGG TTGTGTTCATATGCATGTGTGC
D17Mit20.1 FAM AGAACAGGACACCGGACATC TCATAAGTAGGCACACCAATGC
D17Mit245.1 FAM TGTGCTCTGGCTAGGGAGTT CACATTCATATGTACACACACATGC
D17Mit39.1 YYE CCTCTGAGGAGTAACCAAGCC CACAGAGTTCTACCTCCAACCC
D17Mit51.1 FAM TCTGCCCTGTAACAGGAGCT CTTCTGGAATCAGAGGATCCC
D17Mit81.1 ATTO CAATCTATCTCATATGCATCTCTGTG GTCTGGTGCACCTGTCCTC
D18Mit12.1 YYE TTGTCAGTTTCTTGTGAGGGG TGTTTAATAAGCCTTTTCCTGAGG
D18Mit177.1 FAM CTGTAGTTTATCAGTTCACCCTGTG TGTGCTGTTAAACAAATATCTCTGG
D18Mit186.1 ATTO AAGTGTTGGGCAAAGGCTAA CTTTAGTATAGTGTGCATGAGTGTGA
D18Mit194.1 ATTO CCACCACATAAGGGAGGAAA GTTTGTTGTTGTTCTATTTTCAAACA
D18Mit208.1 YYE GACACATTTATGAGTCAGTCAGCC TGTGAACCCAGGTCATGTGT
D18Mit222.1 FAM AATCCAAGATTGACATGTGGC CTTAGATGCCCTGTCTTAAAAAAA
D18Mit48.1 FAM TTGCACTCACAGGGCACAT TCAGAGTTTCCAGAAGACACCA
D18Mit64.1 FAM TCAGATTCACTGCTAAGTCTTTTC AGCAAGAAAAGCAGGTGAGG
D19Mit103.1 YYE CCCATGTCCTTTGTTTCCC GAAGCGCTATCACTGGATCC
D19Mit26.1 ATTO TTGTTACACAGCAAAATCCTGC TTGAGGAGTAAGGCAAAAAAGG
D19Mit28.1 ATTO TCTTCATGCCCAAAAGAGCT GCATCCTGAATCTCCTGCC
D19Mit33.1 FAM CCTTTTCAAGAGCATCCTTAAA GGTGGGACTTGAGAGATGCA
D19Mit6.1 YYE ATTAGTAAACTGACTCCCATGCG CTCATGAGTCCCCTGGGTTA
D19Mit68.1 ATTO CCAATACAAATCAGACTCAATAGTCG AGGGTCTCCCCATCTTCCTA
D19Mit88.1 ATTO AACAGTGCAACTTTGGAGGC TCATTGGAACTGTCTTAACAGTGC
D19Mit90.1 YYE GTGGGAATCAATTTTAGTATGAACA GGATGCTTGATATCATGTACATACA
DXMit121.1 FAM GGACCCCAGTTCTTTCTTACATA GTAAAACTGGGGGAATGGCTTAG
DXMit132.1 YYE GTTAGGATTGCTGGTTGCGT TCAACTCAACTGCAACATACCC
DXMit172.1 ATTO TACCACAGTTTGAATAAAGATGTGTG GAAGAAACCATGACTCCTCTTTG
DXMit216.1 YYE ATTTGGAACAGCAGCGTTG TGTTTACACAATCTATCCAGTTACAGC
DXMit223.1 YYE TTGGTTTGGGGTTTTTTTTG ATTCCTGATAATGTCTTCTGGACA
DXMit64.1 FAM AATATGTAAGGACAGCCTTCTCAG AGAGGAGAGACAGGTCCAGGA
DXMit81.1 FAM GAGGAGCATCAACCTTCTCG GAGGTGGGGAGAAACAGAGG
2.4. SNP mapping of chromosome 2
For a finer mapping of the region between Rag2 and Prnp we used taqman-SNP genotyping
assays (Applied Biosystems, USA). We chose published SNPs in a 5Mbp distance each.
SNP taqman assay primers and identifiers are listed in the table below. 1 ng DNA
per well was used for each reaction in a total reaction volume of 5µL, consisting of
taqman SNP mastermix (Applied Biosystems) and the respective SNP assay mix. PCR
reactions were performed in an 9600 ABI real time PCR device in a 384-well format.
A post-read allele-calling and data analysis was acquired with the SDS 3.1 software
(Applied Biosystems). Polymorphisms were integrated into the STR-marker profile at
the respective genetic map position and data were analysed with Structure software
according to ([94]).
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Assay ID SNP ID pos (Mb)
M 22285663 10 rs13476663 99.9
M 24382337 10 rs29912618 100.8
M 23720601 10 rs13476670 101.9
M 22354457 10 rs6261478 107.0
M 23043361 10 rs13476705 112.9
M 45281514 20 rs3090608 117.8
M 23028483 10 rs33314425 122.3
M 23908236 10 rs13476764 127.8
M 23300050 10 rs13476769 129.7
M 22299775 10 rs13476772 130.6
M 23938758 10 rs13476802 138.5
Table 2.3.: SNP assays for mapping the region between Rag and Prnp
2.5. Sequencing of the human PRNP coding region for detection of
polymorphism on codon 129
DNA from non target fractions for sequencing of the human PRNP locus was extracted
with the Nucleospin-Blood Kit (Maccherey-Nagel, USA), DNA quality was assessed
with a Nanodrop-Spectrophotometer. Subsequent PCR-amplification and gel-extraction
was performed with a qiagen gel-extraction kit (Qiagen, USA). PCR-fragments were
subjected to the sequencing service of the institue of pathology (Prof. D. Zimmermann).
Sequencing reactions for the full length human PRNP ORF were performed using the
following primer sequences: PRNP up: 5’TAT GCA GGA AAC ATT TAG TAA T PRNP
low 5’TGC CAA GGG TAT TGA TT. Sequence alignment analysis was performed with
Sequencher software (USA) in comparison to a reference sequence.
2.6. Sequencing of Sirpa exon 2 in different mouse strains
Genomic DNA from mouse tails was subjected to PCR for amplification of the Sirpa
exon 2 (IgV domain) using primers SirpExon2fw: 5’TGG CTG CCA TCT TTC TT and
SirpExon2rev: 5’TGA AGA AGG CAC AGG CTT ACT using 35 cycles of (95, 55, 72)
◦C for 1 min each. PCR products were purified with a GelEx-kit (GE-systems, USA)
and concentration determined. Fragments were sequenced by our in-house sequencing
service with the same PCR primers. Sequence alignment and polymorphism assessment
was performed with Sequencher software (USA).
2.7. Histology and immunohistochemistry
Tissues were fixed in 4% buffered formalin and treated with 98% formic acid for 1 hour
then fixed for more than 24 hours prior to paraffin embedding. Bone containing tissues
such as vertebral bodies were further decalcified with 1% EDTA and sonication. 2µm thick
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2.8. Cord blood acquisition and preparation of CD34+ hematopoietic stem cells
sections were cut onto positivey charged glass slides and stained with hematoxylin and
eosin, or immunostained using antibodies for human CD45 (LCA), for human CD20, or
human CD3. Sections were heated to 100◦C in a pressure cooker in citrate buffer(pH 6.0),
cooled for 3 minutes, then washed in distilled water for 5 minutes. Immunohistochemical
stains were performed on an automated Nexus staining apparatus (Ventana Medical
Systems) using an IVIEW DAB Detection Kit (Ventana). After incubation with protease
1 (Ventana) for 16 min, sections were incubated with anti-CD45, CD20 or CD3 for 32
min. Sections were counterstained with hematoxylin.
2.8. Cord blood acquisition and preparation of CD34+ hematopoietic stem
cells
Fresh human cord blood (30-100 mL) was obtained from healthy full-term newborns
with written informed consent of the parents (Department of Gynecology and Obstetrics,
University Hospital Zurich, Triemli-Spital, Kantonsspital St. Gallen). Serology testing of
the mother beforing cord blood acquisition ensured negativity for HIV, HBV and HCV.
Blood was collected in blood bags containing 35 mL of anticoagulants (Macopharma,
France) and stored for a maximum of 9 h at room temperature before processing. We
took blood from Caesarian sections as well as from spontaneous pregnancies immediately
after placentation. The blood was transferred to a biosafety cabinet and filled into
50 mL Falcon tubes containing a filter for density gradient centrifugation (Leucosep,
Germany). Usually, the blood was diluted with 1:1 with PBS to obtain a hematocrit of
about 25-30% for optimal separation results. After density gradient centrifugation with
Lymphoprep (Axon-Lab, Switzerland), 800xg, 20 min, at room temperature, serum was
removed, the mononuclear fraction was collected and washed with PBS. Red blood cells
were lysed using ACK-lysing solution (Cambrex, USA) for 10 min at room temperature.
After a subsequent wash in PBS and centrifugation (300xg, 7 min), cells were incubated
with immunomagnetic beads and Fc-blocking reagent in MACS-buffer (1% BSA, 1mM
EDTA in PBS) on ice for 30 min according to the manufacturers instructions (CD34+
selection kit, Miltenyi Biotec, Bergisch-Gladbach, Germany). We always performed
a magnetic enrichment over two MACS LS-columns. After sorting and washing, the
cell count and size of target and non target fraction were evaluated with a CASY-cell
counter. Furthermore, samples were evaluated by flowcytometry for CD34 and CD3 cell
content using mouse anti-human CD3-PE and mouse-anti-human CD34-APC labelled
antibodies (Pharmingen). Cells were either frozen at-80◦C or -196◦C in heat inactivated
fetal calf serum containing 10% DMSO hybrimax (Sigma) or immediately transplanted
when newborn mice were available. In case of re-thawing of cells, we checked again for
viability and cell count before injection into acceptor mice.
2.9. Cell and tissue culture of hematopoietic stem cells
UCB from full-term deliveries was processed within 10 hours and was diluted with
an equal volume of culture medium (Dulbecco’s Modified Eagle’s Medium (DMEM),
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Gibco, USA), layered onto Histopaque (density 1.077g/mL, Sigma-Aldrich, UK) and
centrifuged for 30 minutes. Mononuclear cells (MNC) were collected and washed twice
with DMEM. Aliquots containing 1x107 cells were cryopreserved in DMEM 10% DMSO
at a fixed cooling rate (1◦C/min) and stored at -80◦C. After thawing, the viable cell
count, percentage of CD34+ and CD3+ subpopulations, number of colony-forming cells
(CFC), number of CFC capable of recloning, cell morphology and growth in in vivo
repopulation assays were determined and utilized as day 0 controls.
Cytokines Recombinant human stem cell factor (rhSCF), Flt-3 ligand, rh IL-6 and
TPO were purchased from R&D Systems (Switzerland ).
Stroma-free long-term cultures For expansion, freshly thawed UCB MNC were seeded
at a concentration of 1x105 cells /mL in RPMI-1640 and pooled human AB serum
(Gibco, USA) used at 10%. Four growth factors were added: these were SCF and Flt-3
(25ng/mL) and TPO and IL-6 (20ng/mL). UCB cultures were grown at 37C in humidified
5% CO2 in air. Wells were demi-depopulated and fed weekly, and a new 24-well plate was
used every week. Cryopreserved UCB MNC (106/mL) were also expanded in a closed
cell culture system with commercial expansion bags (volume 3mL, VueLife TM Bag,
American Fluoroseal Corporation). Similar to wells, MNC were expanded in the same
culture medium as above except that the expansion in bags was carried out for 2 weeks
only. Cell cultured in bags were split after one week. The harvested cells from wells and
bags were counted and suitable aliquots were assayed at week 1 and 2 for bags and 1-3
weeks for wells.
2.10. Immunoblotting
Tissues (brain, spleen, bone marrow) were homogenized with two sets of syringes in 10
volumes of RIPA buffer (3%NP40, 3%Tween 20 in PBS), containing protease inhibitors
(Complete Mini, Roche, Switzerland, 1 Tablet per 10 mL), and the resulting homogenates
were adjusted to 5 mg/mL protein with a custom BCA assay with respective Albumin
standards (Pierce, USA). Total protein (10 to 50µg) was electrophoresed through 12%
Bis-Tris Gels (NuPage, USA) in 1x NuPage Running Buffer (NuPage, USA). Proteins were
transferred to nitrocellulose (Schleicher-Schuell, Germany) by wet-blotting in transfer
buffer (3.3g/L tris, 14.4g/L glycine, 20% methanol). Membranes were blocked with
TBS-T (2,42 g/L Tris base, 8g/L NaCl, pH 7.5, 1mL/L tween 20 in H2O) containing
5% Topblock (Sigma, Switzerland), incubated for 1 hour at room temperature with
monoclonal anti-mouse PrP antibody POM1 diluted 1:10’000 in 1% Topblock in TBS-T
and washed 3 times with TBS-T. Incubation with secondary antibody HRP-anti mouse
IgG1 was performed for 1 hour at room temperature, followed by another 3 washing steps.
Detection of the signal was achieved with ECL solution (Pierce, USA) and a Kodak
imaging station. Alternatively, blots were developed on films (Kodak) after various
exposure times (10s to 5 min). For loading controls, membranes were washed again and
re-incubated with antibodies against beta-actin (Zymed, USA) in a 1:7000 dilution. As a
secondary antibody an HRP-anti mouse IgG1 antibody (1:10000) was used. Blots were
reexposed as previously described.
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2.11. Flowcytometry
Detection of human surface antigens CD45, CD20, CD3 and CD34 on mouse peripheral
blood leukocytes, spleen or bone marrow: 200µL of peripheral blood from the tail vein
was taken directly into ice-cold FACS buffer(PBS, 1mM EDTA, 2% FCS) followed by
centrifugation (300xg, 7 min) and incubation for 30 min on ice with 20µL of antibody
master-mix in FACS buffer. Lysis of red blood cells was performed using 1-2 mL of
BD lysing solution per sample in a 1:10 dilution with millipore H2O (Becton Dickinson,
California, USA). After lysis, cells were washed and centrifuged twice with ice-cold
FACS buffer before acquiring them using a FACSCalibur flow cytometer (Becton Dick-
inson, California, USA) with Cellquest software and appropriate instrument settings
and compensation. Postacquisition analysis including gating and statistical analysis was
performed with FlowJo software.
The following directly labelled mouse-anti-human antibodies were used (all Pharmingen,
Europe): phycoerythrin (PE-) labelled anti-CD20, PE-anti-CD3, APC-anti-CD45, APC-
anti-CD34 and the respective isotype controls. Human peripheral blood leukocytes from
umbilical cord blood non-target fractions out of the MACS-sorting procedure served as a
positive control, unstained and isotype labeled samples defined the negative control.
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Figure 2.1.: Structure and, if applicable, functions of the deleted proteins
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Figure 2.2.: Overview of genetically modified null mice used in this study.
Targeted loci and map of the deletion strategy for Prnp [12], Rag2 [105] and
Il2rg [56] the targeting-strategy for deletion of Rag1 is not shown here.
Representative examples of genotyping PCRs based on the construct design
with outcome possibilities for presence or absence of the respective wildtype
(+) or knockout (-) alleles.
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3.1. Breeding of genetically modified mice
A major goal of this study was to yield reconstitutable acceptor mice that would be
devoid of the murine prion protein, and, in a later stage of the project, would contain an
inserted human PRNP transgene. Several bottlenecks accompanied this task:
• The genetic background of the original Zurich1-Prnp−/− mice and Prnp−/−-
Rag1−/− was not identical to that of the primarily reconstitutable Rag2−/−Il2rg−/−
mice: reconstitution with human CD34(+) cells is only possible on a BALB/c
background for reasons that are unknown to date, whereas our in-house Prnp−/−
mice displayed a mixed C57Bl/6 and Sv129/J background.
• Recombination between Prnp and Rag genes is limited because of spacial proximity
of the two genetic loci: both genes reside on chromosome 2, between the genomic
regions 100 and 130 Mbp.
• Breeding of Il2rg−/− mice on their own is impossible due to the development of an
autoimmune phenotype soon after birth resulting in a markedly reduced lifespan.
Therefore, our breeding strategy became more complicated than initially intended
since we had to intercross Rag2−/−Il2rg−/− mice (BALB/c) with already available
Rag1−/− Prnp−/− animals (mixed B6-129Sv background) to yield “triple knock-out”
Rag1−/− Prnp−/−Il2rg−/− and, in case of a recombination between Prnp and Rag2,
Rag2−/− Prnp−/−Il2rg−/− mice. Further, the resulting strains had to be backcrossed
with Rag2−/−Il2rg−/− mice to a maximally pure BALB/c genetical background to render
them susceptible for reconstitution. However, backcrossing would result in the loss of the
Prnp−/− allele and had to be performed over several generations to minimize variation
and genetic artifacts in experimental outcome. A conventional backcrossing experiment
to generate inbred mice contains at least 10 backcrossing cycles, a procedure that would
last about two years.
“Speed congenics” was the method of choice to accelerate our backcrossing efforts (see
section 3.1.4.
The offsprings of our breeding pairs where genotyped by PCR for the absence or
presence of the following genes: Prnp, Il2rg, Rag2, Rag1 and the PRNP transgene.
Figure 3.3 shows a typical outcome of a screening genotyping PCR.
3.1.1. Rag1−/− Prnp−/− Il2rg−/− mice
Since Il2rg is located on the X-chromosome, we obtained “triple knockout” Rag1−/−
Prnp−/−Il2rg−/− mice with the right genotypic constellation for our intended experiment
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Rag1-/-Prnp-/-
C57Bl/6-129Sv
Rag2-/-Il2rg-/-
BALB/c
Rag1/2-/+Prnp-/+Il2rg-/+
C57Bl/6-129Sv-BALB/c
Rag2-/-Il2rg-/-
BALB/c
Rag1-/-Prnp-/-
C57Bl/6-129Sv
Rag1-/-Prnp-/-Il2rg-/- (m)
C57Bl/6-129Sv-BALB/c
Rag1-/-Prnp-/-Il2rg+/- (f)
C57Bl/6-129Sv-BALB/c
Rag2-/-Prnp-/+Il2rg-/-
C57Bl/6-129Sv-BALB/c
Rag1-/-Prnp-/-Il2rg-/- (m+f)
C57Bl/6-129Sv-BALB/c Rag2
-/-Prnp-/-Il2rg-/-
C57Bl/6-129Sv-BALB/c
Rag2-/-Prnp-/+Il2rg-/-
C57Bl/6-129Sv-BALB/c
Inter-se crossings &
reconstitutions
Rag2-/-Il2rg-/-
BALB/c
Rag2-/-Il2rg-/-
BALB/c
Rag2-/-Il2rg-/-
BALB/c
Mulitple backcrossings 
to a reconstitutable 
background via marker 
assisted genotyping 
and reconstitutions
target genotype:
Rag2-/-Prnp-/-Il2rg-/-BALB/c 
Figure 3.1.: Breeding strategy.
Our “classical” breeding strategy between our mixed Rag1−/− Prnp−/−
and BALB/c Rag2−/−Il2rg−/− to yield “triple knockout” Rag1−/−
Prnp−/−Il2rg−/− (low BALB/c) and Rag2−/− Prnp−/−Il2rg−/− (high
BALB/c) and the subsequent speed congenic backcrossings is depicted.
after two breeding generations. Besides of the genotype, we verified the immunotpye of
these mice per FACS and the absence of PrPC by western blot which clearly showed
that these mice were devoid of B-, T- and NK cells and devoid of PrPC-expression.
However, these mice had a mixed genetic background and could possibly not be used for
reconstitution experiments from the very beginning.
3.1.2. Rag2−/− Prnp−/− Il2rg−/− mice
Klein et al. needed to analyse about 1000 offsprings to finally find a mouse that exhibited
a recombination between Prnp and Rag1 [60]. Rag1 and Rag2 are closely linked on
chromosome 2 (both at 56 cM), whereas Prnp is located upstream, 19 cM or 30 Mb apart
from those two genes. Surprisingly, we found the constellation “Rag2−/− Prnp+/− in one
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Rag2-/-Il2rg-/-
BALB/c
Prnp-/-
BALB/c (10x back-
crossed)
Rag2-/-Il2rg-/-
BALB/c
Prnp-/+Rag2-/+Il2rg-/+
BALB/c
Prnp-/+Rag2-/-Il2rg-/-
BALB/c
Prnp-/+Rag2-/-Il2rg-/-
BALB/c
Prnp+/+,+/- or -/- Rag2-/-Il2rg-/-
BALB/c
Rag2-/-Il2rg-/-
BALB/c
TgPRNP129M-Prnp-/-
Mixed 
Rag2-/-Il2rg-/-
BALB/c
TgPRNP129M-Prnp-/+
Rag2-/+Il2rg-/+
Mixed
Prnp-/+Rag2-/-Il2rg-/-
Mixed
TgPRNP129M +or- 
Prnp+/+,+/- or -/- Rag2-/-Il2rg-/-
Mixed
TgPRNP129M-Prnp-/+
Rag2-/-Il2rg-/-
Mixed
Marker-assisted 
backcrossing to 
BALB/c
a
b
„Prnp-/-BALB/c 
intercrossing“
Crossing with 
mice carrying 
a human PRNP 
transgene 
on a Prnp-/- 
background
Figure 3.2.: Alternative breeding strategy.
a shows a breeding setup between Prnp−/−(BALB/c) and
Rag2−/−Il2rg−/−(“BALB/c”) mice to yield triple ko reconstitutable
Rag2−/− Prnp−/− Il2rg−/− mice. b depicts the strategy applied to yield
mice carrying a human PRNP transgene (TgPRNP129M) and the respective
reconstitutable genetic background. The original TgPRNP129M transgenic
mice were described in [6].
mouse already in the 2nd breeding generation which indicated that the probability of a
recombination event between Prnp and Rag is possibly higher than initially expected and
follows the calculated probability of 20% (10% for each cross-over possibility). We also
saw the reverse case, i.e. recombinations of a Rag2(+)-allele to a Prnp(-) chromosome.
Since those mice could thereafter be backcrossed with the original Rag2−/−Il2rg−/− mice,
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Figure 3.3.: Agarose Gel with specific PCR products.
PCR amplicons were loaded on a 2% agarose gel containing ethidium bromide
and visualised under UV-light. For Prnp, a 546 bp fragment for wt and a 362
bp fragment for knockout alleles could be detected. The Rag2-PCR resulted
amplicons of 1107 bp for mutant and 973 bp for wild type alleles in one primer
set, or in amplicons of 350 bp and 263 bp in a alternative primer set. Primers
for the deleted region within Exon 7 and Exon 8 of Il2rg resulted in PCR
products of 350 bp (mutant) and 660 bp (wildtype allele). The human PRNP
transgene sequence was detected with a PCR resulting in a fragment length of
900 bp. Genotyping of the Rag1-locus which tests for presence or absence of
the wildtype allele is not shown here.
yielding automatically a more elevated percentage of BALB/c specific alleles, we decided
to primarily concentrate on these mice for further backcrossings.
Additionally we also decided to intercross Rag2−/−Il2rg−/− with Prnp−/− that already
have been backcrossed several times to BALB/c to have those mice primarily on a
BALB/c background. This breeding was initiated a little later during the project, but
also in this case we could observe a recombination between Prnp and Rag2 and obtained
suitable “BALB/c” triple knockouts within about half a year (see also 3.2)
3.1.3. Rag2−/− Prnp−/− Il2rg−/− - TgPRNP129M mice
Further, we started to backcross TgPRNP129M mice, carrying a human PRNP transgene
on a mouse Prnp knockout background with BALB/c Rag2−/−Il2rg−/− mice. In this
case, we also observed several recombination events between Prnp and Rag2 as early as in
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the 2nd breeding generation which facilitated the process of generating “triple knockout”
mice carrying a human transgene sequence. However, the genetic background of these
mice is already known from published reports to be different from BALB/c, B6 and
Sv129, which also necessitated the need to backcross these mice to BALB/c, thereby
controlling for the presence of the human transgene and absence of the mouse Prnp allele.
3.1.4. STR-marker assisted backcrossing
In order to control for the genetic background of our various mouse strains and to yield
reconstitutable mice quicker, we established a “speed congenics” strategy. This technique
allows the production of congenic strains on clearly defined genomic intervals in less
than half the number of generations required by the classic protocol and enabled us
to create a baseline profile for our various mouse strains [121]. Additionally, we could
select for mice with the highest number of favorable markers of the target strain and
utilize them for further breedings. The results reported here are based on the assays
we established from markers available in the public domain through the mouse genome
informatics consortium (http://www.informatics.jax.org), all map distances are derived
from NCBI build 37.1. In order to achieve medium- to high throughput typing of our
mice, we developed a multiplex PCR strategy that allowed us to genotype one mouse per
96 well plate and to assess it for 192 polymorphic microsatellite markers on a 16-capillary
sequencer from Applied Biosystems. In such a way, we could analyse 6 mice in 24 hours
(or 14 mice per day when using another capillary sequencer localized at another site of
the university). In order to save on reagents, our setup would be easily robotizable and
could then even be performed on 384 well plates since much smaller volumes could be
pipetted with high accuracy. A typical readout of the capillary electrophoresis unit is
depicted in 3.4
As a baseline, we typed our original mixed Rag1−/−Prnp−/−, the “BALB/c” Rag2−/−
Il2rg−/−, the laboratory reference strains C57Bl/6 and BALB/c (Harlan), and the
TgPRNP129M mice.
Even if a mouse is stated to be “pure” BALB/c, there was always a certain degree
of variation within our markers, especially the Rag2−/−Il2rg−/− mice proposed to be
“BALB/c” showed a considerable degree of variation in different individuals. Our experi-
mentally determined allele lengths for the our tested strains are listed in table 3.1 where
we classified the alleles according to the main strains and some substrains (not all, the
list is therefore a little simplified). It was important to identify C57Bl/6 and BALB/c
specific markers in the first line, but we noticed a large amount of polymorphisms in mice
carrying a “novel allele” which is in most cases attributed to the TgPRNP129M-mice,
but in some respect also to 129Sv-mice which showed a significant overlap there.
Table 3.1.: Experimentally determined allele lenghts
Chromosome Marker Pos
cM
129Sv B6 B6a B6b BalbC BalbCa BalbCb nodiff novel
1 D1Mit430 7 110 114 106
D1Mit169 12 122
D1Mit411 16 97 105
D1Mit132 44 144 161
continued on next page
45
3. Results
Table 3.1 – continued from previous page
Chromosome Marker Pos
cM
129Sv B6 B6a B6b BalbC BalbCa BalbCb nodiff novel
D1Mit215 47 136 142 150 144
D1Mit54 59 139
D1Mit60 59 141 139 143
D1Mit308 65 143 151
D1Mit495 70 115 110
D1Mit159 82 172 152 165 118 130 176
D1Mit206 94 125 117
D1Mit17 110 162 196 166 145
D1Mit292 112 197 195 193
2 D2Mit1 2 121 117 131
D2Mit365 22 97 103 142 69
D2Mit61 36 125 136 141
D2Mit327 40 125 128
D2Mit100 50 105
D2Mit395 56 125 134
D2Mit404 67 189
D2Mit285 72 139 131 146 156
D2Mit411 78 98 91 101
D2Mit113 87 143 142 123
D2Mit148 92 106 108 123
3 D3Mit203 10 141 150
D3Mit51 26 115 107
D3Mit311 34 112 119 109 201
D3Mit57 40 155 152 150 171
D3Mit256 46 149 122
D3Mit320 50 114 106 112
D3Mit200 56 117 128
D3Mit147 59 126 131 139 118
D3Mit352 63 144 151 128 123
4 D4Mit196 16 187 195
D4Mit268 22 124
D4Mit17 30 139 130
D4Mit348 34 171 173 191
D4Mit308 55 60 107 79
D4Mit203 60 104 114 116
D4Mit251 67 120 106
D4Mit170 70 96 114 107
D4Mit256 82 136 134
5 D5Mit146 0 118
D5Mit352 15 109 108 116 122
D5Mit201 28 107 104 87
D5Mit309 31 109 114 99
D5Mit10 37 191 187 179 185
D5MIt158 48 296 329
D5Mit425 55 122 115
D5Mit95 58 103 116 130
D5Mit98 67 153 160 178
6 D6Mit86 0 130 117 142
D6Mit138 2 114 93 135 131 108 127
D6Mit116 6 116 107 91
D6Mit123 18 107 119 111
D6Mit209 22 131 142 128 124
D6Mit100 30 82 80 95
D6Mit284 31 122 128 118 131 135
D6Mit36 40 191 171 164
D6Mit14 63 157 153 172
D6Mit374 67 155 138 146
7 D7Mit21 0 134
D7Mit294 6 97 113
D7Mit228 16 145 139
D7Mit83 25 151 149 103 144 85
D7Mit248 26 121 102 99 105
D7Mit350 31 118 140 124
D7Mit323 37 137 104 114
D7Mit101 46 111 88 107
D7Mit109 62 114
D7Mit223 68 99 79 75 94
D7Mit259 68 146 149 127 110 128
8 D8Mit155 0 120 118 132
D8Mit63 3 107 116 207 110 226
D8MIT124 4 116 126 132 118
D8Mit289 9 147 152
D8Mit292 20 109 97 104
D8Mit339 25 114 97
D8Mit46 30 225 197
D8Mit178 35 158 152 162 142
D8Mit45 40 124
D8Mit211 50 130 121 149 127 159
D8Mit112 56 121 119 126 109
D8Mit47 56 194 192
D8Mit49 69 110 151 105 126 153
continued on next page
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Table 3.1 – continued from previous page
Chromosome Marker Pos
cM
129Sv B6 B6a B6b BalbC BalbCa BalbCb nodiff novel
9 D9Mit250 2 144 107 124
D9Mit90 8 135 137 133 139
D9Mit2 13 168 171
D9Mit285 16 125 119 113
D9Mit129 21 143 117 125 147
D9Mit97 24 145 154 128
D9Mit336 34 113 102 114 99 85
D9Mit355 49 100 124
D9Mit201 63 101 97 80
D9Mit151 70 103 114 110 95
10 D10Mit213 7 129 149 134 122
D10Mit86 12 133 149 127 155
D10Mit38 21 165 149
D10Mit20 25 226 221 215
D10Mit31 31
D10Mit207 40 141
D10Mit230 47 110 106 137
D10Mit95 50 196 176 156
D10Mit233 63 125 109
D10Mit14 70 188 185
D10Mit103 77 135 145 116 118 151
11 D11Mit71 0 209 220 226
D11Mit2 4 100 92 102
D11Mit186 14 128 134
D11Mit189 21 134 119 137
D11Mit86 25 126 100 118 150
D11Mit143 30 107 90 88
D11Mit4 36 251 244
D11Mit326 45 90 87
D11Mit285 49 129 116 120
D11Mit333 70 123 106 87
12 D12Mit182 2 146 129 143 122
D12Mit11 6 115 107 111 110
D12Mit59 10 143 144 146 122 128
D12Mit285 20 122 139 129
D12Mit91 23 127 146 123
D12MIt143 30 142 145 148
D12Mit158 33 139 152 150 135
D12Mit7 45 104 120 150 97
13 D13Mit56 2 228 198
D13Mit275 8 117 94 115
D13Mit88 13 142 175 122
D13Mit19 14 137 127 151
D13Mit213 40 155 145 159
D13Mit151 50 117 311 111
D13Mit78 59 221 202
14 D14Mit48 0 122 113 108
D14Mit40 1 136 134 132
D14Mit126 7 131 127 135
D14Mit127 16 139 129 149
D14Mit44 16 142 141
D14Mit174 18 121 145
D14Mit60 24 140 133 112
D14Mit5 32 167 157
D14Mit263 53 121 114
D14Mit170 70 142 148
15 D15Mit80 4 160
D15Mit252 10 128 119 112
D15Mit67 30 186 189
D15Mit70 35 146 149 133
D15Mit107 42 162 148 142 127
D15Mit262 46 116 108 115
D15Mit159 49 144 138 128 116 142
D15Mit242 54 99 97 82 98
16 D16Mit131 7 143 181 175
D16Mit101 18 141 142 155
D16Mit60 24 199 202
D16Mit189 40 203 196 199
D16Mit153 46 265 267 269
D16Mit52 51 191 109
D16Mit86 51 125 119 112
17 D17Mit245 3 180 172
D17Mit180 29 141 121
D17Mit39 45 102 85
D17Mit143 5 124 105 130
D17Mit81 17 123 107 121 134
D17Mit51 23 159 131 153 150 138
D17Mit20 41 174 162
D17Mit1 57 190 194 188 168
18 D18Mit64 0 150 168
D18Mit222 4 88 148 189 98 130
continued on next page
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Table 3.1 – continued from previous page
Chromosome Marker Pos
cM
129Sv B6 B6a B6b BalbC BalbCa BalbCb nodiff novel
D18Mit12 10 171 165 118
D18Mit177 14 168 195 160
D18Mit194 14 115 122
D18Mit208 24 120 118
D18Mit186 31 126 125 90 108
D18Mit48 35 167 188
19 D19Mit68 3 135 119 120 114
D19Mit28 10 145 130 153 124
D19Mit88 24 148 138 142 128
D19Mit90 28 119 122 128
D19Mit26 38 129 131
D19Mit103 40 130 121 128
D19Mit33 46 222 223 255
D19Mit347 56 108 119 110 99
D19Mit6 58 109
X DXMit64 31 214 209
DXMit172 48.7 149 130
DXMit132 60 116
DXMit216 63 119 112 126 116 122
DXMit121 67 142
DXMit223 74 101 105 87
To visualize better the outcome of a standard STR-typing experiment, we established a
color coding system for the most common strains in correlation to their genetic position on
the chromosome. This makes it easier to see distinct differences at a glance and simplifies
the breeding process by selecting those mice with the highest content of favorable alleles.
The STR-profiles of our baseline mice, i.e. a pure BALB/c mouse, a C57Bl/6-Hsd mouse,
a “BALB/c” Rag2−/−Il2rg−/− mice that is primarily reconstitutable with hematopoietic
stem cells from human umbilical cord blood and a mouse that is expressing human PrP
(TgPRNP129M) as a transgene are depicted in Fig.3.5.
Backcrossing to a reconstitutable target strain was achieved in all presented breeding
strategies depicted in Figures 3.1 and 3.2. We regained reconstitutability in those
mice as soon as about 90% of the markers corresponded to those of the original mice
(Section 3.4.2). In retrospective, the quickest strategy was the intercross between between
BALB/c Prnp−/− mice and the original, reconstitutable mice since most of the markers
already overlapped in this paradigm, and even though a spatial proximity between
Rag and Prnp genes was initially thought to be prohibitive to this approach. We
decided to stop backcrossing of Rag1−/−Prnp−/−Il2rg−/− that had a high degree of
disambigous STR-markers after detecting recombination events between Prnp and Rag2
since it might have become very cumbersome to adjust for the right genetic constellation.
Reliable reconstitutability was also achieved in mice carrying a human transgene on
an immunodeficient background since most of the strain-specific markers of the initial
TgPRNP129M were outcrossed with this marker-assisted approach (Fig. 3.6). However,
all these observations hold only in the presence of at least one allele of mouse Prnp -
reconstitutability was not achieved in mice that were deficient for Prnp, even though
the genetic background monitoring was tight and differences between littermates were
minute (please refer to section 3.4.3 for a more detailed description of these experiments).
The marker-assisted background evaluation was also applied in other projects in our lab
to control for possible genetic background implications in experimental outcome. Briefly,
we checked D6−/− mice from Stefan Prokop and Petra Schwarz’s tga20 mice for identity
to the C57Bl/6 strain.
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Figure 3.4.: Readout of an STR mapping experiment.
(1) Electrophoresis plot (fluorescent intensity versus size, raw-data readout)
of a single capillary within our 3130xl capillary sequencer (ABI) showing the
size-standard peaks (orange), and the respective PCR amplicons characteristic
for a multiplexed reaction (blue for FAM and green for ATTO550) as well as
prominent primer dimers that permanently exist at the small-size end of the
plot.
(2-4) representative examples of three differentially labeled STR markers after
analysis with gene mapper software. The outcome of FAM-labeled D1Mit215,
ATTO550-labeled D6Mit100 and YYE-labeled D10Mit95 in correlation to the
respective mouse strain is shown. Dotted red lines indicate the marker size
range. Gray boxes indicate the bins that allow to call for identical alleles in
further analysis and assign specific names to them. 49
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7 D1Mit430 Balbcb Balbca D1Mit430 Balbcb Balbcb D1Mit430 Balbcb Balbcb D1Mit430 Balbca Balbca
12 D1Mit169 Balbc novel D1Mit169 B6 somecgrag2 D1Mit169 somecgrag2 somecgrag2 D1Mit169 novel novel
16 D1Mit411 nodiff nodiff D1Mit411 nodiff nodiff D1Mit411 nodiff nodiff D1Mit411 nodiff nodiff
33 D1Mit21 nodiffa nodiffa D1Mit21 nodiffa nodiffb D1Mit21 nodiffa nodiffa D1Mit21 nodiffb nodiffb
44 D1Mit132 Balbc Balbc D1Mit132 B6 B6 D1Mit132 Balbc Balbc D1Mit132 somecgrag2 somecgrag2
47 D1Mit215 Balbca Balbca D1Mit215 B6 B6 D1Mit215 Balbca Balbca D1Mit215 novel novel
59 D1Mit54 nodiff nodiff D1Mit54 nodiff nodiff D1Mit54 nodiff nodiff D1Mit54 nodiff nodiff
59 D1Mit60 Balbc Balbc D1Mit60 B6 B6 D1Mit60 Balbc Balbc D1Mit60 Balbc Balbc
65 D1Mit308 Balbc Balbc D1Mit308 B6 B6 D1Mit308 Balbc Balbc D1Mit308 novel novel
70 D1Mit495 Balbc Balbc D1Mit495 B6 B6 D1Mit495 Balbc Balbc D1Mit495 Balbc Balbc
82 D1Mit159 Balbcb B6 D1Mit159 B6a B6a D1Mit159 Balbcb B6 D1Mit159 B6 novel
94 D1Mit206 Balbc Balbc D1Mit206 B6 B6 D1Mit206 Balbc Balbc D1Mit206 Balbc Balbc
110 D1Mit17 Balbc Balbc D1Mit17 B6 B6a D1Mit17 Balbc Balbc D1Mit17 Balbc B6a
112 D1Mit292 Balbc Balbc D1Mit292 B6 B6 D1Mit292 Balbc Balbc D1Mit292 Balbc Balbc
2 D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff D2Mit1 novel novel
22 D2Mit365 Balbc Balbc D2Mit365 B6 B6 D2Mit365 Balbc Balbc D2Mit365 B6 B6
36 D2Mit61 nodiff nodiff D2Mit61 nodiff nodiff D2Mit61 nodiff nodiff D2Mit61 nodiff nodiff
40 D2Mit327 Balbca Balbca D2Mit327 B6 B6 D2Mit327 B6 B6 D2Mit327 B6 B6
50 D2Mit100 Balbc Balbc D2Mit100 somecgrag2 and b6somecgrag2 and b6 D2Mit100 somecgrag2 and b6somecgrag2 and b6 D2Mit100 somecgrag2 and b6somecgrag2 and b6
56 D2Mit395 evBalbc evBalbc D2Mit395 B6 B6 D2Mit395 Balbc Balbc D2Mit395 evBalbc evBalbc
67 D2Mit404 Balbc Balbc D2Mit404 cgrag2 and B6 cgrag2 and B6 D2Mit404 cgrag2 and B6 somecgrag2 D2Mit404 novel novel
72 D2Mit285 Balbc Balbc D2Mit285 B6 B6 D2Mit285 Balbc Balbc D2Mit285 novelb novelb
78 D2Mit411 Balbc Balbc D2Mit411 B6 B6 D2Mit411 Balbc Balbc D2Mit411 B6 B6
87 D2Mit113 Balbc Balbc D2Mit113 B6 B6 D2Mit113 Balbc Balbc D2Mit113 Balbc Balbc
92 D2Mit148 Balbc Balbc D2Mit148 B6 B6 D2Mit148 Balbc Balbc D2Mit148 B6 B6
10 D3Mit203 nodiff nodiff D3Mit203 nodiff nodiff D3Mit203 nodiff nodiff D3Mit203 novel novel
26 D3Mit51 Balbc and B6 Balbc and B6 D3Mit51 Balbc and B6 Balbc and B6 D3Mit51 Balbc and B6 Balbc and B6 D3Mit51 Balbc and B6 Balbc and B6
34 D3Mit311 Balbc Balbc D3Mit311 B6 B6 D3Mit311 Balbc Balbc D3Mit311 B6 B6
40 D3Mit57 Balbc Balbc D3Mit57 B6 B6 D3Mit57 Balbc Balbc D3Mit57 Balbc Balbc
46 D3Mit256 Balbc Balbc D3Mit256 B6 B6 D3Mit256 Balbc Balbc D3Mit256 Balbc Balbc
50 D3Mit320 Balbc Balbc D3Mit320 B6 B6 D3Mit320 Balbc Balbc D3Mit320 novel novel
56 D3Mit200 novel novel D3Mit200 B6 B6 D3Mit200 novel novel D3Mit200 novel novel
59 D3Mit147 Balbc Balbc D3Mit147 B6 B6 D3Mit147 Balbc Balbc D3Mit147 B6 B6
63 D3Mit352 Balbc Balbc D3Mit352 B6 B6 D3Mit352 Balbc Balbc D3Mit352 novel novel
5.2 D4Mit18 Balbc Balbc D4Mit18 cgrag2 and B6 cgrag2 and B6 D4Mit18 cgrag2 and B6 cgrag2 and B6 D4Mit18 cgrag2 and B6 cgrag2 and B6
16 D4Mit196 (Leer) (Leer) D4Mit196 (Leer) (Leer) D4Mit196 (Leer) (Leer) D4Mit196 (Leer) (Leer)
22 D4Mit268 B6 and somecgrag2B6 and somecgrag2 D4Mit268 B6 and somecgrag2B6 and somecgrag2 D4Mit268 B6 and somecgrag2B6 and somecgrag2 D4Mit268 novel novel
30 D4Mit17 Balbc and B6 Balbc and B6 D4Mit17 Balbc and B6 Balbc and B6 D4Mit17 Balbc and B6 Balbc and B6 D4Mit17 novel novel
34 D4Mit348 Balbc Balbc D4Mit348 B6 B6 D4Mit348 (Leer) (Leer) D4Mit348 B6 B6
55 D4Mit308 Balbc Balbc D4Mit308 novel Balbc D4Mit308 Balbc Balbc D4Mit308 novel novel
60 D4Mit203 Balbc Balbc D4Mit203 B6 B6 D4Mit203 Balbc Balbc D4Mit203 novel ?
67 D4Mit251 nodiff Balbc D4Mit251 nodiff nodiff D4Mit251 nodiff Balbc D4Mit251 Balbc Balbc
70 D4Mit170 B6 Balbc D4Mit170 B6 B6 D4Mit170 Balbc Balbc D4Mit170 novel novel
82 D4Mit256 Balbcb Balbcb D4Mit256 B6 B6 D4Mit256 (Leer) (Leer) D4Mit256 Balbcb Balbcb
0 D5Mit10 Balbc Balbc D5Mit10 B6 B6 D5Mit10 Balbc Balbc D5Mit10 novel novel
15 D5Mit352 Balbc Balbc D5Mit352 B6 B6 D5Mit352 Balbc Balbc D5Mit352 novel novel
28 D5Mit201 Balbc Balbc D5Mit201 (Leer) (Leer) D5Mit201 Balbc Balbc D5Mit201 novel novel
31 D5Mit309 Balbc and B6 Balbc and B6 D5Mit309 B6 B6 D5Mit309 Balbc and B6 Balbc and B6 D5Mit309 novel novel
37 D5MIt158 Balbc and B6 Balbc and B6 D5MIt158 Balbc and B6 Balbc and B6 D5MIt158 Balbc and B6 Balbc and B6 D5MIt158 novel novel
48 D5Mit146 Balbc and B6 Balbc and B6 D5Mit146 somecgrag2 somecgrag2 D5Mit146 somecgrag2 somecgrag2 D5Mit146 somecgrag2 somecgrag2
55 D5Mit425 Balbc Balbc D5Mit425 B6 B6 D5Mit425 Balbc Balbc D5Mit425 B6 B6
58 D5Mit95 Balbc Balbc D5Mit95 B6b B6b D5Mit95 Balbc somecgrag2a D5Mit95 B6b B6b
67 D5Mit98 Balbc Balbca D5Mit98 B6 B6 D5Mit98 Balbc Balbca D5Mit98 Balbc Balbca
0 D6Mit86 Balbca Balbcb D6Mit86 B6 B6 D6Mit86 somecgrag2 Balbca D6Mit86 Balbca B6
2 D6Mit138 Balbca Balbca D6Mit138 B6 B6 D6Mit138 Balbca Balbc D6Mit138 Balbca Balbca
6 D6Mit116 Balbc Balbc D6Mit116 B6 B6 D6Mit116 Balbc Balbc D6Mit116 B6 B6
18 D6Mit123 Balbca Balbca D6Mit123 B6 B6 D6Mit123 Balbca Balbca D6Mit123 B6 Balbca
22 D6Mit209 Balbc Balbc D6Mit209 B6 B6 D6Mit209 134 134 D6Mit209 130 130
30 D6Mit100 Balbc Balbc D6Mit100 B6 B6 D6Mit100 Balbc Balbc D6Mit100 novel novel
31 D6Mit284 Balbcb Balbcb D6Mit284 B6 B6 D6Mit284 Balbcb Balbcb D6Mit284 novel novel
40 D6Mit36 Balbc Balbc D6Mit36 B6 B6 D6Mit36 Balbc Balbc D6Mit36 novel novel
63 D6Mit14 Balbc Balbc D6Mit14 B6 B6 D6Mit14 Balbc Balbc D6Mit14 novel novel
67 D6Mit374 nodiff nodiff D6Mit374 nodiff nodiff D6Mit374 nodiff nodiff D6Mit374 novel novel
0 D7Mit21 Balbc and B6 Balbc and B6 D7Mit21 Balbc and B6 Balbc and B6 D7Mit21 Balbc and B6 Balbc and B6 D7Mit21 Balbc and B6 Balbc and B6
6 D7Mit294 Balbca and B6 Balbca and B6 D7Mit294 Balbca and B6 Balbca and B6 D7Mit294 Balbca and B6 Balbcb D7Mit294 ? ?
16 D7Mit228 Balbc Balbc D7Mit228 B6 B6 D7Mit228 Balbc Balbc D7Mit228 ? Balbc
25 D7Mit83 Balbcb Balbca D7Mit83 B6b B6a D7Mit83 Balbcb Balbca D7Mit83 Balbcb Balbca
26 D7Mit248 Balbc nodiff D7Mit248 B6a nodiff D7Mit248 Balbc nodiff D7Mit248 Balbc B6a
31 D7Mit350 Balbc Balbc D7Mit350 B6 B6 D7Mit350 Balbc Balbc D7Mit350 Balbc Balbc
37 D7Mit323 Balbc Balbc a D7Mit323 Balbc a Balbc a D7Mit323 Balbc Balbc a D7Mit323 Balbc Balbc a
46 D7Mit101 Balbc Balbc D7Mit101 B6 B6 D7Mit101 Balbc Balbc D7Mit101 novel novel
53 D7MIt98 Balbc Balbc D7MIt98 B6 B6 D7MIt98 Balbc Balbc D7MIt98 B6 B6
62 D7Mit109 nodiff nodiff D7Mit109 nodiff nodiff D7Mit109 nodiff nodiff D7Mit109 nodiff nodiff
68 D7Mit223 Balbcb Balbcb D7Mit223 B6 B6 D7Mit223 Balbcb Balbcb D7Mit223 novel novel
68 D7Mit259 Balbc Balbcb D7Mit259 B6 B6 D7Mit259 Balbc Balbcb D7Mit259 novel novel
0 D8Mit155 Balbc Balbcb D8Mit155 B6 B6 D8Mit155 Balbc Balbcb D8Mit155 Balbc Balbcb
3 D8Mit63 (Leer) (Leer) D8Mit63 B6b B6b D8Mit63 Balbca Balbca D8Mit63 Balbca Balbcb
4 D8MIT124 Balbc Balbc D8MIT124 B6a B6a D8MIT124 Balbc Balbc D8MIT124 Balbc Balbc
9 D8Mit289 Balbc Balbc D8Mit289 B6 B6 D8Mit289 somecgrag2 Balbc D8Mit289 Balbc Balbc
20 D8Mit292 somecgrag2 Balbca D8Mit292 Balbca Balbca D8Mit292 somecgrag2 Balbca D8Mit292 Balbca Balbca
25 D8Mit339 Balbc 106 D8Mit339 B6 B6 D8Mit339 Balbc Balbc D8Mit339 Balbc Balbc
30 D8Mit46 Balbc Balbc D8Mit46 B6 B6 D8Mit46 Balbc Balbc D8Mit46 Balbc Balbc
35 D8Mit178 Balbc Balbc D8Mit178 (Leer) (Leer) D8Mit178 Balbc Balbc D8Mit178 Balbc Balbc
40 D8Mit45 118 118 D8Mit45 Balbc and B6 Balbc and B6 D8Mit45 118 118 D8Mit45 novel novel
50 D8Mit211 Balbca Balbca D8Mit211 B6 B6b D8Mit211 Balbca Balbcb D8Mit211 B6 Balbcb
56 D8Mit112 Balbca Balbcb D8Mit112 B6 B6 D8Mit112 Balbca Balbcb D8Mit112 Balbca Balbca
56 D8Mit47 Balbc Balbc D8Mit47 B6 B6 D8Mit47 Balbc Balbc D8Mit47 (Leer) (Leer)
69 D8Mit49 Balbc Balbc D8Mit49 B6a B6 D8Mit49 Balbc Balbc D8Mit49 novel novel
71 D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b D8Mit92 nodiff b nodiff b
2 D9Mit250 Balbc and B6 Balbc and B6 D9Mit250 Balbc and B6 Balbc and B6 D9Mit250 Balbc and B6 Balbc and B6 D9Mit250 Balbc and B6 Balbc and B6
8 D9Mit90 Balbc Balbc D9Mit90 B6 B6 D9Mit90 Balbc Balbc D9Mit90 novel novel
13 D9Mit2 Balbc Balbc D9Mit2 B6 B6 D9Mit2 Balbc Balbc D9Mit2 B6 B6
16 D9Mit285 Balbc Balbc D9Mit285 B6 B6 D9Mit285 Balbc Balbc D9Mit285 novel novel
21 D9Mit129 Balbc b Balbc b D9Mit129 B6 B6 D9Mit129 Balbc b Balbc b D9Mit129 novel novel
24 D9Mit97 Balbc Balbc D9Mit97 B6 B6 D9Mit97 (Leer) (Leer) D9Mit97 B6 B6
34 D9Mit336 Balbc Balbc D9Mit336 B6a B6a D9Mit336 Balbc Balbc D9Mit336 novel novel
49 D9Mit355 Balbc Balbc D9Mit355 B6 B6 D9Mit355 Balbc Balbc D9Mit355 Balbc Balbc
63 D9Mit201 Balbc Balbc D9Mit201 B6 B6 D9Mit201 Balbc Balbc D9Mit201 Balbc 130
70 D9Mit151 Balbc Balbc D9Mit151 B6a B6a D9Mit151 Balbc Balbc D9Mit151 Balbc B6a
7 D10Mit213 Balbc B6a D10Mit213 B6a B6a D10Mit213 Balbc Balbc D10Mit213 Balbc ?
12 D10Mit86 Balbc a Balbc a D10Mit86 novel novel D10Mit86 Balbc a Balbc a D10Mit86 Balbc a Balbc a
21 D10Mit38 Balbc Balbca D10Mit38 cgrag2 and B6 B6 D10Mit38 cgrag2 and B6 Balbca D10Mit38 cgrag2 and B6 Balbca
25 D10Mit20 Balbc Balbc D10Mit20 B6 B6 D10Mit20 ? Balbc D10Mit20 B6 B6
31 D10Mit31 cgrag2b cgrag2b D10Mit31 B6 B6 D10Mit31 cgrag2b cgrag2b D10Mit31 novel novel
40 D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff
47 D10Mit230 Balbca Balbcb D10Mit230 B6 B6 D10Mit230 Balbca Balbcb D10Mit230 B6 B6
50 D10Mit95 Balbc Balbc D10Mit95 B6 B6 D10Mit95 Balbc Balbc D10Mit95 B6 B6
63 D10Mit233 Balbc Balbc D10Mit233 B6 B6 D10Mit233 Balbc Balbc D10Mit233 ? ?
70 D10Mit14 Balbc Balbc D10Mit14 B6 B6 D10Mit14 Balbc Balbc D10Mit14 B6 B6
77 D10Mit103 Balbca Balbcb D10Mit103 Balbca B6 D10Mit103 Balbca Balbcb D10Mit103 Balbca B6
0 D11Mit71 Balbc Balbc D11Mit71 B6 B6 D11Mit71 Balbc Balbc D11Mit71 novel novel
4 D11Mit2 Balbc Balbc D11Mit2 B6 B6 D11Mit2 Balbc Balbc D11Mit2 novel novel
14 D11Mit186 Balbc Balbc D11Mit186 (Leer) (Leer) D11Mit186 Balbc Balbc D11Mit186 Balbc Balbc
21 D11Mit189 Balbc Balbc D11Mit189 B6 B6 D11Mit189 somecgrag2 somecgrag2 D11Mit189 novel novel
25 D11Mit86 Balbca Balbcb D11Mit86 Balbca Balbcb D11Mit86 ? Balbcb D11Mit86 novel novel
30 D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff D11Mit143 novel novel
36 D11Mit4 Balbc Balbc D11Mit4 B6 B6 D11Mit4 Balbc Balbc D11Mit4 B6 B6
45 D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff
49 D11Mit285 Balbc Balbc D11Mit285 B6 B6 D11Mit285 Balbc Balbc D11Mit285 Balbc Balbc
70 D11Mit333 Balbc Balbc D11Mit333 B6 B6 D11Mit333 Balbc Balbc D11Mit333 Balbc Balbc
2 D12Mit182 Balbc Balbc D12Mit182 B6 B6 D12Mit182 Balbc Balbc D12Mit182 B6 B6
6 D12Mit11 Balbc Balbc D12Mit11 B6a B6a D12Mit11 Balbc B6a D12Mit11 Balbc Balbc
10 D12Mit59 novel Balbc D12Mit59 somecgrag2 B6 D12Mit59 somecgrag2 Balbc D12Mit59 somecgrag2 B6
20 D12Mit285 Balbc Balbc D12Mit285 B6 B6 D12Mit285 Balbc Balbc D12Mit285 novel novel
23 D12Mit91 Balbc Balbc D12Mit91 B6a Balbc D12Mit91 somecgrag2 Balbc D12Mit91 Balbc ?
30 D12MIt143 Balbc Balbc D12MIt143 B6 B6 D12MIt143 Balbc Balbc D12MIt143 novel novel
33 D12Mit158 Balbc Balbc D12Mit158 B6 Balbc D12Mit158 Balbc Balbc D12Mit158 Balbc Balbc
45 D12Mit7 Balbc Balbc a D12Mit7 B6 B6 D12Mit7 Balbc Balbc a D12Mit7 B6 B6
2 D13Mit56 Balbc and B6 Balbc and B6 D13Mit56 Balbc and B6 Balbc and B6 D13Mit56 Balbc and B6 Balbc and B6 D13Mit56 novel novel
8 D13Mit275 Balbca and B6 Balbca and B6 D13Mit275 Balbca and B6 Balbca and B6 D13Mit275 Balbca and B6 Balbc D13Mit275 novel novel
13 D13Mit88 Balbcb Balbca D13Mit88 B6 B6 D13Mit88 Balbcb Balbca D13Mit88 Balbcb B6
14 D13Mit19 Balbc Balbc D13Mit19 B6 B6 D13Mit19 somecgrag2 Balbc D13Mit19 Balbc Balbc
40 D13Mit213 Balbc Balbc D13Mit213 B6 B6 D13Mit213 (Leer) (Leer) D13Mit213 Balbc Balbc
50 D13Mit151 Balbc Balbc D13Mit151 B6 B6 D13Mit151 Balbc Balbc D13Mit151 novel novel
59 D13Mit78 Balbc Balbc D13Mit78 B6 B6 D13Mit78 Balbc Balbc D13Mit78 Balbc Balbc
0 D14Mit48 Balbc Balbc D14Mit48 B6 B6 D14Mit48 Balbc Balbc D14Mit48 B6 B6
1 D14Mit40 Balbcb Balbcb D14Mit40 B6 B6 D14Mit40 (Leer) (Leer) D14Mit40 novel novel
7 D14Mit126 Balbcb Balbcb D14Mit126 somecgrag2 somecgrag2 D14Mit126 Balbcb somecgrag2 D14Mit126 novel novel
16 D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc
16 D14Mit44 Balbcb Balbcb D14Mit44 B6 B6 D14Mit44 Balbcb Balbcb D14Mit44 novel novel
18 D14Mit174 Balbca and B6 Balbcb D14Mit174 Balbca and B6 Balbca and B6 D14Mit174 Balbcb Balbcb D14Mit174 novel novel
24 D14Mit60 Balbc Balbc D14Mit60 B6 B6 D14Mit60 Balbc Balbc D14Mit60 novel novel
32 D14Mit5 nodiff nodiff D14Mit5 nodiff nodiff D14Mit5 nodiff nodiff D14Mit5 nodiff nodiff
53 D14Mit263 Balbc Balbc D14Mit263 B6 B6 D14Mit263 Balbc Balbc D14Mit263 Balbc Balbc
70 D14Mit170 Balbca Balbca D14Mit170 Balbca Balbca D14Mit170 Balbca Balbca D14Mit170 B6 B6
4 D15Mit80 evB6 evB6 D15Mit80 evB6 evB6 D15Mit80 somecgrag2 somecgrag2 D15Mit80 evB6 evB6
10 D15Mit252 Balbc Balbc D15Mit252 B6 B6 D15Mit252 Balbc Balbc D15Mit252 Balbc Balbc
30 D15Mit67 Balbc and B6 Balbc and B6 D15Mit67 B6 B6 D15Mit67 Balbc and B6 Balbc and B6 D15Mit67 Balbc and B6 Balbc and B6
35 D15Mit70 Balbc Balbc D15Mit70 B6 B6 D15Mit70 Balbc Balbc D15Mit70 Balbc Balbc
42 D15Mit107 Balbc Balbc D15Mit107 novel a B6 D15Mit107 somecgrag2 somecgrag2 D15Mit107 novel novel
46 D15Mit262 Balbc Balbc D15Mit262 B6 B6 D15Mit262 Balbc Balbc D15Mit262 novel novel
49 D15Mit159 Balbc Balbc D15Mit159 B6a B6 D15Mit159 Balbc Balbc D15Mit159 Balbc Balbc
54 D15Mit242 Balbc Balbc D15Mit242 B6 B6 D15Mit242 Balbc Balbc D15Mit242 novel novel
7 D16Mit131 B6 Balbc D16Mit131 B6 B6 D16Mit131 Balbc Balbc D16Mit131 novel novel
18 D16Mit101 Balbca Balbcb D16Mit101 cgrag2b and B6 cgrag2b and B6 D16Mit101 cgrag2b and B6 cgrag2b and B6 D16Mit101 cgrag2b and B6 cgrag2b and B6
24 D16Mit60 220 220 D16Mit60 220 220 D16Mit60 B6 B6 D16Mit60 B6 B6
40 D16Mit189 Balbc Balbc D16Mit189 188 B6 D16Mit189 188 Balbc D16Mit189 188 novel
46 D16Mit153 Balbc Balbc D16Mit153 B6 B6 D16Mit153 (Leer) (Leer) D16Mit153 novel novel
51 D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff
51 D16Mit86 Balbc Balbc D16Mit86 B6 B6 D16Mit86 Balbc Balbc D16Mit86 Balbc Balbc
84 D17Mit245 Balbc Balbc D17Mit245 B6 B6 D17Mit245 Balbc Balbc D17Mit245 novel novel
95 D17Mit180 Balbc Balbc D17Mit180 (Leer) (Leer) D17Mit180 Balbc Balbc D17Mit180 (Leer) (Leer)
110 D17Mit39 Balbc Balbc D17Mit39 B6 B6 D17Mit39 Balbc Balbc D17Mit39 Balbc Balbc
121 D17Mit143 B6a Balbc D17Mit143 B6a B6a D17Mit143 B6a Balbc D17Mit143 Balbc Balbc
129 D17Mit81 Balbc a Balbcb D17Mit81 B6 B6 D17Mit81 Balbcb Balbcb D17Mit81 novel novel
160 D17Mit51 Balbc Balbc D17Mit51 B6a B6a D17Mit51 Balbc Balbc D17Mit51 novel novel
186 D17Mit20 Balbc Balbc D17Mit20 (Leer) (Leer) D17Mit20 Balbc Balbc D17Mit20 Balbc Balbc
226 D17Mit1 Balbc Balbc D17Mit1 B6 B6 D17Mit1 Balbc Balbc D17Mit1 B6 B6
0 D18Mit64 Balbc Balbc D18Mit64 B6 B6 D18Mit64 Balbc Balbc D18Mit64 B6 B6
4 D18Mit222 Balbc Balbca D18Mit222 B6a B6b D18Mit222 Balbc Balbc D18Mit222 B6a B6a
10 D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff
14 D18Mit177 Balbc Balbc D18Mit177 B6 B6 D18Mit177 Balbc Balbc D18Mit177 novel novel
14 D18Mit194 Balbc Balbc D18Mit194 B6 B6 D18Mit194 Balbc Balbc D18Mit194 B6 B6
24 D18Mit208 Balbc Balbc D18Mit208 B6 B6 D18Mit208 Balbc Balbc D18Mit208 Balbc Balbc
31 D18Mit186 Balbcb Balbcb D18Mit186 B6 B6 D18Mit186 Balbcb Balbcb D18Mit186 Balbcb Balbcb
35 D18Mit48 Balbc and B5 Balbc and B6 D18Mit48 Balbc and B5 Balbc and B6 D18Mit48 Balbc and B6 Balbc and B7 D18Mit48 novel novel
3 D19Mit68 Balbc Balbc D19Mit68 B6 B6 D19Mit68 Balbc Balbc D19Mit68 Balbc Balbc
10 D19Mit28 Balbca Balbca D19Mit28 B6 B6 D19Mit28 Balbca Balbca D19Mit28 Balbca Balbca
24 D19Mit88 (Leer) (Leer) D19Mit88 B6 B6 D19Mit88 Balbc Balbc D19Mit88 novel novel
28 D19Mit90 Balbc Balbc D19Mit90 B6 B6 D19Mit90 Balbc Balbc D19Mit90 novel novel
38 D19Mit26 Balbc Balbc D19Mit26 B6 B6 D19Mit26 Balbc Balbc D19Mit26 B6 B6
40 D19Mit103 Balbc Balbc D19Mit103 B6 B6 D19Mit103 Balbc Balbc D19Mit103 B6 B6
46 D19Mit33 (Leer) (Leer) D19Mit33 (Leer) (Leer) D19Mit33 (Leer) (Leer) D19Mit33 Balbc Balbc
56 D19Mit347 (Leer) (Leer) D19Mit347 B6 B6 D19Mit347 Balbc Balbc D19Mit347 novel novel
58 D19Mit6 Balbc and B6 Balbc spec D19Mit6 Balbc and B6 Balbc and B6 D19Mit6 Balbc and B6 Balbc spec D19Mit6 novel novel
9 DXMit81 nodiff nodiff DXMit81 nodiff nodiff DXMit81 nodiff nodiff DXMit81 nodiff nodiff
45 DXMit64 nodiff nodiff DXMit64 nodiff nodiff DXMit64 nodiff nodiff DXMit64 nodiff nodiff
49 DXMit172 Balbc Balbc DXMit172 B6 B6 DXMit172 Balbc Balbc DXMit172 B6 B6
60 DXMit132 Balbc Balbc DXMit132 B6 B6 DXMit132 Balbc Balbc DXMit132 Balbc Balbc
63 DXMit216 Balbc a Balbc DXMit216 B6 B6 DXMit216 Balbc a Balbc DXMit216 Balbc a novel
67 DXMit121 nodiff nodiff DXMit121 nodiff nodiff DXMit121 nodiff nodiff DXMit121 nodiff nodiff
73 DXMit223 Balbc Balbc DXMit223 B6 B6 DXMit223 Balbc Balbc DXMit223 Balbc Balbc
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Figure 3.5.: Calibration strains for STR typing.
Depicted are 192 markers per mouse allocated according to their physical
location on the 19 autosomes and the X chromosome of the mouse genome.
The color code is as follows: yellow for BALB/c and Il2rg alleles; red for
C57Bl/6 alleles; orange for alleles attributed to either Il2rg or C57Bl/B6, but
not in any case to BALB/c; green for alleles which are not informative in
discriminating those strains but might be polymorphic in other strain types;
blue for alleles that are specific for TgPRNP129M-mice and/or 129Sv. In
some rare cases, there are empty fields indicating that the PCR reaction in
this particular case did not work.
50
3.1. Breeding of genetically modified mice
7 D1Mit430 Balbcb Balbcb D1Mit430 Balbcb Balbcb D1Mit430 Balbcb Balbcb D1Mit430 Balbcb Balbcb D1Mit430 63 Balbcb D1Mit430 Balbcb Balbcb D1Mit430 Balbcb Balbcb
12 D1Mit169 somecgrag2somecgrag2D1Mit169 somecgrag2somecgrag2D1Mit169 somecgrag2somecgrag2 D1Mit169 Balbc somecgrag2 D1Mit169 somecgrag2somecgrag2 D1Mit169 Balbc Balbc D1Mit169 somecgrag2somecgrag2
16 D1Mit411 nodiff nodiff D1Mit411 nodiff nodiff D1Mit411 nodiff nodiff D1Mit411 B6 nodiff D1Mit411 nodiff nodiff D1Mit411 nodiff nodiff D1Mit411 B6 nodiff
33 D1Mit21 nodiffa nodiffa D1Mit21 nodiffa nodiffa D1Mit21 nodiffa nodiffa D1Mit21 nodiffa nodiffb D1Mit21 nodiffa nodiffb D1Mit21 nodiffa nodiffb D1Mit21 nodiffa nodiffa
44 D1Mit132 Balbc Balbc D1Mit132 Balbc Balbc D1Mit132 Balbc Balbc D1Mit132 Balbc Balbc D1Mit132 Balbc Balbc D1Mit132 Balbc Balbc D1Mit132 Balbc Balbc
47 D1Mit215 Balbca Balbca D1Mit215 Balbca Balbca D1Mit215 Balbca Balbca D1Mit215 Balbca Balbca D1Mit215 Balbca Balbca D1Mit215 Balbca Balbca D1Mit215 Balbca Balbca
59 D1Mit54 Balbc Balbc D1Mit54 Balbc Balbc D1Mit54 Balbc Balbc D1Mit54 Balbc Balbc D1Mit54 ? Balbc D1Mit54 Balbc Balbc D1Mit54 Balbc Balbc
59 D1Mit60 Balbc Balbc D1Mit60 Balbc Balbc D1Mit60 Balbc Balbc D1Mit60 Balbc Balbc D1Mit60 Balbc Balbc D1Mit60 Balbc Balbc D1Mit60 Balbc Balbc
65 D1Mit308 Balbc Balbc D1Mit308 Balbc Balbc D1Mit308 Balbc Balbc D1Mit308 Balbc Balbc D1Mit308 Balbc Balbc D1Mit308 Balbc Balbc D1Mit308 Balbc Balbc
70 D1Mit495 Balbc Balbc D1Mit495 Balbc Balbc D1Mit495 Balbc Balbc D1Mit495 Balbc Balbc D1Mit495 Balbc Balbc D1Mit495 Balbc Balbc D1Mit495 Balbc Balbc
82 D1Mit159 Balbcb B6 D1Mit159 Balbcb B6 D1Mit159 Balbcb B6 D1Mit159 Balbcb B6 D1Mit159 Balbcb Balbcb D1Mit159 Balbcb Balbcb D1Mit159 Balbcb B6
94 D1Mit206 Balbc Balbc D1Mit206 Balbc Balbc D1Mit206 Balbc Balbc D1Mit206 Balbc Balbc D1Mit206 Balbc Balbc D1Mit206 Balbc Balbc D1Mit206 Balbc Balbc
110 D1Mit17 Balbc Balbc D1Mit17 Balbc Balbc D1Mit17 Balbc Balbc D1Mit17 Balbc Balbc D1Mit17 Balbc Balbc D1Mit17 Balbc Balbc D1Mit17 Balbc Balbc
112 D1Mit292 Balbc Balbc D1Mit292 Balbc Balbc D1Mit292 Balbc Balbc D1Mit292 Balbc Balbc D1Mit292 Balbc Balbc D1Mit292 Balbc Balbc D1Mit292 Balbc Balbc
2 D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff D2Mit1 nodiff nodiff
22 D2Mit365 Balbc Balbca D2Mit365 Balbc Balbca D2Mit365 Balbc Balbca D2Mit365 Balbca Balbca D2Mit365 Balbc Balbc D2Mit365 Balbc Balbc D2Mit365 Balbc Balbc
36 D2Mit61 Balbc Balbc D2Mit61 Balbc Balbc D2Mit61 Balbc Balbc D2Mit61 Balbc Balbc D2Mit61 Balbc Balbc D2Mit61 Balbc Balbc D2Mit61 Balbc Balbc
40 D2Mit327 B6 B6 D2Mit327 B6 B6 D2Mit327 B6 B6 D2Mit327 B6 B6 D2Mit327 B6 B6 D2Mit327 B6 B6 D2Mit327 117 B6
50 D2Mit100 Balbc somecgrag2 and b6D2Mit100 Balbc somecgrag2 and b6D2Mit100 Balbc somecgrag2 and b6D2Mit100somecgrag2 and b6somecgrag2 and b6D2Mit100somecgrag2 and b6somecgrag2 and b6D2Mit100somecgrag2 and b6somecgrag2 and b6D2Mit100 Balbc Balbc
56 D2Mit395 Balbc evBalbc D2Mit395 Balbc evBalbc D2Mit395 Balbc Balbc D2Mit395 B6 Balbc D2Mit395 B6 Balbc D2Mit395 B6 Balbc D2Mit395 Balbc evBalbc
67 D2Mit404 Balbc somecgrag2D2Mit404 Balbc cgrag2 and B6D2Mit404 cgrag2 and B6somecgrag2 D2Mit404cgrag2 and B6cgrag2 and B6D2Mit404 somecgrag2somecgrag2 D2Mit404 Balbc Balbc D2Mit404 Balbc cgrag2 and B6
72 D2Mit285 Balbc Balbc D2Mit285 Balbc Balbc D2Mit285 Balbc Balbc D2Mit285 Balbc Balbc D2Mit285 Balbc Balbc D2Mit285 Balbc Balbc D2Mit285 Balbc Balbc
78 D2Mit411 Balbc Balbc D2Mit411 Balbc Balbc D2Mit411 Balbc Balbc D2Mit411 Balbc Balbc D2Mit411 Balbc Balbc D2Mit411 Balbc Balbc D2Mit411 Balbc Balbc
87 D2Mit113 Balbc Balbc D2Mit113 Balbc Balbc D2Mit113 Balbc Balbc D2Mit113 Balbc Balbc D2Mit113 Balbc Balbc D2Mit113 Balbc Balbc D2Mit113 Balbc Balbc
92 D2Mit148 Balbc Balbc D2Mit148 Balbc Balbc D2Mit148 Balbc Balbc D2Mit148 Balbc Balbc D2Mit148 Balbc Balbc D2Mit148 Balbc Balbc D2Mit148 Balbc Balbc
10 D3Mit203 nodiff nodiff D3Mit203 ? nodiff D3Mit203 nodiff nodiff D3Mit203 nodiff nodiff D3Mit203 nodiff nodiff D3Mit203 nodiff nodiff D3Mit203 nodiff nodiff
26 D3Mit51 Balbc and B6Balbc and B6D3Mit51 Balbc and B6Balbc and B6D3Mit51 Balbc and B6Balbc and B6 D3Mit51 Balbc and B6Balbc and B6D3Mit51 Balbc and B6Balbc and B6D3Mit51 D3Mit51 Balbc and B6Balbc and B6
34 D3Mit311 Balbc Balbc D3Mit311 Balbc Balbc D3Mit311 Balbc Balbc D3Mit311 Balbc Balbc D3Mit311 Balbc Balbc D3Mit311 Balbc Balbc D3Mit311 Balbc Balbc
40 D3Mit57 Balbc Balbc D3Mit57 Balbc Balbc D3Mit57 Balbc Balbc D3Mit57 Balbc Balbc D3Mit57 Balbc Balbc D3Mit57 Balbc Balbc D3Mit57 Balbc Balbc
46 D3Mit256 125 125 D3Mit256 125 125 D3Mit256 125 125 D3Mit256 125 125 D3Mit256 125 125 D3Mit256 125 125 D3Mit256 125 125
50 D3Mit320 Balbc Balbc D3Mit320 Balbc Balbc D3Mit320 Balbc Balbc D3Mit320 Balbc Balbc D3Mit320 Balbc Balbc D3Mit320 Balbc Balbc D3Mit320 Balbc Balbc
56 D3Mit200 novel novel D3Mit200 novel novel D3Mit200 novel novel D3Mit200 novel novel D3Mit200 novel novel D3Mit200 novel novel D3Mit200 novel novel
59 D3Mit147 Balbc Balbc D3Mit147 Balbc Balbc D3Mit147 Balbc Balbc D3Mit147 Balbc Balbc D3Mit147 Balbc Balbc D3Mit147 Balbc Balbc D3Mit147 Balbc Balbc
63 D3Mit352 Balbc Balbc D3Mit352 Balbc Balbc D3Mit352 Balbc Balbc D3Mit352 Balbc Balbc D3Mit352 B6 Balbc D3Mit352 Balbc Balbc D3Mit352 Balbc Balbc
5.2 D4Mit18 cgrag2 and B6cgrag2 and B6D4Mit18 cgrag2 and B6cgrag2 and B6D4Mit18 cgrag2 and B6cgrag2 and B6 D4Mit18 cgrag2 and B6cgrag2 and B6D4Mit18 cgrag2 and B6cgrag2 and B6D4Mit18 D4Mit18 Balbc cgrag2 and B6
16 D4Mit196 Balbc Balbc D4Mit196 Balbc Balbc D4Mit196 Balbc Balbc D4Mit196 ? ? D4Mit196 (Leer) (Leer) D4Mit196 Balbc Balbc D4Mit196 Balbc Balbc
22 D4Mit268 B6 and somecgrag2B6 and somecgrag2D4Mit268 B6 and somecgrag2B6 and somecgrag2D4Mit268 B6 and somecgrag2B6 and somecgrag2D4Mit268B6 and somecgrag2B6 and somecgrag2D4Mit268B6 and somecgrag2B6 and somecgrag2D4Mit268 B6 and somecgrag2B6 and somecgrag2D4Mit268 B6 and somecgrag2B6 and somecgrag2
30 D4Mit17 Balbc and B6Balbc and B6D4Mit17 Balbc and B6Balbc and B6D4Mit17 Balbc and B6Balbc and B6 D4Mit17 Balbc and B6Balbc and B6D4Mit17 Balbc and B6Balbc and B6D4Mit17 Balbc and B6Balbc and B6D4Mit17 Balbc and B6Balbc and B6
34 D4Mit348 Balbc Balbc D4Mit348 Balbc Balbc D4Mit348 Balbc Balbc D4Mit348 Balbc Balbc D4Mit348 Balbc Balbc D4Mit348 Balbc Balbc D4Mit348 Balbc Balbc
55 D4Mit308 Balbc Balbc D4Mit308 Balbc Balbc D4Mit308 Balbc Balbc D4Mit308 Balbc Balbc D4Mit308 Balbc Balbc D4Mit308 Balbc Balbc D4Mit308 Balbc Balbc
60 D4Mit203 Balbc Balbc D4Mit203 Balbc Balbc D4Mit203 Balbc Balbc D4Mit203 B6 B6 D4Mit203 Balbc Balbc D4Mit203 Balbc Balbc D4Mit203 Balbc Balbc
67 D4Mit251 Balbc Balbc D4Mit251 nodiff Balbc D4Mit251 nodiff Balbc D4Mit251 ? Balbc D4Mit251 Balbc Balbc D4Mit251 Balbc Balbc D4Mit251 Balbc Balbc
70 D4Mit170 B6 Balbc D4Mit170 B6 Balbc D4Mit170 B6 Balbc D4Mit170 B6 B6 D4Mit170 B6 Balbc D4Mit170 B6 Balbc D4Mit170 B6 Balbc
82 D4Mit256 Balbcb Balbcb D4Mit256 Balbcb Balbcb D4Mit256 Balbcb Balbcb D4Mit256 Balbcb Balbcb D4Mit256 Balbcb Balbcb D4Mit256 Balbcb Balbcb D4Mit256 Balbcb Balbcb
0 D5Mit10 Balbc and B6Balbc and B6D5Mit10 Balbc and B6Balbc and B6D5Mit10 Balbc and B6Balbc and B6 D5Mit10 Balbc and B6Balbc and B6D5Mit10 Balbc and B6Balbc and B6D5Mit10 Balbc and B6Balbc and B6D5Mit10 Balbc and B6Balbc and B6
15 D5Mit352 Balbc Balbc D5Mit352 Balbc Balbc D5Mit352 Balbc Balbc D5Mit352 Balbc Balbc D5Mit352 Balbc Balbc D5Mit352 Balbc Balbc D5Mit352 Balbc Balbc
28 D5Mit201 Balbc Balbc D5Mit201 Balbc Balbc D5Mit201 Balbc Balbc D5Mit201 Balbc Balbc D5Mit201 Balbc Balbc D5Mit201 Balbc Balbc D5Mit201 Balbc Balbc
31 D5Mit309 Balbc and B6Balbc and B6D5Mit309 Balbc and B6Balbc and B6D5Mit309 Balbc and B6Balbc and B6 D5Mit309Balbc and B6Balbc and B6D5Mit309Balbc and B6Balbc and B6D5Mit309 novel Balbc and B6D5Mit309 novel Balbc
37 D5MIt158 somecgrag2somecgrag2D5MIt158 somecgrag2somecgrag2D5MIt158 somecgrag2somecgrag2 D5MIt158 somecgrag2somecgrag2 D5MIt158 somecgrag2somecgrag2 D5MIt158 somecgrag2somecgrag2D5MIt158
48 D5Mit146 Balbc Balbc D5Mit146 Balbc Balbc D5Mit146 Balbc Balbc D5Mit146 Balbc B6 D5Mit146 Balbc B6 D5Mit146 Balbc Balbc D5Mit146 Balbc Balbc
55 D5Mit425 balbc balbc D5Mit425 balbc balbc D5Mit425 balbc balbc D5Mit425 Balbc B6 D5Mit425 Balbc B6 D5Mit425 balbc balbc D5Mit425 Balbc balbc
58 D5Mit95 Balbc Balbc D5Mit95 Balbc Balbc D5Mit95 Balbc Balbc D5Mit95 Balbc Balbc D5Mit95 Balbc Balbc D5Mit95 Balbc Balbc D5Mit95 Balbc Balbc
67 D5Mit98 Balbc balbca D5Mit98 Balbc balbca D5Mit98 Balbc balbca D5Mit98 Balbc Balbca D5Mit98 Balbc Balbca D5Mit98 Balbc Balbc D5Mit98 Balbc balbca
0 D6Mit86 Balbca Balbca D6Mit86 Balbca Balbca D6Mit86 Balbca Balbca D6Mit86 ? somecgrag2 D6Mit86 Balbca Balbca D6Mit86 Balbca Balbca D6Mit86 Balbca Balbca
2 D6Mit138 Balbc Balbc D6Mit138 Balbca Balbc D6Mit138 Balbca Balbc D6Mit138 Balbc Balbc D6Mit138 novel Balbc D6Mit138 Balbc Balbc D6Mit138 novel Balbc
6 D6Mit116 Balbc Balbc D6Mit116 Balbc Balbc D6Mit116 Balbc Balbc D6Mit116 Balbc Balbc D6Mit116 Balbc Balbc D6Mit116 Balbc Balbc D6Mit116 Balbc Balbc
18 D6Mit123 Balbca Balbca D6Mit123 Balbca Balbca D6Mit123 Balbca Balbca D6Mit123 B6 Balbca D6Mit123 Balbca Balbca D6Mit123 Balbca ? D6Mit123 Balbc Balbca
22 D6Mit209 134 134 D6Mit209 134 134 D6Mit209 134 134 D6Mit209 130 134 D6Mit209 134 134 D6Mit209 D6Mit209 134 134
30 D6Mit100 Balbc Balbc D6Mit100 Balbc Balbc D6Mit100 Balbc Balbc D6Mit100 Balbc novel D6Mit100 Balbc Balbc D6Mit100 Balbc Balbc D6Mit100 Balbc Balbc
31 D6Mit284 Balbcb Balbcb D6Mit284 Balbcb Balbcb D6Mit284 Balbcb Balbcb D6Mit284 Balbcb novel D6Mit284 Balbcb Balbcb D6Mit284 Balbcb Balbcb D6Mit284 Balbcb Balbcb
40 D6Mit36 Balbc Balbc D6Mit36 Balbc Balbc D6Mit36 Balbc Balbc D6Mit36 novel Balbc D6Mit36 Balbc Balbc D6Mit36 Balbc Balbc D6Mit36 Balbc Balbc
63 D6Mit14 Balbc Balbc D6Mit14 Balbc Balbc D6Mit14 Balbc Balbc D6Mit14 Balbc 168 D6Mit14 Balbc Balbc D6Mit14 Balbc Balbc D6Mit14 Balbc 168
67 D6Mit374 nodiff nodiff D6Mit374 nodiff nodiff D6Mit374 nodiff nodiff D6Mit374 nodiff novel D6Mit374 nodiff nodiff D6Mit374 nodiff nodiff D6Mit374 nodiff nodiff
0 D7Mit21 balbc and B6balbc and B6D7Mit21 balbc and B6balbc and B6D7Mit21 balbc and B6balbc and B6 D7Mit21 Balbc and B6Balbc and B6D7Mit21 Balbc and B6Balbc and B6D7Mit21 balbc and B6balbc and B6D7Mit21 balbc and B6balbc and B6
6 D7Mit294 Balbcb Balbcb D7Mit294 Balbca and B6Balbcb D7Mit294 Balbcb Balbcb D7Mit294 B6 Balbcb D7Mit294 Balbcb Balbcb D7Mit294 B6 Balbcb D7Mit294 B6 Balbcb
16 D7Mit228 Balbc Balbc D7Mit228 Balbc Balbc D7Mit228 Balbc Balbc D7Mit228 Balbc Balbc D7Mit228 Balbc Balbc D7Mit228 Balbc Balbc D7Mit228 Balbc Balbc
25 D7Mit83 Balbcb Balbca D7Mit83 Balbcb Balbca D7Mit83 Balbcb Balbca D7Mit83 Balbcb Balbca D7Mit83 Balbcb Balbca D7Mit83 Balbcb Balbca D7Mit83 Balbcb Balbca
26 D7Mit248 Balbc Balbc D7Mit248 Balbc Balbc D7Mit248 Balbc Balbc D7Mit248 Balbc Balbc D7Mit248 Balbc Balbc D7Mit248 Balbc Balbc D7Mit248 Balbc Balbc
31 D7Mit350 Balbc Balbc D7Mit350 Balbc Balbc D7Mit350 Balbc Balbc D7Mit350 Balbc Balbc D7Mit350 Balbc Balbc D7Mit350 Balbc Balbc D7Mit350 Balbc Balbc
37 D7Mit323 Balbc Balbc D7Mit323 balbc B6 D7Mit323 balbc balbc D7Mit323 ? Balbc D7Mit323 Balbc Balbc a D7Mit323 balbc balbc D7Mit323 balbc balbc a
46 D7Mit101 Balbc Balbc D7Mit101 Balbc Balbc D7Mit101 Balbc Balbc D7Mit101 Balbc B6 D7Mit101 Balbc B6 D7Mit101 Balbc Balbc D7Mit101 Balbc B6
53 D7MIt98 Balbc Balbc D7MIt98 Balbc Balbc D7MIt98 Balbc Balbc D7MIt98 Balbc B6 D7MIt98 Balbc Balbc D7MIt98 Balbc Balbc D7MIt98 Balbc B6
62 D7Mit109 somecgrag2somecgrag2D7Mit109 somecgrag2somecgrag2D7Mit109 somecgrag2somecgrag2 D7Mit109 somecgrag2somecgrag2 D7Mit109 somecgrag2somecgrag2 D7Mit109 somecgrag2somecgrag2 D7Mit109 somecgrag2somecgrag2
68 D7Mit223 Balbcb Balbcb D7Mit223 Balbcb Balbcb D7Mit223 Balbcb Balbcb D7Mit223 Balbcb Balbcb D7Mit223 Balbcb Balbc D7Mit223 Balbcb Balbcb D7Mit223 Balbcb Balbcb
68 D7Mit259 somecgrag2somecgrag2D7Mit259 somecgrag2somecgrag2D7Mit259 somecgrag2somecgrag2 D7Mit259 somecgrag2somecgrag2 D7Mit259 somecgrag2somecgrag2 D7Mit259 somecgrag2asomecgrag2D7Mit259 somecgrag2129Sv
0 D8Mit155 Balbc Balbcb D8Mit155 Balbc Balbcb D8Mit155 Balbc Balbcb D8Mit155 Balbc Balbcb D8Mit155 Balbc Balbcb D8Mit155 Balbc Balbcb D8Mit155 Balbc Balbcb
3 D8Mit63 Balbca Balbcb D8Mit63 Balbca Balbca D8Mit63 Balbca Balbcb D8Mit63 Balbca Balbc D8Mit63 Balbca Balbc D8Mit63 Balbca Balbc D8Mit63 Balbca Balbcb
4 D8MIT124 Balbc Balbc D8MIT124 Balbc Balbc D8MIT124 Balbc Balbc D8MIT124 Balbc Balbc D8MIT124 Balbc Balbc D8MIT124 Balbc Balbc D8MIT124 Balbc Balbc
9 D8Mit289 Balbc Balbc D8Mit289 somecgrag2Balbc D8Mit289 Balbc Balbc D8Mit289 Balbc Balbc D8Mit289 Balbc Balbc D8Mit289 Balbc Balbc D8Mit289 Balbc Balbc
20 D8Mit292 somecgrag2somecgrag2D8Mit292 somecgrag2Balbca D8Mit292 somecgrag2Balbca D8Mit292 somecgrag2 B6 D8Mit292 somecgrag2somecgrag2 D8Mit292 somecgrag2somecgrag2 D8Mit292 somecgrag2B6
25 D8Mit339 Balbc Balbc D8Mit339 Balbc Balbc D8Mit339 Balbc Balbc D8Mit339 Balbc Balbc D8Mit339 Balbc Balbc D8Mit339 Balbc Balbc D8Mit339 Balbc ?
30 D8Mit46 Balbc Balbc D8Mit46 Balbc Balbc D8Mit46 Balbc Balbc D8Mit46 Balbc Balbc D8Mit46 Balbc Balbc D8Mit46 Balbc Balbc D8Mit46 Balbc Balbc
35 D8Mit178 Balbc Balbc D8Mit178 Balbc Balbc D8Mit178 Balbc Balbc D8Mit178 Balbc Balbc D8Mit178 Balbc Balbc D8Mit178 Balbc Balbc D8Mit178 Balbc Balbc
40 D8Mit45 118 118 D8Mit45 118 118 D8Mit45 118 118 D8Mit45 118 118 D8Mit45 118 118 D8Mit45 118 118 D8Mit45 98 118
50 D8Mit211 Balbca Balbcb D8Mit211 Balbca Balbcb D8Mit211 Balbca Balbcb D8Mit211 B6 Balbcb D8Mit211 B6 Balbcb D8Mit211 Balbcb Balbcb D8Mit211 Balbca Balbcb
56 D8Mit112 Balbcb Balbcb D8Mit112 Balbcb Balbcb D8Mit112 Balbcb Balbcb D8Mit112 Balbca Balbcb D8Mit112 Balbca Balbcb D8Mit112 Balbca Balbcb D8Mit112 Balbca Balbcb
56 D8Mit47 Balbc Balbc D8Mit47 D8Mit47 Balbc Balbc D8Mit47 Balbc Balbc D8Mit47 (Leer) (Leer) D8Mit47 D8Mit47 Balbc Balbc
69 D8Mit49 D8Mit49 B6a Balbc D8Mit49 B6a Balbc D8Mit49 B6a Balbc D8Mit49 B6a Balbc D8Mit49 Balbc Balbc D8Mit49
71 D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b D8Mit92 nodiff a nodiff b
2 D9Mit250 Balbc and B6Balbc and B6D9Mit250 Balbc and B6Balbc and B6D9Mit250 Balbc and B6Balbc and B6 D9Mit250Balbc and B6Balbc and B6D9Mit250Balbc and B6Balbc and B6D9Mit250 Balbc and B6Balbc and B6D9Mit250 Balbc and B6Balbc and B6
8 D9Mit90 Balbc Balbc D9Mit90 Balbc Balbc D9Mit90 Balbc Balbc D9Mit90 Balbc Balbc D9Mit90 Balbc novel D9Mit90 Balbc Balbc D9Mit90 Balbc Balbc
13 D9Mit2 Balbc Balbc D9Mit2 Balbc Balbc D9Mit2 Balbc Balbc D9Mit2 Balbc Balbc D9Mit2 B6 Balbc D9Mit2 Balbc Balbc D9Mit2 Balbc Balbc
16 D9Mit285 Balbc Balbc D9Mit285 Balbc Balbc D9Mit285 Balbc Balbc D9Mit285 Balbc Balbc D9Mit285 novel Balbc D9Mit285 Balbc Balbc D9Mit285 Balbc Balbc
21 D9Mit129 Balbc b Balbc b D9Mit129 Balbc b Balbc b D9Mit129 Balbc b Balbc b D9Mit129 Balbc b Balbc b D9Mit129 Balbc b Balbc b D9Mit129 Balbc b Balbc b D9Mit129 Balbc b Balbc b
24 D9Mit97 balbc balbc D9Mit97 balbc balbc D9Mit97 balbc balbc D9Mit97 Balbc Balbc D9Mit97 Balbc Balbc D9Mit97 balbc balbc D9Mit97 balbc balbc
34 D9Mit336 Balbc Balbc D9Mit336 Balbc Balbc D9Mit336 Balbc Balbc D9Mit336 Balbc Balbc D9Mit336 Balbc B6a D9Mit336 Balbc B6a D9Mit336 Balbc Balbc
49 D9Mit355 Balbc Balbc D9Mit355 Balbc Balbc D9Mit355 Balbc Balbc D9Mit355 Balbc Balbc D9Mit355 Balbc Balbc D9Mit355 Balbc Balbc D9Mit355 Balbc Balbc
63 D9Mit201 Balbc Balbc D9Mit201 Balbc Balbc D9Mit201 Balbc Balbc D9Mit201 Balbc Balbc D9Mit201 Balbc 130 D9Mit201 Balbc 130 D9Mit201 Balbc 130
70 D9Mit151 Balbc Balbc D9Mit151 Balbc Balbc D9Mit151 Balbc Balbc D9Mit151 Balbc Balbc D9Mit151 Balbc Balbc D9Mit151 Balbc Balbc D9Mit151 Balbc Balbc
7 D10Mit213 Balbc Balbc D10Mit213 Balbc Balbc D10Mit213 Balbc Balbc D10Mit213 Balbc Balbc D10Mit213 Balbc Balbc D10Mit213 Balbc Balbc D10Mit213 Balbc Balbc
12 D10Mit86 Balbc a Balbc a D10Mit86 Balbc a Balbc a D10Mit86 Balbc a Balbc a D10Mit86 Balbc a Balbc a D10Mit86 Balbc a Balbc a D10Mit86 Balbc a Balbc a D10Mit86 Balbc a Balbc a
21 D10Mit38 cgrag2 and B6 161 D10Mit38 cgrag2 and B6 161 D10Mit38 cgrag2 and B6 161 D10Mit38cgrag2 and B6 161 D10Mit38cgrag2 and B6 ? D10Mit38 cgrag2 and B6cgrag2 and B6D10Mit38 cgrag2 and B6cgrag2 and B6
25 D10Mit20 Balbc B6 D10Mit20 Balbc B6 D10Mit20 Balbc B6 D10Mit20 Balbc B6 D10Mit20 Balbc Balbc D10Mit20 Balbc Balbc D10Mit20 Balbc Balbc
31 D10Mit31 cgrag2b cgrag2b D10Mit31 cgrag2b cgrag2b D10Mit31 cgrag2b cgrag2b D10Mit31 cgrag2b cgrag2b D10Mit31 cgrag2b cgrag2b D10Mit31 cgrag2b cgrag2b D10Mit31 cgrag2b cgrag2b
40 D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff D10Mit207 nodiff nodiff
47 D10Mit230 Balbca Balbcb D10Mit230 Balbca Balbcb D10Mit230 Balbca Balbcb D10Mit230 Balbca Balbcb D10Mit230 Balbca Balbcb D10Mit230 Balbca Balbcb D10Mit230 Balbca Balbcb
50 D10Mit95 Balbc Balbc D10Mit95 Balbc Balbc D10Mit95 Balbc Balbc D10Mit95 Balbc Balbc D10Mit95 Balbc Balbc D10Mit95 Balbc Balbc D10Mit95 Balbc Balbc
63 D10Mit233 Balbc Balbc D10Mit233 Balbc Balbc D10Mit233 Balbc Balbc D10Mit233 B6 Balbc D10Mit233 Balbc Balbc D10Mit233 Balbc Balbc D10Mit233 Balbc Balbc
70 D10Mit14 Balbc Balbc D10Mit14 Balbc Balbc D10Mit14 166 Balbc D10Mit14 Balbc Balbc D10Mit14 Balbc B6 D10Mit14 Balbc Balbc D10Mit14 Balbc B6
77 D10Mit103 Balbca Balbcb D10Mit103 Balbca Balbcb D10Mit103 Balbca Balbcb D10Mit103 Balbca Balbcb D10Mit103 Balbca B6 D10Mit103 Balbca Balbcb D10Mit103 Balbca Balbca
0 D11Mit71 Balbc Balbc D11Mit71 Balbc Balbc D11Mit71 Balbc Balbc D11Mit71 ? ? D11Mit71 Balbc Balbc D11Mit71 Balbc Balbc D11Mit71 189 Balbc
4 D11Mit2 Balbc Balbc D11Mit2 Balbc Balbc D11Mit2 Balbc Balbc D11Mit2 Balbc B6 D11Mit2 Balbc Balbc D11Mit2 Balbc Balbc D11Mit2 Balbc B6
14 D11Mit186 121 Balbc D11Mit186 Balbc Balbc D11Mit186 121 Balbc D11Mit186 B6 Balbc D11Mit186 Balbc Balbc D11Mit186 Balbc Balbc D11Mit186 B6 Balbc
21 D11Mit189 somecgrag2somecgrag2D11Mit189 somecgrag2Balbc D11Mit189 somecgrag2Balbc D11Mit189 ? B6 D11Mit189 B6 somecgrag2 D11Mit189 somecgrag2somecgrag2D11Mit189 somecgrag2somecgrag2
25 D11Mit86 Balbca Balbcb D11Mit86 Balbca Balbcb D11Mit86 Balbca Balbcb D11Mit86 Balbca Balbcb D11Mit86 Balbca Balbcb D11Mit86 Balbca Balbca D11Mit86 B6 Balbca
30 D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff D11Mit143 nodiff nodiff
36 D11Mit4 Balbc Balbc D11Mit4 Balbc Balbc D11Mit4 Balbc Balbc D11Mit4 Balbc B6 D11Mit4 Balbc B6 D11Mit4 Balbc Balbc D11Mit4 Balbc B6
45 D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff D11Mit326 nodiff nodiff
49 D11Mit285 Balbc Balbc D11Mit285 Balbc Balbc D11Mit285 Balbc Balbc D11Mit285 B6 Balbc D11Mit285 B6 Balbc D11Mit285 Balbc Balbc D11Mit285 B6 Balbc
70 D11Mit333 Balbc Balbc D11Mit333 Balbc Balbc D11Mit333 117 117 D11Mit333 Balbc Balbc D11Mit333 Balbc Balbc D11Mit333 Balbc Balbc D11Mit333 Balbc Balbc
2 D12Mit182 Balbc Balbc D12Mit182 Balbc Balbc D12Mit182 Balbc Balbc D12Mit182 Balbc Balbc D12Mit182 Balbc Balbc D12Mit182 Balbc Balbc D12Mit182 Balbc Balbc
6 D12Mit11 Balbc Balbc D12Mit11 Balbc Balbc D12Mit11 Balbc Balbc D12Mit11 Balbc novel D12Mit11 Balbc Balbc D12Mit11 Balbc Balbc D12Mit11 Balbc Balbc
10 D12Mit59 somecgrag2Balbc D12Mit59 somecgrag2Balbc D12Mit59 somecgrag2Balbc D12Mit59 somecgrag2 Balbc D12Mit59 somecgrag2 Balbc D12Mit59 somecgrag2Balbc D12Mit59 Balbc somecgrag2
20 D12Mit285 Balbc Balbc D12Mit285 Balbc Balbc D12Mit285 Balbc Balbc D12Mit285 Balbc Balbc D12Mit285 Balbc Balbc D12Mit285 Balbc Balbc D12Mit285 Balbca Balbc
23 D12Mit91 Balbc Balbc D12Mit91 Balbc Balbc D12Mit91 Balbc Balbc D12Mit91 somecgrag2 Balbc D12Mit91 somecgrag2 Balbc D12Mit91 somecgrag2Balbc D12Mit91 Balbc Balbc
30 D12MIt143Balbc Balbc D12MIt143Balbc Balbc D12MIt143Balbc Balbc D12MIt143 Balbc Balbc D12MIt143 Balbc Balbc D12MIt143Balbc Balbc D12MIt143Balbc Balbc
33 D12Mit158 Balbc Balbc D12Mit158 Balbc Balbc D12Mit158 Balbc Balbc D12Mit158 Balbc Balbc D12Mit158 Balbc Balbc D12Mit158 Balbc Balbc D12Mit158 Balbc Balbc
45 D12Mit7 Balbc balbc a D12Mit7 Balbc balbc a D12Mit7 Balbc balbc a D12Mit7 novel B6 D12Mit7 B6 Balbc D12Mit7 novel Balbc D12Mit7 Balbc Balbc
2 D13Mit56 Balbc and B6Balbc and B6D13Mit56 Balbc and B6Balbc and B6D13Mit56 D13Mit56Balbc and B6Balbc and B6D13Mit56Balbc and B6Balbc and B6D13Mit56Balbc and B6Balbc and B6D13Mit56 Balbc and B6?
8 D13Mit275 Balbc Balbc D13Mit275 Balbc Balbc D13Mit275 Balbc Balbc D13Mit275 Balbc Balbc D13Mit275 Balbc Balbc D13Mit275 Balbc Balbc D13Mit275 Balbc Balbc
13 D13Mit88 Balbcb Balbca D13Mit88 Balbcb Balbca D13Mit88 Balbcb Balbca D13Mit88 Balbcb Balbca D13Mit88 Balbcb Balbca D13Mit88 Balbcb Balbca D13Mit88 Balbcb Balbca
14 D13Mit19 Balbc Balbc D13Mit19 Balbc Balbc D13Mit19 Balbc Balbc D13Mit19 somecgrag2 Balbc D13Mit19 Balbc Balbc D13Mit19 Balbc Balbc D13Mit19 somecgrag2Balbc
40 D13Mit213 Balbc Balbc D13Mit213 Balbc Balbc D13Mit213 Balbc Balbc D13Mit213 Balbc Balbc D13Mit213 Balbc Balbc D13Mit213 Balbc Balbc D13Mit213 Balbc Balbc
50 D13Mit151 Balbc Balbc D13Mit151 Balbc Balbc D13Mit151 Balbc Balbc D13Mit151 Balbc Balbc D13Mit151 Balbc Balbc D13Mit151 Balbc Balbc D13Mit151 Balbc Balbc
59 D13Mit78 Balbc Balbc D13Mit78 Balbc Balbc D13Mit78 Balbc Balbc D13Mit78 Balbc B6 D13Mit78 Balbc Balbc D13Mit78 Balbc Balbc D13Mit78 Balbc Balbc
0 D14Mit48 Balbc Balbc D14Mit48 Balbc Balbc D14Mit48 Balbc Balbc D14Mit48 Balbc B6 D14Mit48 Balbc Balbc D14Mit48 Balbc B6 D14Mit48 Balbc B6
1 D14Mit40 Balbcb Balbcb D14Mit40 Balbcb Balbcb D14Mit40 Balbcb Balbcb D14Mit40 Balbcb Balbcb D14Mit40 Balbcb Balbcb D14Mit40 Balbcb Balbcb D14Mit40 Balbcb Balbcb
7 D14Mit126 Balbcb Balbcb D14Mit126 Balbcb Balbcb D14Mit126 Balbcb Balbcb D14Mit126 Balbcb Balbcb D14Mit126 Balbcb Balbcb D14Mit126 Balbcb Balbcb D14Mit126 Balbcb Balbcb
16 D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc D14Mit127 Balbc Balbc
16 D14Mit44 Balbcb Balbcb D14Mit44 Balbcb Balbcb D14Mit44 Balbcb Balbcb D14Mit44 Balbcb Balbcb D14Mit44 Balbcb Balbcb D14Mit44 Balbcb Balbcb D14Mit44 Balbcb Balbcb
18 D14Mit174 Balbca and B6Balbcb D14Mit174 Balbcb Balbcb D14Mit174 Balbca and B6Balbca and B6 D14Mit174Balbca and B6Balbca and B6D14Mit174Balbca and B6 Balbcb D14Mit174 Balbcb Balbcb D14Mit174 Balbcb Balbcb
24 D14Mit60 Balbc Balbc D14Mit60 Balbc Balbc D14Mit60 Balbc Balbc D14Mit60 Balbc Balbc D14Mit60 Balbc Balbc D14Mit60 Balbc Balbc D14Mit60 Balbc Balbc
32 D14Mit5 Balbca and B6Balbca and B6D14Mit5 Balbca and B6Balbca and B6D14Mit5 Balbca and B6Balbca and B6 D14Mit5 Balbca and B6Balbca and B6D14Mit5 Balbca and B6Balbca and B6D14Mit5 Balbca and B6Balbca and B6D14Mit5 Balbcb Balbcb
53 D14Mit263 Balbc Balbc D14Mit263 Balbc Balbc D14Mit263 Balbc Balbc D14Mit263 Balbc Balbc D14Mit263 Balbc Balbc D14Mit263 Balbc Balbc D14Mit263 Balbc Balbc
70 D14Mit170 balbca balbca D14Mit170 balbca balbca D14Mit170 balbca balbca D14Mit170 B6 Balbca D14Mit170 B6 Balbca D14Mit170 balbca balbca D14Mit170 balbca balbca
4 D15Mit80 somecgrag2somecgrag2D15Mit80 somecgrag2somecgrag2D15Mit80 somecgrag2somecgrag2 D15Mit80 evB6 somecgrag2 D15Mit80 somecgrag2somecgrag2 D15Mit80 somecgrag2somecgrag2 D15Mit80 somecgrag2somecgrag2
10 D15Mit252 Balbc Balbc D15Mit252 Balbc Balbc D15Mit252 Balbc Balbc D15Mit252 Balbc B6 D15Mit252 Balbc Balbc D15Mit252 Balbc Balbc D15Mit252 Balbc Balbc
30 D15Mit67 Balbc and B6Balbc and B6D15Mit67 Balbc and B6Balbc and B6D15Mit67 Balbc and B6Balbc and B6 D15Mit67Balbc and B6Balbc and B6D15Mit67Balbc and B6Balbc and B6D15Mit67Balbc and B6Balbc and B6D15Mit67 Balbc and B6Balbc and B6
35 D15Mit70 137 137 D15Mit70 137 137 D15Mit70 137 137 D15Mit70 Balbc B6 D15Mit70 Balbc Balbc D15Mit70 Balbc Balbc D15Mit70 137 137
42 D15Mit107 somecgrag2Balbc D15Mit107 Balbc Balbc D15Mit107 somecgrag2Balbc D15Mit107somecgrag2 novel a D15Mit107 Balbc Balbc D15Mit107 Balbc Balbc D15Mit107 Balbc Balbc
46 D15Mit262 Balbc Balbc D15Mit262 Balbc Balbc D15Mit262 Balbc Balbc D15Mit262 Balbc B6 D15Mit262 Balbc Balbc D15Mit262 Balbc Balbc D15Mit262 Balbc Balbc
49 D15Mit159 Balbc Balbc D15Mit159 Balbc Balbc D15Mit159 Balbc Balbc D15Mit159 Balbc novel D15Mit159 Balbc Balbc D15Mit159 Balbc Balbc D15Mit159 Balbc Balbc
54 D15Mit242 Balbc Balbc D15Mit242 Balbc Balbc D15Mit242 Balbc Balbc D15Mit242 Balbc B6 D15Mit242 Balbc Balbc D15Mit242 Balbc Balbc D15Mit242 Balbc Balbc
7 D16Mit131 B6 Balbc D16Mit131 B6 Balbc D16Mit131 B6 Balbc D16Mit131 B6 Balbc D16Mit131 B6 Balbc D16Mit131 Balbc Balbc D16Mit131 Balbc Balbc
18 D16Mit101 cgrag2b and B6cgrag2b and B6D1 Mit101 cgrag2b and B6cgrag2b and B6D16Mit101 cgrag2b and B6cgrag2b and B6 D16Mit101cgrag2b and B6cgrag2b and B6D16Mit101cgrag2b and B6cgrag2b and B6D16Mit101 cgrag2b and B6cgrag2b and B6D1 Mit101 cgrag2b and B6cgrag2b and B6
24 D16Mit60 Balbc Balbc D16Mit60 Balbc Balbc D16Mit60 Balbc Balbc D16Mit60 B6 B6 D16Mit60 B6 Balbc D16Mit60 B6 B6 D16Mit60 B6 B6
40 D16Mit189 Balbc 188 D16Mit189 188 Balbc D16Mit189 188 Balbc D16Mit189 188 Balbc D16Mit189 Balbc Balbc D16Mit189 Balbc Balbc D16Mit189 Balbc 188
46 D16Mit153 Balbc Balbc D16Mit153 Balbc Balbc D16Mit153 Balbc Balbc D16Mit153 Balbc Balbc D16Mit153 Balbc novel D16Mit153 Balbc Balbc D16Mit153 Balbc Balbc
51 D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff D16Mit52 nodiff nodiff
51 D16Mit86 Balbc Balbc D16Mit86 Balbc Balbc D16Mit86 Balbc Balbc D16Mit86 Balbc Balbc D16Mit86 Balbc Balbc D16Mit86 Balbc Balbc D16Mit86 Balbc Balbc
84 D17Mit245 somecgrag2somecgrag2D17Mit245 somecgrag2somecgrag2D17Mit245 somecgrag2somecgrag2 D17Mit245 B6 somecgrag2 D17Mit245somecgrag2somecgrag2 D17Mit245 somecgrag2somecgrag2D17Mit245 somecgrag2somecgrag2
95 D17Mit180 Balbc Balbc D17Mit180 Balbc Balbc D17Mit180 Balbc Balbc D17Mit180 Balbc Balbc D17Mit180 Balbc Balbc D17Mit180 Balbc Balbc D17Mit180 Balbc Balbc
110 D17Mit39 Balbc Balbc D17Mit39 Balbc Balbc D17Mit39 Balbc Balbc D17Mit39 Balbc Balbc D17Mit39 Balbc Balbc D17Mit39 Balbc Balbc D17Mit39 Balbc Balbc
121 D17Mit143 Balbc Balbc D17Mit143 Balbc Balbc D17Mit143 Balbc Balbc D17Mit143 Balbc Balbc D17Mit143 Balbc Balbc D17Mit143 Balbc Balbc D17Mit143 Balbc Balbc
129 D17Mit81 Balbcb Balbcb D17Mit81 Balbc a Balbcb D17Mit81 Balbcb Balbcb D17Mit81 Balbcb B6 D17Mit81 Balbcb Balbcb D17Mit81 Balbcb Balbcb D17Mit81 Balbcb B6
160 D17Mit51 Balbc Balbc D17Mit51 Balbc Balbc D17Mit51 Balbc Balbc D17Mit51 Balbc B6a D17Mit51 Balbc Balbc D17Mit51 Balbc Balbc D17Mit51 Balbc B6a
186 D17Mit20 Balbc Balbc D17Mit20 Balbc Balbc D17Mit20 Balbc Balbc D17Mit20 Balbc Balbc D17Mit20 Balbc Balbc D17Mit20 Balbc Balbc D17Mit20 Balbc Balbc
226 D17Mit1 Balbc Balbc D17Mit1 Balbc Balbc D17Mit1 Balbc Balbc D17Mit1 Balbc Balbc D17Mit1 Balbc Balbc D17Mit1 Balbc Balbc D17Mit1 Balbc B6
0 D18Mit64 Balbc Balbc D18Mit64 Balbc Balbc D18Mit64 Balbc Balbc D18Mit64 Balbc Balbc D18Mit64 Balbc Balbc D18Mit64 Balbc Balbc D18Mit64 Balbc Balbc
4 D18Mit222 Balbc Balbca D18Mit222 Balbc Balbc D18Mit222 Balbc Balbca D18Mit222 Balbc Balbca D18Mit222 Balbc Balbc D18Mit222 Balbc Balbca D18Mit222 Balbc Balbca
10 D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff D18Mit12 nodiff nodiff
14 D18Mit177 Balbc Balbc D18Mit177 Balbc Balbc D18Mit177 Balbc Balbc D18Mit177 Balbc Balbc D18Mit177 Balbc Balbc D18Mit177 Balbc Balbc D18Mit177 Balbc Balbc
14 D18Mit194 Balbc Balbc D18Mit194 Balbc Balbc D18Mit194 ? ? D18Mit194 Balbc Balbc D18Mit194 Balbc Balbc D18Mit194 Balbc Balbc D18Mit194 Balbc Balbc
24 D18Mit208 Balbc Balbc D18Mit208 Balbc Balbc D18Mit208 Balbc Balbc D18Mit208 Balbc Balbc D18Mit208 Balbc Balbc D18Mit208 Balbc Balbc D18Mit208 Balbc Balbc
31 D18Mit186 Balbcb Balbcb D18Mit186 Balbcb Balbcb D18Mit186 Balbcb Balbcb D18Mit186 Balbcb Balbcb D18Mit186 Balbcb Balbcb D18Mit186 Balbcb Balbcb D18Mit186 Balbcb Balbcb
35 D18Mit48 Balbc and B6Balbc and B6D18Mit48 Balbc and B6Balbc and B6D18Mit48 Balbc and B6Balbc and B6 D18Mit48Balbc and B6 Balbca D18Mit48Balbc and B6Balbc and B6D18Mit48 Balbc and B6Balbc and B6D18Mit48 Balbc and B6Balbc and B6
3 D19Mit68 Balbc Balbc D19Mit68 Balbc Balbc D19Mit68 Balbc Balbc D19Mit68 Balbc B6 D19Mit68 Balbc B6 D19Mit68 Balbc Balbc D19Mit68 Balbc B6
10 D19Mit28 Balbca Balbca D19Mit28 Balbca Balbca D19Mit28 Balbca Balbca D19Mit28 B6 Balbca D19Mit28 B6 Balbca D19Mit28 Balbca Balbca D19Mit28 B6 Balbca
24 D19Mit88 Balbc Balbc D19Mit88 Balbc Balbc D19Mit88 Balbc Balbc D19Mit88 novel Balbc D19Mit88 novel Balbc D19Mit88 novel Balbc D19Mit88 Balbc Balbc
28 D19Mit90 Balbc Balbc D19Mit90 Balbc Balbc D19Mit90 Balbc Balbc D19Mit90 Balbc 132 D19Mit90 Balbc 132 D19Mit90 Balbc Balbc D19Mit90 Balbc Balbc
38 D19Mit26 Balbc Balbc D19Mit26 Balbc Balbc D19Mit26 Balbc Balbc D19Mit26 B6 Balbc D19Mit26 Balbc Balbc D19Mit26 B6 Balbc D19Mit26 Balbc Balbc
40 D19Mit103 Balbc Balbc D19Mit103 Balbc Balbc D19Mit103 Balbc Balbc D19Mit103 B6 Balbc D19Mit103 B6 Balbc D19Mit103 B6 Balbc D19Mit103 Balbc Balbc
46 D19Mit33 Balbc Balbc D19Mit33 Balbc Balbc D19Mit33 Balbc Balbc D19Mit33 Balbc Balbc D19Mit33 Balbc Balbc D19Mit33 Balbc Balbc D19Mit33 Balbc Balbc
56 D19Mit347 Balbc Balbc D19Mit347 Balbc Balbc D19Mit347 Balbc Balbc D19Mit347 Balbc Balbc D19Mit347 Balbc Balbc D19Mit347 novel Balbc D19Mit347 novel Balbc
58 D19Mit6 Balbc specBalbc spec D19Mit6 Balbc specBalbc spec D19Mit6 Balbc specBalbc spec D19Mit6 Balbc novel D19Mit6 novel Balbc spec D19Mit6 Balbc Balbc D19Mit6 Balbc Balbc
9 DXMit81 nodiff nodiff DXMit81 nodiff nodiff DXMit81 nodiff nodiff DXMit81 nodiff nodiff DXMit81 nodiff nodiff DXMit81 nodiff nodiff DXMit81 nodiff nodiff
45 DXMit64 nodiff nodiff DXMit64 nodiff nodiff DXMit64 nodiff nodiff DXMit64 nodiff nodiff DXMit64 nodiff nodiff DXMit64 nodiff nodiff DXMit64 nodiff nodiff
49 DXMit172 Balbc Balbc DXMit172 Balbc Balbc DXMit172 Balbc Balbc DXMit172 Balbc Balbc DXMit172 Balbc Balbc DXMit172 Balbc Balbc DXMit172 Balbc Balbc
60 DXMit132 cgrag2 cgrag2 DXMit132 cgrag2 cgrag2 DXMit132 cgrag2 cgrag2 DXMit132 cgrag2 cgrag2 DXMit132 cgrag2 cgrag2 DXMit132 cgrag2 cgrag2 DXMit132 cgrag2 cgrag2
63 DXMit216 Balbc a Balbc DXMit216 Balbc a Balbc DXMit216 Balbc a Balbc DXMit216 Balbc Balbc DXMit216 Balbc a Balbc DXMit216 Balbc a Balbc DXMit216 Balbc a Balbc
67 DXMit121 nodiff nodiff DXMit121 nodiff nodiff DXMit121 nodiff nodiff DXMit121 nodiff nodiff DXMit121 nodiff nodiff DXMit121 nodiff nodiff DXMit121 nodiff nodiff
73 DXMit223 Balbc Balbc DXMit223 Balbc Balbc DXMit223 Balbc Balbc DXMit223 Balbc Balbc DXMit223 Balbc Balbc DXMit223 Balbc Balbc DXMit223 Balbc Balbc
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Figure 3.6.: Backcrossed strains.
The first column shows littermates out of a breeding between multiply marker-
evaluated backcrossed Rag2−/−Il2rg−/−Prnp+/− parents. A large proportion
of the markers correspond to the initial Rag2−/−Il2rg−/− indicated in yellow
and depicted in Figure 3.5. No remarkable difference between Prnp genotypes
can be detected in this medium-resolution setup.
The second column shows a gradual outcrossing of unfavorable markers in mice
carrying the human PRNP transgene on an immunodeficient background: the
left mouse still possesses a fair quantity of blue and red alleles whilst they are
gradually eliminated in further breeding generations. For comparison to the
original TgPRNP129M constellation, refer to Figure 3.5
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3.2. Enrichment of human umbilical cord blood CD34+ hematopoietic stem
cells
Despite logistical and other obstacles1, we succeeded in collecting more than 100 samples
from various donors and succeeded in enriching a copious amount of CD34+ stem cells.
Usually, cells were directly frozen and stored in liquid nitrogen after enrichment and
only thawed when newborn mice were available. The amount of CD34+ cells per sample
varied widely depending on the initial cord blood volume: the best result we obtained
was 6 million stem cells from a twin pregnancy, but in most cases the numbers ranged
between 0.5 to 1.5 million (Figure 3.7).
3.2.1. Sequence analysis for human PRNP polymorphisms in the donor cord blood
The PRNP -ORF of all non target fractions was sequenced. We could observe a distribution
of 15% MV, 83%MM and 2%VV constellation at codon 129 of the reading frame. However,
a correlation between cord blood PRNP constellation and behaviour or susceptibility
proneness of a CJD-PrP inoculum is yet to established in the humanized mouse model.
1Collecting human umbilical cord blood turned out to be one of the most challenging parts of this
work, since many groups in the University Hospital Zurich seemed to be interested in physiol-
ogy/pathology/embryology of the placenta and associated structures. Fortunately we had a very good
support from people in the obstetrics department who were willing to provide me with samples during
the weekend or on their nightshifts, so we could escape the routine of most other research groups
with the drawback of investing a lot of flexibility and patience. Additionally we had great support
from other hospitals (mainly St. Gallen) who provided us with samples. The management of the
informed consent procedure was greatly facilitated after mid 2006 when a general form for “research
purposes” was implemented at the obstetrics department. Before, it was sometimes impossible to
fetch the patient at the right time and location to explain a procedure which imposes no risk at all to
mother and child. In the course of this work, we also tried a 50/50 strategy to provide the newborn
child with half of the enriched sample and store it at our N2 tank if needed whereas the other half
could be used for research purposes: installation of a GMP unit, however, would be very cost- and
labor intensive and we therefore offered this strategy only to a few patients with the clear caveat that
our selected cells would not meet international cord blood banking standards. Research in this field
could be generally made much more easier, if big maternity clinics had standard cord blood banking
units reserving half of the blood for research and the other half for patient care.
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Figure 3.7.: Flowcytometric analysis of enriched CD34+ stem cells (TF) and the
respective non target fractions (NTF).
Illustration of our standard cord blood screening flowcytometric analysis after
MACS-sorting. We assessed the TF and NTF for the absence/presence and
amount of CD34(+) (APC-label, X-axis) and CD3(+)(PE-label, Y-axis) cells.
The lower panel shows the distribution of the CD34(+) cell count as well as the
purity of the samples indicated by CD34(+) and CD3(+) content. Depicted
are samples collected in 2006 and 2007 from various donors (n=100).
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3.3. Reconstition of immunodeficient Prnp−/− mice with allogeneic mouse
bone marrow
It is known that immunodeficient Prnp−/− mice can be engrafted with syngeneic
bone marrow from a syngeneic or allogeneic donor. However, reconstitution efforts
in Rag2−/−Il2rg−/−Prnp−/− have never been performed, and to rule out a possible
implication of Prnp in allografting, we transplanted bone marrow from adult BALB/c
mice intrahepatically into newborn and sublethally irradiated Prnp−/−, Prnp+/− and
Prnp+/+ littermates (newborns were genotyped just after birth). Peripheral blood was
assessed 6 weeks after transplantation for the presence of mouse B-cell markers. All
the littermates showed a positive, stable and equally strong engraftment for a lifelong
duration, indicating that the absence of Prnp in Rag2−/−Il2rg−/− does not influence the
homing of allogeneic cells in a immune-depleted host. Confirmation of the genotypes was
complemented by western blot analysis of perfused brains because PrP-expression from
the grafted cells migth influence the Prnp-genotyping results.
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Figure 3.8.: Reconstitution of immunodeficient mice with mouse bone marrow.
Reconstitution of newborn Rag2−/−Il2rg−/−Prnp−/−, Prnp+/−, Prnp+/+
mice with bone marrow of a wildtype adult BALB/c mouse is equally effec-
tive as indicated by re-expression of the B-cell marker CD19 6 weeks after
reconstitution. To rule out misleading genotyping results by contamination
of donor-related Prnp-expression in tail biopsies we performed immunoblot
analysis of perfused brains confirming the Prnp genotype of the grafted mice.
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3.4. Reconstitution experiments with enriched CD34+ hematopoietic stem
cells from human umbilical cord blood
3.4.1. Reconstitution of Rag2−/−Il2rg−/− mice (BALB/c), prion experiments
Applying the protocol of Traggiai et al.[119], we and others were readily able to reproduce
the engraftment of BALB/c Rag2−/−Il2rg−/− mice with sorted stem cells from human
umbilical cord blood. Assessment of peripheral blood about 6 weeks after transplantation
for human CD45 showed in 50 to 80% of the cases a lymphoid population of human
cells which persisted for a period of about 4-6 months and differentiated mainly into the
B-cell lineage and to a much lesser proportion into T-cells. Analysis of spleen, lymph
nodes and thymus as well as Peyer’s patches reproduced the findings of Traggiai et al.,
yet, a follicular structure of the spleen as depicted in their paper was never observed
to this extent. Nonetheless, the same experiment, when performed by Baenziger and
Heikenwaelder (personal communication) did not work in a C57Bl/10 strain background.
Thus, genetic factors seem to influence the microenvironment for the engraftment of stem
cells although both strains were equally devoid of B-cells, T-cells and NK-cells.
Engraftment success in these mice was directly related to the amount and quality
of the cord blood cells injected. The best values with nearly 100% human cells in the
lymphoid gate were obtained when more than 200’000 fresh cells per mouse were injected;
freezing of the cells did not significantly alter the quality but resulted in a loss of viable
cells, so that fewer mice could be injected.
I will not report here on the results of ongoing prion inoculation experiments in
humanized BALB/c Rag2−/−Il2rg−/−-Prnp+/+ mice, but in the last 2 years, many very
well engrafted mice have been grouped and inoculated intraperitoneally with prions from
sCJD patients, CWD brains and BSE-brains to see whether the human cells in these
mice could replicate those species. These experiments are ongoing and will be dealt with
in more detail in the Discussion section of my thesis.
3.4.2. Reconstitution of backcrossed Rag1−/− Prnp−/− Il2rg−/− and Rag2−/−
Prnp−/− Il2rg−/− mice
The first reconstitution trials in largely mixed Rag1−/− Prnp−/− Il2rg−/− and Rag2−/−
Prnp−/− Il2rg−/− mice were not succesful although reconstitution with the same donor
cord blood could be realised in control immunodeficient BALB/c mice. We never detected
human cell engraftment in mixed Rag1−/− Prnp−/− Il2rg−/− mice and since we had
mice with a much more favorable STR-marker profile, we decided to lay emphasis on the
Rag2−/− line.
As soon as a threshold of about 90% in marker-overlap was achieved, we regained
reconstitutability in our backcrossed mice. Our goal was to have reconstitutable Prnp−/−
mice and therefore one marker-assisted backcrossing cycle (thereby loosing one Prnp-
allele) had to follow intercrossings between Prnp+/− mice with a good STR marker
profile. In breedings between Prnp+/− parents, only 25% of the offsprings were Prnp−/−,
but another experimental approach was not possible.
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Interestingly enough, although nearly optimal in terms of the STR profile, reconsti-
tutability seemed to depend on the Prnp genotype. We observed this phenomenon in
all our breeding strategies, i.e. in the “classical” as well in the “alternative” scheme as
depicted in Figures 3.1 and 3.2. In littermates with an equivalent genetic background,
we found only positive engraftment in the presence of at least one Prnp allele whereas its
absence seemed to abolish reconstitutability (Fig. 3.9).
The distribution and differentiation of the engrafted cells as well as the kinetics of the
process seemed to be identical to those of the mice published by Traggiai [119] as de-
picted in Figures 3.10 and 3.11 although the recovery of a near-intact follicular splenic
architecture compared to non-reconstituted mice was not demonstrated. The survival of
the graft and the relative number of grafted cells related to host cells seemed to depend
on the dosage of Prnp with Prnp+/− animals displaying a shorter graft survival than
Prnp+/+ animals. Most of the engrafted cells homed to the bone marrow where they
resided for a long time whereas detection in peripheral blood peaked around 8-12 weeks
after transplantation.
Prnp-/- Prnp+/- Prnp+/+-/- +/- Prnp+/+
Figure 3.9.: Prnp-dependent reconstitutability.
Littermates of a breeding between high-BALB/c or pure BALB/c Prnp+/−
parents showed a Prnp dependent engraftment behaviour. Human-CD45
positive cells 4 weeks after transplantation are only detectable in mice carrying
at least one allele of moPrnp. The effect seems to be gene-dosage dependent
since Prnp+/+ showed a tendency towards higher engraftment compared to
heterozygous littermates.
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3.4.3. Reconstitution of backcrossed Rag2−/− Prnp−/− Il2rg−/−-TgPRNP129M
mice - a transgenic rescue?
Since we also intended to model neuroinvasion more accurately in our model, we back-
crossed our reconstitutable mice with mice expressing the human PRNP as a transgene
as depicted in Fig.3.2b. In parallel, this strategy could also be exploited to evaluate a
possible transgenic rescue effect of the observation that Prnp itself seemed to influence
engraftment capacity of xenogeneic cells in a host mouse. Reconstitutability in immunode-
ficient TgPRNP129M mice carrying at least one copy of mouse Prnp could be established
as far as 90% of the STR marker profile overlapped, yet we failed to detect engrafted cells
in mice devoid of murine Prnp that reexpressed human PRNP as a transgene. Moreover,
we observed a correlation of mouse Prnp expression levels and the number of engrafted
cells, i.e. Prnp heterozygous mice showed less engraftment than Prnp homozygous mice.
Analysis of bone marrow and spleen of reconstituted, backcrossed PRNP+Prnp+ mice
showed an equivalent differentiation status of the engrafted cells compared to the other
mouse strains evaluated. The profile of engrafted cells in bone marrow and peripheral
blood and its histological and immunohistchemical appearance is depicted in Figures 3.10
and 3.11. Of particular interest was the fact that the engrafted cells express PrP and
would therefore theoretically be able to replicate prions as shown in Figure 3.10.
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Figure 3.10.: Flowcytometric analysis of engrafted cells in bone marrow 12 weeks
after transplantation.
Subtype analysis of engrafted human cells in PRNP -Prnp+, PRNP+Prnp+
and PRNP-Prnp- mice. Only live cells are gated. 1 Expression level of
human CD45-APC versus human CD20-PE is plotted. 2 PrP-expression of
cells positive for human CD45-PE is assessed with a Cy5-labeled antibody
against the prion protein (POM2). This antibody binds to mouse and human
PrP indicated by a POM2+fraction in the CD45-PE- quadrant in case of
presence of mouse andor human PrP. 3 The third panel shows expression
of the human stem cell marker CD34, indicating a significant fraction of
human self-renewing cells within the bone marrow. 4 Evidence of a myeloid
differentiation of a small subset of engrafted cells is indicated with staining
against human CD14.58
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Figure 3.11.: Histology of engrafted mice and flowcytomtric readout in periph-
eral blood.
Histological sections of the marrow compartment of spinal vertebrae. H&E
stains show no overt differences in morphology between the various strains
whereas the immunohistochemical stainings with antibodies specific for hu-
man CD45 and human CD20 show the presence of human cells indicated by a
cytoplasmic immunoperoxidase staining reaction in mice carrying at least one
allele of mouse PrP. Expression of a human transgene shows no influence on
engraftment behaviour in the absence of Prnp. No engraftment is detectable
in the absence of Prnp. Scale bar 50µm.
Detection of engrafted human cells in peripheral blood 6 weeks after intra-
hepatic transplantation with antibodies specific for human CD45 and human
CD20.
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3.5. Reconstitution with cultivated and expanded human umbilical cord
blood cells
Based on a collaboration with Dr. R. Peters from the oncology research department,
we initiated as a side project an attempt to economize on CD34+ stem cells using in
vitro expansion of these cells. The motivation behind this was the fact that only a small
number of mice could be produced with one batch of identical cord blood. Because
of advancements in in vitro expansion techniques, however, a significantly increased
number of mice would be injected with genetically identical stem cells, which would
be advantageous for genetic susceptibility studies. Cord blood leukocytes from frozen
samples were cultivated and expanded in cell culture bags or wells and injected into
primarily reconstitutable, sublethally irradiated newborn acceptor mice. In parallel,
enriched CD34+ samples from the same donor were applied in another set of mice. We
achieved an in vitro expansion of up to 20 fold after 3 weeks, yet when we injected these
cells intrahepatically, engraftment behaviour was significantly worse compared to the
primarily enriched fraction. Expansion with cytokines and subsequent CD34-selection
resulted in better engraftment properties, but the expansion technique is cost- and labour
intensive and a reasonable cost-benefit-ratio was not obtained.
3.6. Expression analysis of murine PrP in spleen and bone marrow
subpopulations
To evaluate whether expression of PrP is a prerequisite for homing of human stem cells
into the bone marrow we reevaluated PrP expression in subsets of bone marrow cells using
high affinity antibodies specific to PrP to identify possible cellular mediators for this effect.
This analysis was performed in six different genotypes of age- and sex-matched 3 month
old mice: immunocompetent TgPRNP129M-mice (1), immunodeficient Prnp+/−(2),
Prnp+/+(3), TgPRNP129M(4) and Prnp−/−(5) mice as well as a wildtype control (6).
Cells were co-labeled with respective subset markers and the amount of double positive
cells in the lymphoid, the large lymphoid, the erythroid and the myeloid gate according
to the FSC/SSC clustering was assessed. Interestingly, TgPRNP129M mice did not show
expression of the transgene in the erythroid population whereas we could detect a strong
PrP-expression in this region in all the immunodeficient and wild type mice (Figure
3.12), additionally confirmed by colabeling with the erythroid specific marker ter119. A
strong positivity for PrP was further detected in macrophages (CD11b), granulocytes
(ly6g), CD14-positive cells and B-cell precursors (Early-B and CD43 positive cells) in
the absence of functional B-cells. In the wildtype mouse, we identified B220+PrP+ and
CD19+PrP+ as well as CD3+PrP+ cells confirming previous results. A weaker PrP
staining was observed in CD34+ cells; no PrP expression was detectable in dendritic cells
(CD11c+), regulatory T-cells (CD25+) and Nk cells. A stromal PrP expression in bone
marrow could not be detected (data not shown). To pinpoint strong positivity of PrP
expression in bone marrow, we additionally performed immunoblotting and qRT-PCR
from the same mice and could find consistent evidence for a strong expression of PrP in
total mouse bone marrow isolates (Figure 3.12).
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3.6. Expression analysis of PrP in bone marrow
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Figure 3.12.: Detailed PrP expression analysis in bone marrow subpopulations
by flowcytometry.
Confirmation of PrP expression by qPCR and proof of presence of the protein
by western blot. For further explanation to the figure refer to section 3.6
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3. Results
3.7. SNP and STR mapping of the genetic region between Prnp and Rag
Since PrP itself or a genetic determinant around it seemed to modulate the engraftment
behaviour of human hematopoietic stem cells in immunodeficient mice, we decided to
search for additional genetic markers in the region between Prnp and Rag (a region
spanning over 30 megabases including around 450 known or unknown genes) to map
and delimit the recombination breakpoints more accurately. First, we choose additional
STR markers near Prnp and near Rag from the UniSTS database, second, we selected
single nucleotide polymorphic markers in a 5 Mb interval deciphering this region. Out
of the STR analysis, the markers D2Mit447(128.6 Mb) and D2Mit256(126.4 Mb) were
always linked to the Prnp knockout allele even in multiply backcrossed Rag2−/− Prnp−/−
Il2rg−/− mice to a background very similar to reconstitutable mice, indicating that this
region of the original Prnp- chromosome and its linked genes cosegregate in most if not
all of our backcrossed strains. A linkage to the Prnp- allele was also found in some cases
in D2Mit395(119.3 Mb) and even D2Mit421(104 Mb). Heterozygosity downstream of
D2Mit256 towards Rag2 indicated that multiple meiotic recombination events could have
taken place at various sites.
Our SNP analysis with a spacing of 5 Mb confirmed that markers next to Prnp were
linked to the respective Prnp-BALB/c or 129Sv-allelotype. However, not all of the
applied SNPs were informative in discriminating between 129Sv and BALB/c since they
displayed the same nucleotide conformation (Fig. 3.14). The markers just next to Prnp,
rs13476769(129.7 Mb) and rs13476772(130.6 Mb) were not informative, but the SNPs
rs33314425 (122.3 Mb) and rs13476764 (127.8 Mb) clearly cosegregated in most cases with
the Prnp- allele, which confirmed the additional STR data. The situation in rs33314425
was not in all cases identical since a homozygous “BALB/c” constellation for this marker
was found in some Prnp−/− mice indicating that different recombination events closer
to the Prnp locus had occurred. Interestingly, a marker upstream of Prnp at 138 Mbp,
rs13476802, was only linked to the Prnp- allele in mice from the original backcrossing
strategy (Fig. 3.1) whereas it displayed a “BALB/c” constellation in mice derived from
the alternative breeding strategy starting from multiply backcrossed Prnp−/− mice to
BALB/c (Fig. 3.2).
The identifiers of possible candidate genes that might influence engraftment of human
cells known to have a function assigned to the immune system between Prnp and Rag
are listed in table 3.2.
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3.7. Additional SNP and STR on Chromosome 2
Table 3.2.: Genes putatively involved in the immune system and stem cell
homeostasis between Rag and Prnp.
The transcriptional start position is based on NCBI build 37.1. of mouse
chromosome 2.
Gene start Gene ID Gene name
101518597 Traf6 Tnf receptor-associated factor 6
102651298 Cd44 CD44 antigen
103911167 Cd59b CD59b antigen
103936010 Cd59a CD59a antigen
104839813 Ga17 dendritic cell protein GA17
105516602 Pax6 paired box gene 6
115688805 Mrg1 myeloid ecotropic viral integration site-related gene 1
117937658 Thbs1 thrombospondin 1
119577062 Ltk leukocyte tyrosine kinase
120843953 Epb4.2 erythrocyte protein band 4.2
120967877 Adal adenosine deaminase-like
121973423 B2m beta-2 microglobulin
127458966 Mal myelin and lymphocyte protein, T-cell differentiation protein
129125346 Il1a interleukin 1 alpha
129190315 Il1b interleukin 1 beta
129419314 Sirpa signal-regulatory protein alpha
130121675 Ebf4 early B-cell factor 4
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3. Results
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99383485 99396042 similar to L-lactate dehydrogenase A chain (LDH-A) (LDH muscle subunit) (LDH-M)
99855274 99899445 similar to 39S ribosomal protein L28, mitochondrial precursor (L28mt) (MRP-L28)
100176345 100176952 hypothetical protein LOC100042907
100300293 100301850 similar to pyruvate kinase 3
100466802 100468359 similar to pyruvate kinase 3
101400938 101469143 RIKEN cDNA B230118H07 gene
101464905 101472685 recombination activating gene 2
101478409 101489689 recombination activating gene 1
101518335 101519265 hypothetical protein LOC100042930
101518597 101541133 Tnf receptor-associated factor 6
101555269 101637862 RIKEN cDNA 2600010E01 gene
101672228 101723184 hypothetical protein LOC100043302
101726419 101741796 COMM domain containing 9
101790358 102026534 low density lipoprotein receptor class A domain containing 3
102014417 102015056 similar to 60S ribosomal protein L29
102140276 102241057 tripartite motif-containing 44
102289523 102291949 four jointed box 1 (Drosophila)
102390207 102483194 RIKEN cDNA E430002G05 gene
102498840 102621900 solute carrier family 1 (glial high affinity glutamate transporter), member 2
102651298 102741822 CD44 antigen
102861234 102913668 pyruvate dehydrogenase complex, component X
102913832 102932778 APAF1 interacting protein
103103590 103143353 ets homologous factor
103264234 103291142 E74-like factor 5
103294160 103325277 catalase
103406467 103558580 ankyrin repeat and BTB (POZ) domain containing 2
103561416 103601407 N-acetyltransferase 10
103605176 103637754 cell cycle associated protein 1
103658636 103659822 similar to Trafficking protein particle complex subunit 6B
103677258 103679139 hypothetical protein LOC100042961
103683548 103712698 hypothetical protein LOC100042965
103810380 103822031 LIM domain only 2
103867956 103903394 F-box protein 3
103911167 103925114 CD59b antigen
103936010 103955506 CD59a antigen
103962926 103964903 RIKEN cDNA A930018P22 gene
103983230 104250491 RIKEN cDNA D430041D05 gene
104131648 104151079 similar to glyceraldehyde-3-phosphate dehydrogenase
104269921 104334401 homeodomain interacting protein kinase 3
104377594 104378616 similar to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
104396815 104398718 hypothetical protein LOC668733
104430680 104505582 cleavage stimulation factor, 3' pre-RNA, subunit 3
104520137 104552319 t-complex 11 like 1
104551766 104552931 predicted gene, EG622282
104554083 104556447 predicted gene, OTTMUSG00000014964
104561941 104582958 DEP domain containing 7
104594950 104629781 glutamine and serine rich 1
104629833 104656917 similar to glutamine and serine rich 1
104656991 104659148 RIKEN cDNA 2310047K21 gene
104660315 104662334 similar to TAR DNA-binding protein 43 (TDP-43)
104670898 104689831 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane)
104792061 104839894 coiled-coil domain containing 73
104839813 104857184 dendritic cell protein GA17
104857125 104858164 RIKEN cDNA 2210415I11 gene
104872023 104931454 similar to Acyl carrier protein, mitochondrial precursor (ACP) (NADH-ubiquinone oxidoreductase 9.6 kDa subunit) (CI-SDAP)
104966686 105013771 Wilms tumor homolog
105064501 105219950 RIKEN cDNA 0610012H03 gene
105226105 105239476 reticulocalbin 1
105376237 105510487 Pax6 opposite strand transcript 1
105377748 105395044 similar to QM protein
105516602 105537226 paired box gene 6
105540266 105744657 elongation protein 4 homolog (S. cerevisiae)
105549156 105550255 hypothetical protein LOC100043394
105744795 105805715 IMP1 inner mitochondrial membrane peptidase-like (S. cerevisiae)
105786254 105791147 hypothetical protein LOC100043402
105806874 105843706 DPH4 homolog (JJJ3, S. cerevisiae)
105851661 105909545 similar to doublecortin domain containing 1
106034936 106244223 doublecortin domain containing 5
106307262 106363260 hypothetical protein 9330126M15
106658215 106659689 RIKEN cDNA C130023O10 gene
106766722 106770957 hypothetical protein LOC677260
106802686 106814554 RIKEN cDNA 2700007P21 gene
106851095 106851958 similar to solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3
106896297 106899808 follicle stimulating hormone beta
107130811 107138661 potassium voltage-gated channel, shaker-related subfamily, member 4
108286583 108382726 hypothetical protein LOC100043078
108412747 108413688 similar to Eukaryotic translation initiation factor 2 subunit 1 (Eukaryotic translation initiation factor 2 alpha subunit) (eIF-2-alpha) (EIF-2alpha) (EIF-2A)
108573364 108583168 similar to Phosphoglucomutase-1 (Glucose phosphomutase 1) (PGM 1)
108715028 108715478 similar to ribosomal protein L35a
108788926 108790904 similar to hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit
108932457 109118447 methyltransferase 5 domain containing 1
109120895 109181904 kinesin family member 18A
109514857 109567200 brain derived neurotrophic factor
109632082 109632779 similar to high-mobility group box 1
109731035 109741094 lin-7 homolog C (C. elegans)
109757804 109854414 leucine-rich repeat-containing G protein-coupled receptor 4
109857996 109884805 coiled-coil domain containing 34
110049329 110050323 hypothetical protein LOC668797
110105240 110145882 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 1 (gamma-butyrobetaine hydroxylase)
110201082 110203150 RIKEN cDNA 1110018M03 gene
110258279 110259783 similar to 40S ribosomal protein S3a (V-fos transformation effector protein)
110437456 110487926 solute carrier family 5 (sodium/glucose cotransporter), member 12
110561765 110578120 mucin 15
110790263 110946133 hypothetical protein LOC668802
110974271 110995335 hypothetical LOC623270
111022700 111027635 similar to RB1-inducible coiled-coil 1
111033411 111069755 RIKEN cDNA 4930430A15 gene
111071010 111071948 olfactory receptor 1275
111097274 111098212 olfactory receptor 1276
111109611 111110522 olfactory receptor 1277
111132427 111133368 olfactory receptor 1278
111146358 111147299 olfactory receptor 1279
111155638 111156555 olfactory receptor 1280
111168578 111169495 olfactory receptor 1281
111175316 111176233 olfactory receptor 1282
111208791 111209708 olfactory receptor 1283
111219159 111220094 olfactory receptor 1284
111246681 111248387 hypothetical protein LOC100043465
111248550 111255439 olfactory receptor 1285
111260189 111261106 olfactory receptor 1286
111289299 111290216 olfactory receptor 1287
111318943 111319881 olfactory receptor 1288
111323589 111324485 olfactory receptor 1289
111329375 111330292 olfactory receptor 1290
111339926 111340391 olfactory receptor 1291
111348730 111349668 olfactory receptor 1292, pseudogene 1
111366877 111374674 olfactory receptor 1293
111377506 111378444 olfactory receptor 1294
111404661 111405599 olfactory receptor 1295
111433371 111434168 similar to olfactory receptor Olr768
111461291 111462229 olfactory receptor 1297
111485214 111486152 olfactory receptor 1298
111501610 111505323 olfactory receptor 1299
111531677 111532610 olfactory receptor 1300, pseudogene 1
111594408 111595346 olfactory receptor 1301
111620470 111621417 olfactory receptor 1302
111653943 111654881 olfactory receptor 1303
111663397 111663549 olfactory receptor 249, pseudogene 1
111664933 111691995 similar to olfactory receptor 1303
111713072 111714010 olfactory receptor 1305
111752147 111753085 olfactory receptor 1306
111766586 111774572 similar to SUMO1/sentrin specific protease 1
111784673 111785611 olfactory receptor 1307
111800266 111801228 olfactory receptor 1308
111823291 111824253 olfactory receptor 1309
111840260 111841717 hypothetical LOC433463
111848403 111849341 olfactory receptor 1310
111861071 111862009 olfactory receptor 1311
111882234 111883187 olfactory receptor 1312
111911803 111912738 olfactory receptor 1313
111931918 111932856 olfactory receptor 1314
111950469 111950972 olfactory receptor 1315, pseudogene 1
111970028 111970972 olfactory receptor 1316
111982104 111983054 olfactory receptor 1317
111996110 111997072 olfactory receptor 1318
112007882 112008139 olfactory receptor GA_x5J8B7W3P0G-705890-705633
112050416 112052133 hypothetical protein LOC100043187
112079998 112087268 1-acylglycerol-3-phosphate O-acyltransferase 7 (lysophosphatidic acid acyltransferase, eta)
112088105 112099448 nuclear protein in testis
112102126 112103057 nucleolar protein family A, member 3
112106976 112203313 solute carrier family 12, member 6
112203176 112208184 transmembrane protein 85
112219219 112221966 predicted gene, EG668839
112219368 112254394 RIKEN cDNA 2410042D21 gene
112295182 112307593 RIKEN cDNA 2900064A13 gene
112319328 112320926 cholinergic receptor, muscarinic 5
112333121 112471227 apoptosis, caspase activation inhibitor
112471537 112870488 ryanodine receptor 3
113125889 113137345 RIKEN cDNA 4930563P21 gene
113167893 113556924 formin 1
113588832 113598803 gremlin 1
113595659 113598805 hypothetical protein LOC100043520
113616470 113669248 secretogranin V
113671649 113688818 Rho GTPase activating protein 11A
113671652 113673136 similar to DNA directed RNA polymerase II polypeptide A
113835337 113839355 gap junction membrane channel protein alpha 9
113839087 113858028 RIKEN cDNA A530058N18 gene
113873025 113878547 actin, alpha, cardiac
113926908 114001055 aquarius
113929103 113929174 transfer RNA aspartic acid (anticodon GUC)
114019199 114027168 zinc finger protein 770
114342154 114480664 ATP binding domain 4
114531521 114534629 hypothetical protein LOC100043219
114630072 114766408 similar to hCG1997831
115321270 115338651 hypothetical protein LOC100043232
115386354 115407508 hypothetical protein LOC100043236
115407512 115604504 cDNA sequence BC052040
115688805 115890848 myeloid ecotropic viral integration site-related gene 1
115892222 115908709 RIKEN cDNA G630016G05 gene
115900908 115901832 RIKEN cDNA 2810405F15 gene
116351206 116359270 similar to RAB5B, member RAS oncogene family
116704444 116718230 transmembrane and coiled-coil domains 5
116798319 116802164 hypothetical protein LOC100043557
116881278 116881797 similar to ribosomal protein L27a
116947186 117005073 sprouty protein with EVH-1 domain 1, related sequence
117010862 117010961 microRNA 674
117066619 117067177 similar to Ras-related protein Rap-1A precursor (Ras-related protein Krev-1)
117075475 117097276 RIKEN cDNA 2610510H03 gene
117105729 117168613 RAS guanyl releasing protein 1
117937658 117952869 thrombospondin 1
118030624 118082690 fibrous sheath-interacting protein 1
118102846 118199047 G protein-coupled receptor 176
118130650 118133902 RIKEN cDNA 1700054M17 gene
118214353 118300969 eukaryotic translation initiation factor 2 alpha kinase 4
118301579 118305432 signal recognition particle 14
118309036 118309956 similar to Aldose reductase (AR) (Aldehyde reductase)
118354493 118375414 Bcl2 modifying factor
118418997 118420394 similar to eukaryotic translation initiation factor 5A
118423992 118467327 budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae)
118489039 118522972 p21 (CDKN1A)-activated kinase 6
118524839 118529699 gene model 1337, (NCBI)
118533253 118554174 phospholipase C, beta 2
118571503 118572309 similar to F32B6.11
118579894 118587402 RIKEN cDNA A430105I19 gene
118605654 118620911 dispatched homolog 2 (Drosophila)
118639739 118660375 DNA segment, Chr 2, ERATO Doi 750, expressed
118687736 118707093 isovaleryl coenzyme A dehydrogenase
118727351 118750260 bromo adjacent homology domain containing 1
118752260 118754321 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14
118833878 118834397 hypothetical protein LOC677379
118843897 118855093 coiled-coil domain containing 32
118860526 118865505 RNA pseudouridylate synthase domain containing 2
118872486 118872567 transfer RNA serine (anticodon GCU)
118872855 118929857 cancer susceptibility candidate 5
118938553 118961806 RAD51 homolog (S. cerevisiae)
118962737 118982691 RIKEN cDNA 1200015F23 gene
118993524 118998125 GTP cyclohydrolase I feedback regulator
118998236 119034510 DnaJ (Hsp40) homolog, subfamily C, member 17
119000245 119003300 predicted gene, OTTMUSG00000015762
119013229 119014053 similar to 40S ribosomal protein S6
119034693 119042785 zinc finger, FYVE domain containing 19
119043859 119055588 protein phosphatase 1, regulatory (inhibitor) subunit 14D
119063096 119075250 serine protease inhibitor, Kunitz type 1
119094937 119096956 ras homolog gene family, member V
119114493 119124189 vacuolar protein sorting 18 (yeast)
119147079 119151300 hypothetical protein LOC100043609
119151565 119161392 delta-like 4 (Drosophila)
119176992 119180117 ChaC, cation transport regulator-like 1 (E. coli)
119198778 119303365 INO80 complex homolog 1 (S. cerevisiae)
119303591 119304425 hypothetical protein LOC100043612
119345140 119373363 Vexonuclease 3'-5' domain-like 1
119373443 119412760 RIKEN cDNA 1500003O03 gene
119412056 119422393 hypothetical protein LOC100043307
119435268 119444241 Opa interacting protein 5
119444034 119475896 nucleolar and spindle associated protein 1
119481187 119488534 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 1
119490822 119507312 similar to H3 histone, family 3B
119494895 119495796 hypothetical protein LOC100043622
119500810 119561163 Rtf1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)
119568073 119576989 inositol 1,4,5-trisphosphate 3-kinase A
119577062 119586167 leukocyte tyrosine kinase
119589700 119613233 RNA polymerase II associated protein 1
119625250 119643840 TYRO3 protein tyrosine kinase 3
119696095 119700366 RIKEN cDNA 6330405D24 gene
119702665 119705532 similar to Fatty acid-binding protein, epidermal (E-FABP) (Psoriasis-associated fatty acid-binding protein homolog) (PA-FABP) (Keratinocyte lipid-binding protein)
119722964 119795317 MAX gene associated
119798435 119853132 mitogen activated protein kinase binding protein 1
119860328 119867351 phospholipase A2, group IVB (cytosolic)
119867830 119911660 spectrin beta 5
119915223 119980311 EH-domain containing 4
119992148 120071071 phospholipase A2, group IVE
120070653 120071334 hypothetical protein LOC100043635
120091605 120114805 phospholipase A2, group IVD
120125702 120139901 phospholipase A2, group IVF
120143273 120178846 vacuolar protein sorting 39 (yeast)
120181048 120229825 transmembrane protein 87A
120229632 120286602 glucosidase, alpha; neutral C
120289609 120330235 calpain 3
120332566 120389567 zinc finger protein 106
120393407 120426458 synaptosomal-associated protein 23
120429974 120435010 leucine rich repeat containing 57
120435172 120446556 centrosomal protein 27
120454960 120541822 START domain containing 9
120541890 120557253 congenital dyserythropoietic anemia, type I (human)
120558552 120676320 tau tubulin kinase 2
120687382 120796451 ubiquitin protein ligase E3 component n-recognin 1
120802798 120833579 transmembrane protein 62
120829825 120830044 U3B small nuclear RNA pseudogene 2
120834144 120842648 cyclin D-type binding-protein 1
120843953 120862491 erythrocyte protein band 4.2
120871847 120911495 transglutaminase 5
120919325 120942132 similar to transglutaminase 7
120954043 120966774 leucine carboxyl methyltransferase 2
120967877 120982414 adenosine deaminase-like
120985990 120996885 zinc finger SCAN domains 29
120996942 121022854 DNA segment, Chr 2, ERATO Doi 435, expressed
121023987 121096856 transformation related protein 53 binding protein 1
121115336 121136568 microtubule-associated protein 1 A
121136299 121176753 histidine acid phosphatase domain containing 2A
121184377 121189473 creatine kinase, mitochondrial 1, ubiquitous
121189463 121206676 stereocilin
121218367 121239528 cation channel, sperm associated 2
121239638 121264423 protein disulfide isomerase associated 3
121264763 121268337 elongation factor RNA polymerase II-like 3
121274964 121279162 small EDRK-rich factor 2
121276913 121282500 hypothetical LOC574418
121282837 121284175 RIKEN cDNA 2310003F16 gene
121287400 121299759 microfibrillar-associated protein 1B
121299829 121317250 WD repeat domain 76 pseudogene
121318417 121332392 microfibrillar-associated protein 1A
121332459 121370596 WD repeat domain 76
121371265 121632793 FERM domain containing 5
121692866 121761595 cancer susceptibility candidate 4
121779507 121781828 melanoma antigen, family B, 3
121782189 121839322 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase like 2
121854282 121882334 eukaryotic translation initiation factor 3, subunit 1 alpha
121945844 122011925 RIKEN cDNA 4930424G05 gene
121973423 121978818 beta-2 microglobulin
121986436 122004763 tripartite motif-containing 69
122012008 122032129 RIKEN cDNA 4933406J08 gene
122040356 122041109 similar to developmental pluripotency associated 4
122045642 122046157 similar to ribosomal protein S12
122060575 122091073 sorbitol dehydrogenase
122106173 122123901 dual oxidase 2
122124636 122128621 dual oxidase maturation factor 2
122129285 122139466 dual oxidase maturation factor 1
122141439 122173708 dual oxidase 1
122174628 122194654 Src homology 2 domain containing F
122201230 122201301 transfer RNA histidine(anticodon GUG)
122203099 122203170 transfer RNA histidine(anticodon GUG)
122203704 122203775 transfer RNA histidine(anticodon GUG)
122252213 122286866 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2
122292311 122309739 BMP and activin membrane-bound inhibitor, pseudogene (Xenopus laevis)
122311623 122353778 novel protein similar to solute carrier family 28 (sodium-coupled nucleoside transporter) member 2 (Slc28a2)
122420208 122436994 glycine amidinotransferase (L-arginine:glycine amidinotransferase)
122456364 122463552 spermatogenesis associated 5-like 1
122463623 122466814 expressed sequence AA467197
122506975 122528399 solute carrier family 30 (zinc transporter), member 4
122564241 122575223 pallidin
122607735 122635289 sulfide quinone reductase-like (yeast)
123949372 123988148 RIKEN cDNA 4930517E11 gene
124129252 124132414 hypothetical protein LOC100043360
124436032 124493506 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D
124534391 124536910 hypothetical protein LOC100043367
124554535 124570547 hypothetical protein LOC100043369
124893863 124914413 solute carrier family 24, member 5
124914610 124942611 myelin basic protein expression factor 2, repressor
124950092 124956481 hypothetical protein LOC100043375
124978336 125055738 solute carrier family 12, member 1
125073471 125084785 deoxyuridine triphosphatase
125100300 125102908 RIKEN cDNA A530010F05 gene
125108424 125109714 hypothetical protein LOC100043698
125126330 125332174 fibrillin 1
125388824 125450849 centrosomal protein 152
125453183 125549884 SHC (Src homology 2 domain containing) family, member 4
125498831 125500519 EP300 interacting inhibitor of differentiation 1
125562722 125608606 RIKEN cDNA 3110001I20 gene
125656040 125684754 COP9 (constitutive photomorphogenic) homolog, subunit 2 (Arabidopsis thaliana)
125684954 125810034 galactokinase 2
125860520 125916261 fibroblast growth factor 7
125977911 125991012 DTW domain containing 1
126148481 126200339 ATPase, class I, type 8B, member 4
126378760 126413979 solute carrier family 27 (fatty acid transporter), member 2
126419404 126444401 histidine decarboxylase
126454649 126501223 GA repeat binding protein, beta 1
126533099 126585033 ubiquitin specific peptidase 8
126534886 126535308 similar to RNA polymerase II subunit
126587158 126609180 ubiquitin specific peptidase 50
126617301 126701947 transient receptor potential cation channel, subfamily M, member 7
126719868 126758971 RIKEN cDNA 2010106G01 gene
126834447 126895550 adaptor-related protein complex AP-4, epsilon 1
126896393 126922820 biliverdin reductase A
126929565 126959639 non-SMC condensin I complex, subunit H
126966089 126968365 RIKEN cDNA 1700041B20 gene
127012091 127034016 RIKEN cDNA 1810024B03 gene
127030421 127034173 hypothetical protein LOC100043408
127034140 127066187 activating signal cointegrator 1 complex subunit 3-like 1
127066674 127073478 cytosolic iron-sulfur protein assembly 1 homolog (S. cerevisiae)
127073711 127086500 transmembrane protein 127
127095191 127096174 predicted gene, ENSMUSG00000074822
127095975 127124669 START domain containing 7
127161895 127164113 dual specificity phosphatase 2
127164375 127183387 astacin-like metalloendopeptidase (M12 family)
127189022 127192957 adrenergic receptor, alpha 2b
127250935 127261828 RIKEN cDNA A530057A03 gene
127261951 127270241 fumarylacetoacetate hydrolase domain containing 2A
127282234 127347106 Kv channel interacting protein 3, calsenilin
127352209 127367203 prominin 2
127401271 127410404 zinc finger protein 661
127413162 127429722 mitochondrial ribosomal protein S5
127458966 127482431 myelin and lymphocyte protein, T-cell differentiation protein
127509881 127516275 similar to poly (A) polymerase alpha
127530126 127555633 mal, T-cell differentiation protein-like
127566468 127614590 nephronophthisis 1 (juvenile) homolog (human)
127618033 127618203 RIKEN cDNA 1500011K16 gene
127626857 127657531 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae)
127680364 127949609 acyl-Coenzyme A oxidase-like
127951774 127988283 BCL2-like 11 (apoptosis facilitator)
128021730 128259976 hypothetical protein LOC100043424
128249389 128250301 hypothetical protein LOC100043729
128382990 128383970 similar to glyceraldehyde-3-phosphate dehydrogenase
128413535 128413904 similar to high mobility group nucleosomal binding domain 2
128418077 128422579 gene model 355, (NCBI)
128438440 128513116 anaphase promoting complex subunit 1
128524733 128627923 c-mer proto-oncogene tyrosine kinase
128644039 128679997 transmembrane protein 87B
128689714 128721539 RIKEN cDNA 1600015H20 gene
128752004 128769756 zinc finger CCCH type containing 8
128778708 128779186 hypothetical protein LOC100043735
128791242 128793486 hypothetical protein LOC100043736
128827915 128844299 zinc finger CCCH type containing 6
128850809 128873902 similar to Vinculin CG3299-PA
128891725 128919485 tubulin tyrosine ligase
128919724 128926674 hypothetical protein LOC100043738
128926774 128952331 RNA polymerase 1-2
128955558 128959843 coiled-coil-helix-coiled-coil-helix domain containing 5
128994318 128997021 similar to CG32732-PA
129022988 129025387 hypothetical protein LOC100043431
129024536 129037345 solute carrier family 20, member 1
129044705 129061340 RIKEN cDNA A730036I17 gene
129072112 129094386 hypothetical protein LOC671466
129094617 129122900 cytoskeleton associated protein 2-like
129125346 129135708 interleukin 1 alpha
129190315 129196856 interleukin 1 beta
129195633 129201484 predicted gene, OTTMUSG00000015529
129203530 129205132 hypothetical protein LOC668896
129284095 129362338 RIKEN cDNA F830045P16 gene
129419314 129457964 signal-regulatory protein alpha
129512302 129525569 prodynorphin
129575637 129576353 peptidylprolyl isomerase A (Ppia) pseudogene 2_1620.1
129626297 129658023 serine/threonine kinase 35
129838110 129876135 transglutaminase 3, E polypeptide
129926130 129929111 expressed sequence AU015228
129945541 129948791 similar to Ubtf protein
129949021 129979961 transglutaminase 6
129997372 130005100 small nuclear ribonucleoprotein B
130020930 130090181 transmembrane channel-like gene family 2
130100148 130105049 nucleolar protein 5A
130105048 130118046 isocitrate dehydrogenase 3 (NAD+) beta
130121675 130196202 early B-cell factor 4
130210546 130211098 similar to ribosomal protein L27a
130216511 130223310 carboxypeptidase X 1 (M14 family)
130223525 130227062 hypothetical protein LOC100043446
130230995 130231810 RIKEN cDNA 1700020A23 gene
130232258 130233530 RIKEN cDNA 4933425O20 gene
130243960 130250008 RIKEN cDNA A930025D01 gene
130250125 130269470 vacuolar protein sorting 16 (yeast)
130329210 130379759 protein tyrosine phosphatase, receptor type, A
130389493 130391130 mitochondrial ribosomal protein S26
130401909 130402724 oxytocin
130406413 130408277 arginine vasopressin
130414794 130415749 RIKEN cDNA 1700012O15 gene
130415738 130455722 U box domain containing 5
130439582 130455670 FAST kinase domains 5
130458508 130468580 ProSAPiP1 protein
130479819 130490381 RIKEN cDNA 2600009E05 gene
130493577 130507350 inosine triphosphatase (nucleoside triphosphate pyrophosphatase)
130509844 130523255 solute carrier family 4, sodium bicarbonate transporter-like, member 11
130533567 130665846 RIKEN cDNA 4930402H24 gene
130628722 130632283 similar to PKC-potentiated PP1 inhibitory protein
130665924 130666704 RIKEN cDNA C030014O09 gene
130706559 130708149 similar to 26S proteasome non-ATPase regulatory subunit 11 (26S proteasome regulatory subunit S9) (26S proteasome regulatory subunit p44.5)
130732232 130856065 attractin
130813594 130814355 similar to high mobility group box 1
130865912 130868418 glial cell line derived neurotrophic factor family receptor alpha 4
130876845 130889550 a disintegrin and metallopeptidase domain 33
130894956 130912501 sialic acid binding Ig-like lectin 1, sialoadhesin
130931899 130934135 hypothetical protein LOC100043457
130953148 130971721 heat shock protein 12B
130972061 130985756 RIKEN cDNA 1700037H04 gene
130995997 131000546 sperm flagellar 1
131003025 131005748 centromere protein B
131012815 131024201 cell division cycle 25 homolog B (S. pombe)
131036176 131039250 RIKEN cDNA 2310035K24 gene
131059874 131073761 RIKEN cDNA D430028G21 gene
131088236 131122427 pantothenate kinase 2 (Hallervorden-Spatz syndrome)
131113787 131113872 microRNA 103-2
131124224 131178561 ring finger protein 24
131209452 131241018 hypothetical protein LOC100043463
131317679 131350908 spermine oxidase
131371093 131388021 adrenergic receptor, alpha 1d
131729689 131730773 laminin receptor 1 (ribosomal protein SA), pseudogene 1
131735693 131764163 prion protein
131776598 131781866 prion protein dublet
131818586 131855546 Ras association (RalGDS/AF-6) domain family 2
131878232 131970844 solute carrier family 23 (nucleobase transporters), member 2
131925602 131926635 similar to heterogeneous nuclear ribonucleoprotein A3
132003085 132005969 hypothetical protein LOC100043470
132040704 132041069 predicted gene, EG329521
132065230 132073518 RIKEN cDNA 5730494N06 gene
132075022 132078916 proliferating cell nuclear antigen
132088993 132137777 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2
132196901 132211136 prokineticin receptor 2
132316464 132349793 RIKEN cDNA 1700026D11 gene
132354819 132403984 preimplantation protein 4
132402201 132403728 hypothetical protein LOC100043781
132487978 132488432 hypothetical LOC383801
132502883 132515639 hypothetical protein LOC668906
132607014 132620808 chromogranin B
132629951 132641791 RIKEN cDNA 3300001M20 gene
132642071 132669933 minichromosome maintenance deficient 8 (S. cerevisiae)
132672402 132692509 cardiolipin synthase 1
132694252 132706598 RIKEN cDNA B430119L13 gene
132729915 132771772 RIKEN cDNA 5830467P10 gene
132805887 132806904 hypothetical protein LOC668908
133025303 133025985 similar to ribosomal protein L15
133257805 133279098 RIKEN cDNA A430048G15 gene
133378935 133388621 bone morphogenetic protein 2
134323097 134380088 hydroxyacid oxidase 1, liver
134420237 134469857 thioredoxin domain containing 13
134556531 134557414 hypothetical LOC627897
134587803 134589371 zinc finger, AN1-type domain 1 pseudogene
134612266 135298158 phospholipase C, beta 1
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Figure 3.13.: Additional STRs and SNPs between Rag and Prnp.
A shows the genomic region on chromosome 2 between 99 and 135 megabases
according to NCBI build 37.1. This region includes around 450 genes that
are irregularly dispersed, in certain spots more than 30 genes reside within a
megabase whereas other regions display a gene density of less than 5 genes
per megabase (alternating grey and white coloring of one megabase sections).
Genes putatively involved in the immune system are highlighted in yellow.
Additional SNP and STR markers are placed at the right position of the
chromosome.
B STR marker profile of backcrossed immunodeficient Prnp−/−, Prnp+/−
and Prnp+/+ mice. Polymorphic markers D2Mit447 and D2Mit256, in various
cases also D2Mit395 remain in the “PrPRag1”-constellation (red) in case of
deficiency of Prnp and cosegregate with the Prnp- allele.64
3.7. Additional SNP and STR on Chromosome 2
SNP ID Mb Rag2-Il2rg-/- Prnp-Rag1-/- Rag2-Il2rg-/-Prnp+/+ Rag2-Il2rg-/-Prnp+/- Rag2-Il2rg-/-Prnp+/- C57Bl/6
backcrossed "Balb/C" "Balb/C"
rs13476663 99.9 M__22285663_10-T M__22285663_10-T M__22285663_10-T M__22285663_10-T M__22285663_10-T M__22285663_10-T
rs29912618 100.8 M__24382337_10-C M__24382337_10-C M__24382337_10-C M__24382337_10-C M__24382337_10-C M__24382337_10-T
rs13476670 101.9 M__23720601_10-A M__23720601_10-A M__23720601_10-A M__23720601_10-G Both M__23720601_10-A
rs6261478 107.0 M__22354457_10-G M__22354457_10-G M__22354457_10-G M__22354457_10-C M__22354457_10-C M__22354457_10-G
rs13476705 112.9 M__23043361_10-A M__23043361_10-G M__23043361_10-A M__23043361_10-A M__23043361_10-A M__23043361_10-G
rs33314425 122.3 M__23028483_10-T M__23028483_10-C M__23028483_10-T Both Both M__23028483_10-C
rs13476764 127.8 M__23908236_10-C M__23908236_10-T M__23908236_10-C Both Both M__23908236_10-T
rs13476769 129.7 M__23300050_10-C M__23300050_10-C M__23300050_10-C M__23300050_10-C M__23300050_10-C M__23300050_10-T
rs13476772 130.6 M__22299775_10-C M__22299775_10-C M__22299775_10-C M__22299775_10-C M__22299775_10-C M__22299775_10-T
rs13476802 138.5 M__23938758_10-A M__23938758_10-C M__23938758_10-A M__23938758_10-A M__23938758_10-A M__23938758_10-C
SNP ID Mb Reconstituted Prnp+/- mice
rs13476663 99.9 M__22285663_10-T M__22285663_10-T M__22285663_10-T M__22285663_10-T
rs29912618 100.8 M__24382337_10-C M__24382337_10-C M__24382337_10-C M__24382337_10-C
rs13476670 101.9 M__23720601_10-A M__23720601_10-A M__23720601_10-A M__23720601_10-A
rs6261478 107.0 M__22354457_10-G M__22354457_10-G M__22354457_10-G M__22354457_10-G
rs13476705 112.9 M__23043361_10-A M__23043361_10-A M__23043361_10-A M__23043361_10-A
rs33314425 122.3 Both M__23028483_10-T Both Both
rs13476764 127.8 Both Both Both Both
rs13476769 129.7 M__23300050_10-C M__23300050_10-C M__23300050_10-C M__23300050_10-C
rs13476772 130.6 M__22299775_10-C M__22299775_10-C M__22299775_10-C M__22299775_10-C
rs13476802 138.5 Both Both Both Both
SNP ID Mb Reconstituted Prnp+/+ mice
rs13476663 99.9 M__22285663_10-T M__22285663_10-T M__22285663_10-T M__22285663_10-T
rs29912618 100.8 M__24382337_10-C M__24382337_10-C M__24382337_10-C M__24382337_10-C
rs13476670 101.9 M__23720601_10-A M__23720601_10-A M__23720601_10-A M__23720601_10-A
rs6261478 107.0 M__22354457_10-G M__22354457_10-G M__22354457_10-G M__22354457_10-G
rs13476705 112.9 M__23043361_10-A M__23043361_10-A M__23043361_10-A M__23043361_10-A
rs33314425 122.3 M__23028483_10-T M__23028483_10-T M__23028483_10-T M__23028483_10-T
rs13476764 127.8 M__23908236_10-C M__23908236_10-C M__23908236_10-C M__23908236_10-C
rs13476769 129.7 M__23300050_10-C M__23300050_10-C M__23300050_10-C M__23300050_10-C
rs13476772 130.6 M__22299775_10-C M__22299775_10-C M__22299775_10-C M__22299775_10-C
rs13476802 138.5 M__23938758_10-A M__23938758_10-A M__23938758_10-A M__23938758_10-A
SNP ID Mb Triple ko mice (not reconstituted) 
rs13476663 99.9 M__22285663_10-T M__22285663_10-T M__22285663_10-T M__22285663_10-T
rs29912618 100.8 M__24382337_10-C M__24382337_10-C M__24382337_10-C M__24382337_10-C
rs13476670 101.9 M__23720601_10-A M__23720601_10-A M__23720601_10-A M__23720601_10-A
rs6261478 107.0 M__22354457_10-G M__22354457_10-G M__22354457_10-G M__22354457_10-G
rs13476705 112.9 M__23043361_10-G M__23043361_10-A M__23043361_10-A M__23043361_10-A
rs33314425 122.3 M__23028483_10-C M__23028483_10-C M__23028483_10-C M__23028483_10-C
rs13476764 127.8 M__23908236_10-T M__23908236_10-T M__23908236_10-T M__23908236_10-T
rs13476769 129.7 M__23300050_10-C M__23300050_10-C M__23300050_10-C M__23300050_10-C
rs13476772 130.6 M__22299775_10-C M__22299775_10-C M__22299775_10-C M__22299775_10-C
rs13476802 138.5 M__23938758_10-C M__23938758_10-C M__23938758_10-C M__23938758_10-C
Figure 3.14.: SNP analysis of backcrossed and reconstituted mice.
The upper panel shows calibration strains (original strains and C57Bl/6) and
Prnp+/− mice from both breeding strategies. The lower panels show mice
subjected to reconstitution experiments displaying different Prnp genotypes.
Informative markers rs33314425 (122.3 Mb) and rs13476764 (127.8 Mb) seem
to be linked to respective Prnp alleles. 65
3. Results
3.8. Analysis of signal regulatory protein alpha haplotypes and correlation
to reconstitution outcomes
In November 2007, the group of Jayne Danska found a polymorphic gene coding for signal
regulatory protein alpha (Sirpa), claimed to modulate engraftment of human hematopoi-
etic stem cells in immunodeficient mice depending on the haplotype configuration of its
underlying gene Sirpa [116] applying a positional genetic approach. Surprisingly, Sirpa
is located very close to Prnp, 2 Mb apart at 73.1 cM on mouse chromosome 2 between
D2Mit447 and Prnp. We therefore sequenced Sirpa exon 2, the domain known to be
most polymorphic within mouse strains and found a clear correlation between Sirpa
haplotypes and reconstitution outcomes. 3 different haplotypes could be identified within
our colony: BALB/c, 129Sv, C57Bl/6 showing many polymorphisms resulting in silent
and effective mutations. The Prnp knockout allele clearly cosegregated with the Sirpa
haplotype 129Sv, whereas a BALB/c allele cosegregated with the Prnp(+) allele. Even
in the case of multiple backcrossings to BALB/c, the Prnp(-) mice retained their 129Sv
Sirpa haplotype. Reconstitution was only possible in mice carrying at least one BALB/c
Sirpa. Meiotic recombinations between a Prnp(-) allele and Sirpa-BALB/c took place in
one case in a retrospective analysis (Fig. 3.15, we decided therefore to initiate a meiotic
recombination screening strategy.
3.9. Meiotic recombination screening between Sirpa and Prnp, subsequent
reconstitutions
Using the polymorphic microsatellite marker D2Mit447, we initiated multiple breedings
to achieve meiotic recombinations between Sirpa and Prnp and finally succeeded in
identifying mice carrying the constellation SirpaBALB/c/129Sv - Prnp−/−. These mice
were further bred to homozygous colonies and subjected to our humanization assay.
We could definitely show that Sirpa129Sv recessively suppresses successful engraftment
of human stem cells since in a litter of 5 mice, 4 being Prnp−/− and Sirpa129Sv/129Sv
had no detectable human CD45+ cells in the peripheral blood whereas the only mouse
showing the constellation Prnp−/− and SirpaBALB/c/129Sv had an engraftment of 38%
human cells in the lymphoid gate. These data were later confirmed in bone marrow
analysis. The long-time survival of the graft seemed to be limited because of a single
allele of Sirpa129Sv. Currently, the colony of SirpaBALB/c/BALB/c-Prnp−/− mice is being
continuously expanded to homozygous littermates which will ensure a longer graft survival.
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3.9. Meiotic recombination screening between Sirpa and Prnp, subsequent reconstitutions
67753-5 1949-6 113416-109 71 1951-5
114950 
129MMTg13
5 2200-1 66 113417-105 1951-10 2106-1 1985-3
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Figure 3.15.: Comparison of Sirpa polymorphisms and Prnp-allelotype and its
correlation to reconstitution outcome.
Retrospective analysis of Sirpa haplotypes in mice that were subjected to
our humanization assay. All Prnp−/− mice displayed two Sirpa alleles of the
129Sv strain, whereas all the Prnp+/+ mice carried two alleles of the BALB/c
strain. Prnp+/− mice carried both Sirpa-alleles. No meiotic recombination
event between Sirpa and Prnp was detected. Only mice carrying at least
one Sirpa-BALB/c allele were engraftable with human cells, i.e. detection of
human CD45+ cells in peripheral blood (n=152).
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3. Results
Meiotic recombination breedings: 
Out of 169 mice, 3 recombinants were detected:
Expansion 
of colony, 
reconstitutions Reconstitution outcomes in a litter of 5 mice
(Prnp-/-SirpaBALB/c/129Sv x Prnp-/-SirpaBALB/c/129Sv)
1 0 0
2 0 0
3 0 0
4 0 0
5 38 10
C57Bl/6 0 0
Mouse Genotype
% 
Reconstitution 
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weeks)
% 
Reconstitution 
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Figure 3.16.: Sirpa meiotic recombination breedings and subsequent reconstitu-
tions.
Meiotic recombination breedings were initiated using primers for Prnp and
D2Mit447, an informative microsatellite marker closely linked to Sirpa. Out
of 169 mice, 3 recombinants could be detected, while only one male mouse
displayed the genetic constellation Prnp−/−- SirpaBALB/c/129Sv. Further
breedings could expand the colony and subsequently lead to reconstitution
experiments that pointed out the importance of the SirpaBALB/c-allele for
xenograft survival and differentiation. The data was controlled by sequencing
of Sirpa exon 2 in all screened mice.
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The goal of this study was the establishment of a “humanized mouse model” to study the
immunology of peripheral prion disease initiation, for reevaluation of the concept of the
species barrier and for developing tools to investigate novel diagnostic tests and disease
specific genetic susceptibility factors. To impose a realistic model, PrP expression should
only be present on the engrafted cells but not on confounding host cells. We succeded in
reproducing long-term engraftment with hematopoietic stem cells in immunodeficient
mice applying the same protocol as published by Traggiai et al. [119]. Reproducible
engraftment success was only possible when high amounts of high-quality CD34+ stem
cells were injected, whereas high variability was observed when smaller inocula were
applied.
SirpaBALB/c instead of Sirpa129Sv in Rag2−/−Il2rg−/−Prnp−/− mice rescues
reconstitutability.
Rag2−/−Il2rg−/− mice devoid of Prnp could reproducibly be engrafted with bone marrow
from allogeneic donors (Figure 3.8) However, we failed to reconstitute mice devoid of
PrPC expression with xenogeneic hematopoietic stem cells for a long time (Figures 3.9,
3.10) although we implemented a stringent microsatellite-based “speed congenics” strategy
to monitor and adjust for the genetic background of the recipient mice (Figures 3.5, 3.6).
In fact, Prnp(+) littermates with a near-identical genetical profile showed a detectable
longterm engraftment whereas this was absent in all our assessed Prnp(-) mice.
Since PrPC is widely expressed in hematopoietic cells, mainly in macrophages and lym-
phoid precursors, but also in hematopoietic stem cells, we reasoned that PrPC itself
might modulate the homing capacity of xenogeneic cells by a yet to be defined mecha-
nism. We speculated that PrPC might represent a homing receptor for xenogeneic cells
on macrophages or elsewhere in the bone marrow since this observation seemed to be
restricted to foreign cells. Expression analysis in bone marrow stroma did not reveal signif-
icant PrPC expression there, possibly ruling out an impact of PrPC in the stem cell niche
compartments (data not shown). However, complementation attempts by expression of a
transgenic human PRNP on a mouse Prnp−/− background did not restore engraftment,
even though the genetic background of the tested mice was extremely homogeneous.
This suggested a different mechanism for the observed phenomenon (Figure 3.11). A
closer analysis of the genetic region around Prnp and Rag genes using higher resolution
STR and SNP mapping revealed that still quite a large portion of the genetic material
around and downstream of Prnp displayed a configuration of a 129Sv-chromosome and
was uniquely present in our Rag2−/−Il2rg−/−Prnp−/− animals, indicating that other
genetic factors might be responsible for the observed phenotype (Figures 3.13, 3.14). This
analysis clarified further that more than one meiotic recombination event between these
two genes must have occurred.
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Very recently published strain polymorphisms in mouse signal regulatory protein alpha
(Sirpa), a gene that is closely linked to Prnp on chromosome 2 less than 2 cM apart
from Prnp, situated between Prnp and Rag, were finally able to explain the observed
phenomenon [116].
Putative role of Sirpa in innate immunity. Cells of the innate immune system are likely
to have other tools determining self and non-self that are being deciphered only recently.
Unmasking these functions will strongly enhance the understanding of innate immunity,
a field with significant novel discoveries during the last decade. The “Sirpa family” of
receptors has been discovered only recently and seems to be a fundamental contributor
to innate immune functions [9]. Sirpa is expressed on macrophages and is quoted to
be a receptor for foreign or self CD47. In case of efficient binding between Sirpa and
human CD47, macrophages are instructed to downregulate their phagocytic machinery
via tyrosine-kinase signaling and become tolerant to non-self organisms as described by
[116], [54]. As a immunoglobulin-like protein with a hypervariable IgV-domain, Sirpa is
reported to be highly polymorphic between different mouse strains and therefore exhibits
varying binding properties to CD47 [67]. Its binding site seems to be reminiscent of the
T-cell receptor [44] and MHC molecules. The NOD-Sirpa (see also Figure 1.3) seems
to have the best binding to its human CD47 counterpart, whereas many other strains,
including C57Bl/6 and 129Sv are basically non-binders.
Sirpa haplotypes in Prnp deficient mice were of the 129Sv-type, whereas in all our
successfully reconstituted and backcrossed mice at least one BALB/c-Sirpa allele was
present in conjunction with the wild type Prnp allele according to our sequence align-
ment comparison (Figure 3.15). A microsatellite marker closely associated with Sirpa,
D2Mit447, served as a surrogate for recombination events between Sirpa and Prnp. In
a retrospective analysis of all our reconstituted mice we observed only one favorable
recombination event in our mouse colony, and we therefore initiated a screening strategy
for meiotic recombinations between Prnp and Sirpa to yield a BALB/c Sirpa on a
Prnp−/− (129Sv) chromosome in order to have reconstitutable Prnp−/− mice, an event
that statistically should occur in 1 in 100 mice. Applying this screen, we generated as well
the reverse situation (Prnp+/+-Sirpa129Sv/129Sv) on a basically pure BALB/c background
which could easily be used for control and future in vivo and in vitro experiments,
further elucidating the a putative role of Sirpa or Prnp in phagocytosis. So far a single
proof of principle experiment in a well-controlled setting disclosed a clear correlation
between the negative impact of Sirpa129Sv/129Sv and reconstitution outcome: in a litter
of solely Prnp−/− mice with varying Sirpa haplotypes, only the mouse with a permissive
SirpaBALB/c allele was positively engrafted and showed sustained engrafting in bone mar-
row after 9 weeks. We could not detect human engraftment in the other littermates, since
binding of the 129Sv-Sirpa to CD47 seems to be less efficient compared to its BALB/c
polymorphic counterpart. This confirms the recent publication of [116] in a different way
and impressively demonstrates the importance of different Sirpa strain polymorphisms
in xenografting. Therefore, SirpaBALB/c would be placed in between Sirpa129Sv and
SirpaNOD in terms of affinity to xenogeneic CD47 elucidating an all-or-nothing response
for macrophage activation. However, other cofactors influencing the activation status
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of innate immunity might also contribute to the very variable innate response towards
xenografts. So far, SirpaNOD might bind best to human CD47 and therefore represent
the ideal strain for humanization experiments.
Variability of the experiment for other reasons?
Engraftment of human cells sometimes highly varied even in BALB/c Rag2−/−Il2rg−/−
mice. Technical reasons or qualitative differences in the stem cell inoculum might have
been the cause for this variability, but other genetic factors related to this phenomenon,
even on different regions in the genome than the ones described in our work might
contribute to the observed variations as well. Other polymorphic or differentially regulated
target genes of influence might be identified by application of high-resolution SNP chips
for QTL-mapping or microarrays of myeloid cell cDNA with the limitation that the power
of the observed phenotype (engraftment versus no/subclinical engraftment) might not
be sufficiently strong to identify clear-cut associations. Therefore, one must carefully
select the samples and perform a quantitative and kinetic analysis of the engraftment
behaviour in a defined cohort of mice and controls before applying these very expensive
techniques to identify other factors involved in xenografting.
Steps towards optimization of humanized mouse models - manipulating myeloid
cells
It is reported that liposomal clodronate treatment as a preconditioning regimen efficiently
depletes macrophages for a certain timeframe [120]. Attempts with clodronate in our triple
knockout mice are currently ongoing and in their early days - this might represent another
effective but nevertheless harsh way to achieve engraftable mice and reduce variability in
our experiments. Another approach to optimize the model would consist in expressing the
human Sirpa transgenically in the mouse, either ubiquitously or macrophage-specifically.
One might aim at expressing human Sirpa cDNA under the control of the CD11b promoter
[26] (a macrophage specific promoter) in our Rag2−/−Il2rg−/−Prnp−/− mice, thereby
removing the obstacle of the Sirpa-huCD47 incompatibility. Our screening approach
for favorable recombinations between the Prnp- allele and SirpaBALB/c was successful
although this still will not yield optimal engraftment results, as SirpaBALB/c is inferior
to SirpaNOD in terms of binding to human CD47. The making of a transgenic mouse
and its breeding into the appropriate genetic environment may take much more time but
should finally be the most promising strategy for future directions.
Inoculation studies of humanized BALB/c Rag2−/−Il2rg−/− mice - an optimal
model?
PrPSc inoculation experiments with humanized BALB/c Il2rg−/−Rag2−/− mice have been
performed in our lab for the last two years, and western blot analysis of spleens 60 days
post inoculation revealed PrPSc deposition in case of a CJD inoculum in reconstituted, but
not in unreconstituted littermates. PrPSc was detected using standard western blotting
techniques with an antibody, 3F4, that binds specifically to human PrPSc because of
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a human specific epitope. However, Il2rg−/−Rag2−/− mice express a large amount of
endogenous mouse Prnp in their hematopoietic compartment, which is well capable of
sequestering or replicating CJD prions as reported by others [74], especially in the myeloid
and macrophage compartment. In this study, we can reconfirm a high PrP-expression in
the hematopoietic and myeloid compartment in mice.
Further, it has been known for more than 20 years that CJD can easily be transmitted
in small rodents, thereby circumventing a possible species barrier, and infectivity was
detectable in all major lymphatic organs upon intraperitoneal inoculation [117]. In these
reported cases, the endogenous mouse PrPC served as a template for the initiation of the
replication process, and it might well be that de novo replicated prions carry the human
sequence since the nature of the replication process is not yet fully clarified.
According to our observations, Il2rg−/−Rag2−/− mice possess an enlarged macrophage and
myeloid compartment in response to their missing adaptive immune sytem. Further, the
conditioning regimen includes sublethal irradiation steps which elicit further macrophage
activation and accumulation reactions. Additionally, all stromal cells and other organ-
specific cells express mouse Prnp at a level similar to immunocompetent wildtype mice.
Although these mice lack functional FDCs due to impaired cytokine signaling [72], other
stromal and hematopoietic cell types could take over prion replication. Moreover, FDC or
FDC-like formation might be induced by graft-secreted cytokines. Whether or not FDCs
represent a prion replication machinery is still unclear. Reports by our group suggest that
the absence of functional FDCs abrogate peripheral prion replication and neuroinvasion
of RML-inoculated mice in spleens [93], but others report that the absence of FDCs
does not alter the incubation times [87] and suggest that neither FDC nor CD11c(+)
cells are essential for neuroinvasion after high doses of RML. A more radical study even
claims that neither the absence of FDCs nor the absence of B-cells significantly altered
incubation times in case of CJD-inoculated mice [106] and emphasizes the contribution
of myeloid cells involved in the replication process. To study the response of a humanized
immune system in vivo it is therefore indispensable to have a system available that is
devoid of any other PrP-species. The inoculum will exhibit a specific tropism to engrafted
and PrP expressing cells and assure that no other entity than human cells is involved in
the replication process.
Impact of Sirpa polymorphisms to the prion field
Genetic background artefacts and effects will impact mouse research in the near future
to a much larger extent, while many of the described phenotypes of knock-out mice will
have to be reevaluated. Also in case of mice devoid of PrPC , most of the phenotypes
attributed to a physiological function of the protein might be artefactual since the genetic
background was poorly controlled in these studies.
Sirpa and Prnp are genetically close in other mammals, especially in humans (on
chromosome 20), in cattle (on chromosome 13) and in non-human primates. All the
studies describing immunological phenotypes in Prnp−/− mice compared to wildtype
mice used Prnp−/− mice with a Sirpa129Sv constellation, whereas in most of the wildtype
controls, a different genetic configuration with probably different Sirpa haplotypes might
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have been used. This holds especially true for the the studies that attribute an enhanced
phagocytosis and leukocyte infiltration phenotype to Prnp−/− mice [22] and claim a role
for PrP in Brucella infection [122] since Sirpa polymorphisms with a clear impact on
macrophage function could provide a very likely explanation for these observations as
well. Another recent study claimed that clearance of splenic endogenous retroviruses
upon immune stimulation was Prnp-dependent [70], an observation that likewise could
be challenged because of the different genetic environment of the mice that were used
in the experiment. Further, PrP was claimed to be involved in hematopoietic stem cell
self-renewal in a series of transplantation experiments [130] with Prnp−/− bone marrow
cells performing worse than wildtype cells - a study that might also be worth reevaluating
in the context of polymorphic Sirpa. Additionally, mice that overexpress Prnp under
the control of the Prnp-promoter in a Prnp-deficient background have often been used
for control experiments that are supposed to complement Prnp-deficient mice from
their immunological phenotype. However, sequence analysis of Sirpa in 10 generation
backcrossed tga20 mice (to C57Bl/6 or BALB/c) show different Sirpa configurations in
individual mice, which implies that the observed genetic rescue might equally well be
explained by polymorphic Sirpa.
Interestingly, Sirpa and Prnp are co-mentioned in another very recent study investigating
the transcriptional response in macrophages of two different cattle breeds to a zoonotic
parasite, Theileria annulata. Both Sirpa and Prnp are upregulated upon infection in one
breed and the physiological response in the two strains is reported to be highly different
expecially in terms of T-cell activation [57]. Bovine Sirpa is located on Chromosome 13 at
position 53810kB whereas Prnp is located at 46690kB on the same chromosome, further
apart than in the mouse. Nevertheless, Sirpa and Prnp seem to be co-regulated on a
transcriptional level in myeloid cells upon infection with distinct pathogens which adds
another step of complexity to a possible involvment of Prnp in innate immune function.
This report could give another hint that a polymorphic and co-regulated gene linked to
Prnp rather than Prnp itself plays the major role in phenomena related to innate and
specific immune responses.
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5. Conclusion
Throughout this work we aimed to solve three specific problems (section 1.7):
• First, we were readily able to reproduce the basic experiment published by Traggiai
et. al. exploiting excellent infrastructural and logistical resources.
• Second, despite some natural obstacles, a genetically sound and reproducible basis
was laid for a humanized mouse model devoid of murine endogenous Prnp. Prion
replication in these mice will take place exclusively in the grafted cells and therefore
open new frontiers in prion research. Interfering polymorphisms of a genetically
linked gene - Sirpa - might represent a clue to many artefactual immune-phenotypes
described and published in Prnp−/− mice.
• Immunodeficient mice devoid of endogenous murine Prnp and re-expressing a
human PRNP transgene that are equally well reconstitutable with human stem
cells have been generated. These mice will soon represent a new model system for
human prion diseases, especially neuroinvasion, and will be used as a novel tool for
diagnostic and therapeutic purposes.
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Part II.
Global Gene Expression Analysis of PrPSc infected
neuronal cells
77

6. Introduction
Outline
This part of my thesis is a modified version of a manuscript published in
November 2007 in the Journal of Molecular Biology with the title
Transcriptional stability of cultured cells upon prion infection
Christian Julius1,2, Gregor Hutter1,2, Ulrich Wagner3, Harald Seeger1, Veronika Kana1,
Jan Kranich1, Peter Kloehn4, Charles Weissmann5, Gino Miele6,7, Adriano Aguzzi1,7
PII: S0022-2836(07)01463-5 DOI: doi: 10.1016/j.jmb.2007.11.003 Reference: YJMBI 59919 To
appear in: Journal of Molecular Biology
Received date: 15 August 2007
Revised date: 30 October 2007
Accepted date: 1 November 2007
Please cite this article as: Julius, C., Hutter, G., Wagner, U., Seeger, H., Kana,
V., Kranich, J., Kloehn, P., Weissmann, C., Miele, G. & Aguzzi, A., Transcriptional
stability of cultured cells upon prion infection, Journal of Molecular Biology (2007), doi:
10.1016/j.jmb.2007.11.003
1Institute of Neuropathology, University Hospital of Zu¨rich, Schmelzbergstrasse 12, CH-8091 Zu¨rich,
Switzerland
2These autors contributed equally to this study
3Functional Genomics Center, Federal Institute of Technology (ETH) and University of Zurich, Win-
terthurerstrasse 190, CH-8057 Zu¨rich, Switzerland
4Medical Research Council Prion Unit and Department of Neurodegenerative Disease, Institute of
Neurology, University College London, Queen Square, London WC1N 3BG, United Kingdom
5Scripps Florida, 5353 Parkside Drive, Jupiter, Florida 33480, USA
6Translational Medicine Research Collaboration, Sir James Black Centre, University of Dundee, Dow
Street, Dundee, DD1 5EH, United Kingdom
7Correspondence: Adriano Aguzzi (adriano.aguzzi@usz.ch) or Gino Miele (g.miele@dundee.ac.uk
79
6. Introduction
Abstract
Prion infections induce severe disruption of the central nervous system with neuronal
vacuolation and extensive glial reactions, and invariably lead to death of affected in-
dividuals. The molecular underpinnings of these events are not well understood. In
order to better define the molecular consequences of prion infections, we analyzed the
transcriptional response to persistent prion infection in a panel of three murine neural
cell lines in vitro. Colony spot immunochemistry assays indicated that 65 to 100%
cells were infected in each line. Only the Nav1 gene was marginally modulated in one
cell line, whereas those transcripts previously reported to be derailed in prion-infected
cells were not confirmed in the present study. We attribute these discrepancies to the
experimental stringency of the current study, which was performed under conditions
designed to minimize potential genetic drifts. These findings are at striking variance
with gene expression studies performed on whole brains upon prion infections in vivo,
suggesting that many of the latter changes represent secondary reactions to infection.
We conclude that, suprisingly, there are no universal transcriptional changes induced by
prion infection of neural cells in vitro.
6.1. Introduction
Prions are the causative agents of transmissible spongiform encephalopathies (TSEs),
which include Creutzfeldt-Jakob disease (CJD) in humans, scrapie in sheep, bovine
spongiform encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) in
cervids [3]. One hallmark of most forms of prion disease is the conversion of the host
encoded cellular prion protein (PrPC) to an abnormally folded form, termed PrPSc
[80]. Although prion replication can occur in extraneural tissues prior to neuroinvasion
after peripheral challenge, pathological changes have only been observed in the central
nervous system (CNS) [32] [92]. These include neuronal vacuolation (spongiosis), neuronal
death and pronounced glial reactions, which invariably lead to death of the affected
individuals [1]. The molecular mechanisms underlying prion replication and pathways
leading to subsequent neural damage are not understood [123]. Transcriptional profiling
is a powerful technology that allows for interrogating very large datasets without the
need to place the typical constraints of hypothesis-testing experimentation. This inherent
lack of bias reflects the strength of the approach. The transcribed genome has been
analyzed in whole brains of rodents experimentally infected with various prion strains
[99], [100], [129], spleens of prion-infected mice [81], primary cells isolated from tissues
[7], and prion-infected cell lines [24], [42]. Studies on whole brain or isolated microglia
yielded differentially expressed genes possibly involved in systemic responses to prion
infection. Instead, studies on neuronal cell lines may identify cellular responses to prion
infection. Also, the use of cell lines highly susceptible to prion infection at high infection
rates circumvents potential issues with using either whole or dissected brain, where only
a small proportion of the interrogated transcriptome is contributed by prion-infected cells.
One such recent study has reported that a number of candidate genes are differentially
expressed as a direct result of prion infection [42]. Here we describe the outcome of
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transcriptional analyses of cultured cells in vitro under stringently controlled conditions.
Our original aim was to identify changes in gene expression after prion infection conserved
over different neuronal cell lines. Besides pointing to possible players in the pathogenesis
of prion diseases, any robust and consistent transcriptional changes could be utilized for
constructing reporter systems, which in turn would allow for identifying and isolating
single prion infected cells in intact tissues and in cell cultures. We employed high-density
oligonucleotide microarrays analysis of N2aPK1 cells to identify gene expression changes
directly resulting from prion infection. After exhaustive interrogation of datasets with
several techniques of bioinformatics, we were only able to identify very modest differential
expression, even under conditions of low filter stringencies. Subsequent quantitative
PCR analyses confirmed modest but statistically significant differential expression of
only one transcript (Nav1), which was not differentially expressed in another in vitro
cell culture model of prion infection utilized in our laboratory. Our investigations of
expression levels in independent cell culture models of prion infection of candidate genes
previously reported by others to be profoundly differentially expressed [42] revealed that
none of these were differentially expressed in any of the cell culture models of in vitro
prion infection utilized here, including those employed by Greenwood et al. [42]. In
contrast to reports by others [24], [42], we found no significant changes in the expression
profile of our N2aPK1 cells interrogated here as assessed by transcriptional profiling,
or in three highly infected neuronal cell lines as assessed by quantitative RT-PCR of
several candidate genes recently proposed in the literature [42]. We hypothesize that
this discrepancy results from fundamental differences in the experimental design. We
conclude therefore that prion agents in cultured neuronal cells infected at high rates do
not induce general or specific changes in the transcriptome.
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7. Material and Methods
7.1. Cell culture (N2aPK1 cells, CAD cells, GT1 cells)
The N2aPK1 subclone of mouse neuroblastoma N2a cells was selected for high suscep-
tibility to prion infection and kindly provided by Charles Weissmann and Peter Klo¨hn
(MRC Prion Unit, The Institute of Neurology, London, UK) [61]. CAD cells, a subclone
of the CNS catecholaminergic cell line Cath.a, were a gift of Dona Chikaraishi (Tufts
University School of Medicine, Boston, Massachusetts, USA) [96]. The mouse hypotha-
lamic neuronal cell line GT1 was kindly donated by Ina Vorberg (Institute of Virology,
Technical University of Munich, Germany). All cell lines were cultured in Optimem/10%
FBS, Pen/Strep. N2aPK1 and CAD cells were split at confluency at a ratio of 1:3 every
three or 1:10 every four days. GT1 cells were split at confluency at a ratio of 1:3 every
four or 1:10 every five days. For RNA isolation and Western blot analysis, cells were
grown to approximately 75% confluence.
7.2. Prion infection of cell lines (N2aPK1RML, CADRML, GT1RML cells)
Prion infection of cells was performed as reported previously [61]. Briefly, 17’000 cells
were seeded in six wells of a 96 well plate and after 16h of incubation infected with a
10−2 dilution of 10% homogenate of mock CD1 brain homogenate or 10% homogenate of
RML infected brain homogenate, respectively. Independent infections were performed in
quadruplicate to achieve four true biological replicates of Mock or RML infected cells.
After three days of incubation cells were split three times (1:3) and subsequently a further
three times (1:10). At that point six wells were pooled and cells were expanded in a
T75 cell culture flask. At approximately 75% confluency cells were harvested for RNA
isolation or split 1:10 to obtain material for Western blot analysis and clarification of the
infection ratio The infection and splitting protocol is visualized in Figure 7.1.
7.3. Assessment of the infection ratio in RML infected cells (N2aPK1RML,
CADRML, GT1RML cells)
To assess the proportion of prion infected cells in the N2aPK1RML, CADRML and
GT1RML cells cultures we utilized the ELISPOT assay as described previously [61]. A
dilution series of cells ranging from aliquots of 2000 to 8 cells per well was performed in
a 96 well plate. The cells were transferred to a sterile Multi Screen Immobilon-P 96-well
Filtration ELISPOT plate, activated with 70% ethanol (Millipore) and the cell suspension
was filtered by vacuum filtration, followed by incubation for 1h at 50◦C. Subsequently,
50µL of proteinase K (PK; 0.25 µg/mL in lysis buffer [50 mM Tris·HCl, pH 8.0/150 mM
NaCl/0.5% sodium deoxycholate/0.5% Triton X-100]) was added to each well, and the
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Figure 7.1.: Infection and cell splitting protocol of neuronal cell lines.
17000 cells (N2aPK1, CAD or GT1) were seeded in each of six wells of a 96
well plate. After 16h of incubation cells were infected with a 10−2 dilution of
10% homogenate of mock CD1 brain homogenate or 10% homogenate of RML
infected brain homogenate, respectively.
Independent infections were performed in quadruplicate to achieve four true
biological replicates of Mock or RML infected cells. After three days of
incubation cells were split three times (1:3) and subsequently a further three
times (1:10). At that point six wells were pooled and cells were expanded in a
T75 cell culture flask. At approximately 75% confluency cells were harvested
for RNA isolation or split 1:10 to obtain material for Western blot analysis
and clarification of the infection ratio.84
7.4. Western blot detection of PrPSc
plates incubated for 90 min at 37◦C followed by removal of the proteinase K solution by
vacuum filtration. The wells were washed several times with PBS, incubated with 2 mM
PMSF for 10 min, and washed again several times with PBS. After incubation with 160
µL of 3 M guanidinium thiocyanate in 10 mM Tris·HCl (pH 8.0) for 10 min, the filters
were washed four times with PBS and incubated with 160 µL 5% TopBlock for 60 min.
50 µL of 0.4 µg/ml anti-PrP antibody POM1, in TBST/1% TopBlock, [91] was added
and the plates incubated at RT for 1h, followed by removal of the antibody solution.
Next, the wells were washed eight times with TBST followed by addition of 50 µL of
alkaline phosphatase-conjugated anti-mouse IgG1 (Southern Biotechnology Associates;
1:4,500 in TBST/1% milk powder) was added for 1 h. Wells were washed eight times with
TBST and dried at RT. 50 µL of alkaline phosphatase conjugate substrate (Bio-Rad) was
added for 16 min followed by two washes with water. PrPSc positive cells were counted
manually using an Olympus SZX12 stereo microscope. Mock control cells did not give
rise to background. The infection ratio was calculated by division of total cells seeded by
PrPSc positive spots counted per well. This was performed for three different dilutions.
7.4. Western blot detection of PrPSc
To confirm persistent prion infection, cells were screened for PrPSc content in the different
independent biological replicates. For PrPSc detection, cells were grown on T75 flasks
until approximately 75% confluent. Monolayers were rinsed with PBS, harvested and
lysed in RIPA lysis buffer (10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM EDTA,
0.5% (v/v) Triton X-100, 0.5% (v/v) (deoxycholate) followed by three freeze-thaw cycles.
Following centrifugation at 1000xg for 5 min the supernatant was removed and protein
content quantitated by BCA-protein assay (BioRad) to allow equal amounts of protein
to be applied the blot after either treatment with 20 mg/ml of proteinase K for 30
minutes at 37◦C for PrPSc detection or no treatment (for PrPC detection). Proteins
were subjected to SDS-PAGE (12.5% Bis-Tris gels, NuPAGE, Invitrogen). PrPC and
PrPSc were detected using the mouse monoclonal antibody POM1 (1:10’000) followed
by HRP-anti-mouse IgG1, and blots were developed with ECLplus according to the
manufacturer’s instructions (Amersham Corporation).
7.5. Preparation of labeled cRNA, microarray hybridization and data
analysis
Total RNA was extracted from all samples using TRIzol (Invitrogen Life Technologies)
according to the manufacturer’s instructions. RNA was subjected to a further clean-
up step using RNeasy mini columns (Qiagen). RNA quality was assessed by Agilent
2100 Bioanalyzer. Processing of 15 g of total RNA was continued to cDNA synthesis
using a cDNA Synthesis kit (cat. no. 11917-010; Invitrogen Life Technologies) and
primer 5’-GGCCAGTGAATTGTAATACG ACTCACTATAGGGAGGCGG(dT)24-3’.
Biotin-labeled cRNA was synthesized, using Enzo BioArray HighYield RNA transcript
labeling kit (T7) (Enzo Biochem), purified using RNeasy mini columns, quantified by
spectrophotometry, and quality was assessed again by Agilent 2100 Bioanalyzer. Labeled
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cRNA (15 µg) was fragmented in 40 mM Tris-acetate, 100 mM KOAc, 30 mM MgOAc,
pH 8.1, at 95◦C for 35 min followed by hybridisation to Affymetrix MOE430A and
MOE430B chips. All hybridizations were conducted for 16 h at 45◦C at 60 rpm. After
hybridization chips were washed and conjugated with streptavidin-PE according to
the manufacturer’s instructions on the Affymetrix GeneChip Fluidics Station 450 with
and scanned using the Affymetrix GS Scanner 2500 in conjunction with Affymetrix
Microarray Suite 5.0 software. All experiments were performed in biological triplicates.
After hybridization and scanning, probe cell intensities were calculated with the MAS5.0
algorithm of the Affymetrix GCOS software (Santa Clara, CA). Summarization and
normalization of intensities for the respective probe sets were carried in two independent
approaches using two different algorithms. For the first approach the MAS5.0 algorithms
was employed as detailed in [53], present and absent calls were calculated by application
of a signed-rank call algorithm [71]. Using the Genespring 7.3 software (Agilent, CA)
results were median per-chip and median per-gene normalized. For the second approach,
the GCRMA summary algorithm [128] as implemented in Genespring 7.3 was used to
generate and normalize raw gene expression data from probe intensities. Independently
of each other, genes were filtered out from the two lists of normalized expression values
in Genespring 7.3 when not showing an expression value of at least 50 in all replicate
measurements of at least one condition. Subsequently, the significance of 1.5 fold changes
in expression was tested in Genespring by an equal-variance t-test with a significance
threshold of p< 0.05. Data sets have been deposited in the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/); accession number GSE7229.
7.6. Quantitative Real-time PCR
cDNA of mock and RML infected cells was synthesized using the Quantitect reverse
transcription kit (Qiagen, Switzerland) according to the manufacturers description. As
negative controls, 1 µg of each RNA was processed without addition of reverse transcrip-
tase. Complete removal of contaminating genomic DNA was confirmed by performing
-actin PCR on all samples. Specific primers (supplementary table 1) were designed using
primer3-software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi).
Table 7.1.: Primers designed for quantitative real time PCR reactions
Affymetrix ID fw Primer rev Primer
1416759 at ggctacatgaatcgggaaga aggtacagcccttgtgatgg
1436448 a at gaaggtcctgttcctggtca gagtccatctgttccctcca
1418539 a at gcctccgtaagacacagagc agtgaccaagagacgcacct
1423946 at gaaggggtgatagcaggtga ccatacgctttcgtgtcaaa
1433855 at gcttgtcagttgtgcaggaa atgctcgctagctgtggttt
1418175 at ctgggaggaaaagacagcag ggtttggactcctcccctac
1418835 at tcatcacagttgcaggaagc ctttttctttttggcgagga
1455099 at gtccctgatgctgcttcttc cattaaggctggggaaactg
1415834 at caccaaaattgtgggttcact cacgaacatcatggagcaag
1417976 at aggggacttgacaatcatgc cgcttctgcaggaaagagac
1451386 at gctgaaatacgtggcagtga ccacctaggtcagggtgcta
1420737 at acccgaggatctgtgtcaag ggggactcaatgtcctctga
1451110 at cattgttggcagaaggtgtg ggggttaacggtcctgattt
1416147 at ttgaatgggacaggatgaga gtagactggccccaggagta
1450459 at tgtaccaggcctgttgattg tgctgcctttccagaacttt
1449275 at ctcccatggtgcagtctgtat ctttggctggggacgtaata
1448623 at gctgctgagaaagccacact ccccaactcagtggaaatgt
1451385 at ttgatgctgcgaagaacaag gccttactcctgggttttcc
Continued on next page
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Affymetrix ID fw Primer rev Primer
1422136 at tgtggccaccctttatttgt agagcatccagtgccagcta
1425140 at acatggtgctggaaaaggag aatagaaacggcccccatag
1416922 a at tgagaagcaggcttcgtttt tgtaaggaatgacgccagtg
1451149 at gcccttgtctccctacatca gcagatgggagatgcaaaat
1448364 at gcacctgtgtgaaagcagaa ccatcaccacacagaattgc
1452444 at ctctgcctcccagttcagtc tgcgggattacaagtgttca
1420760 s at ggaacttgcttccctctcct tgactcccaacgatcaagtg
1418709 at aaaaccgtgtggcagagaag tttgtccaagtcctccaagc
1416686 at tctcaggggaagctcatgtc aggaacaggctcaaaaacca
1451461 a at attgctgtacccgagaccac gagtcagggctggagttcac
1452670 at accctacaaggagggaccac ggtgctgagacaactccaca
1423748 at ggaaaacatgctttgccact taaggatctgggctgaccac
1420664 s at agctcatatgacgccaaaca cccccaagtctatggtctga
1436004 at gatggatggatggatggaac cttcctcaacagggctacca
1436195 at ttatccaccaaccagcacaa tggcctgtaaggctgttctt
1455403 at tgtacctgaagatcattgtgga tgcaattccagctgtgtttc
1433649 at cactcttctcccctgtcaaag agcacacaaagctcaagtgc
1435543 at ccagggtttctttgcagcta cctgggtttacagaagtcacg
1428774 at ctgccagaagagcaaaggag tctcagtgaagtcccaagca
1429146 at tttcctttggccatgtcttt agagagcctttccacagtgc
1441894 s at ctttctgccctcccctaaac tccatcgtggatctcctctc
1440966 at gttggcgttgctttgttttt ggcttattaccgctgcatgt
1437414 at gcaaggtgattgacaccatct aatctgaaaggccccaaaat
1440739 at gggaagaagttccaccatca ccatggtcccacagagtctt
1435822 at tctgccatacaaaggaatgaaa gacccttgttcaaccttttcc
1438310 at tttgccattgaaatggacct cattaacaaagccacccaaa
1434338 at atttggatcgtggcagtagc acagccctatcagccttcct
1434969 at cgcaccgtctagttcatgttt gatttgccgttgagaagctc
1446550 at ggcactaaagcgacctgaag cacgccattcagaaaaagtct
1458232 at tggttggtgcttttgcctat aatcacttgcttgggcattc
1437862 at aacctggagggcagaagagt cgagtggcaagctactgact
1436907 at cagagctgggtgttccaact gaggcagttggaatggaaga
1435033 at ccccagtgcacttgtaacct cccagctacagggaactgtc
1456930 at tctgtgtcgatgtgggatgt ttcaatgttgcctgaagcag
1432205 a at ctcctctggaccctcctctc taccaggatggtcttgcaca
1455210 at gctgaaatcttgccaaaagc cctcagctggcttctcaact
1428517 at ttggcttcattgctcatctg tcacacttgcacgctacaca
1456661 at acagcctgcatgaatcagtt ggaagaatttgccacatggt
1428767 at tgtctggtgcttgactctgg ggattcttttcatcccagca
1453465 x at gacaaggccaggtgtgtttt ggaaagcacaggtttattcca
1435483 x at ttgaaatttggggacaatgaa acctgggagatctgaattgc
1419985 s at cccaatcccagatcatcagt ggctagatgtggtgggacat
1435109 at gtttgctgctttgacccatc accttgcagaagccactctc
1432638 at tgggaacctgtctgagatcc gtccgacttcatgtccaggt
1434099 at ccctttttgatggctgtacg ctcactttccctcttcagca
1424698 s at aaacagaagccacaccatga atgcaccgttgtttgaactg
1426155 a at ggcagaacttctagcgaagc ggtttggaagggggtagtgt
1426092 a at ctggaccctgggagtttaca ctgtgccctcttcacagtca
1452565 x at tctgctgcaaacttggcata tgaaggacaaagtcggtgtg
1419093 at cagccgagtacagtgacagc cctcctaatcgctcaccatc
1438083 at gagtgaccagggcaggtatc tgccaacatacatgctgagag
1417835 at agtgtgtcaggggaaggatg cagcaatcaccatgttggag
1438642 at ttgagttttgcctcaacacg gggatgtgaggtatggatgg
1427026 at gagctgaagaaggagcagga gcttacgaagacccttgacg
1458173 at ctacgtgattctccaggaactt cccaggattttccattcaag
1459882 at accccatatcctctggctct ctcctgtgcatcatcaccat
1438858 x at gggcaccatcttcatcattc acagcctcagggtcaagaga
1457004 at tccgatacccagcctacttg atggaaaacgcaaacgagtc
1442146 at agggcaggaggatcagaaat gtgtgtgtgcttgtgtgtgc
1447139 at cgtgtctccctgtgatgtgt cgcagacgtgacttgtccta
1423603 at agcagcctgtccacttcat aagtgtcaagggtcctggtg
1421924 at cctctgctaggtggagcttg acctcacacctttccattgc
1416516 at cctgccctgttggttgta aggtgtctggagacgtggag
1419157 at agcattggcatggagaaact gctactcccagcacatctcc
1430584 s at atgtgaaaaggcagggtcac cccatgaatgcttcaattcc
1456658 at tgatcaccattggaaacgaa cttctgcatcctgtcagcaa
1416239 at tcgcagaggctcgtatacac ctcatagtcgccctgcacgt
1424492 at tgggcaacagactgacagag ccatcaaggccatctcctaa
1417580 s at agcactggctcacgagcttc cagagatgctgctctacaga
1423281 at gaaccttccaacgtgctgat taatgcagcaaccagctcac
1420376 a at tgaagaagcctcaccgctac ggcgtggatggcacacagat
1417365 a at caacgaagtggatgctgatg tccgtcgccatcaatatctg
1418626 a at gtgaagctgtttgactctga acactcctacatataggaag
1460214 at tgatatcgacatggatgcac tattgagtgaggatgacttc
1416196 at ctgctgctgagaaggctgtg agctgctgaccaatcctcag
Quantitative real time PCR analysis (Applied Biosystems Sequence Detection System
9330, Rotkreuz, Switzerland) using SYBR Green (Qiagen) was performed according
to manufacturer’s instructions. Briefly, reactions consisted of 10µL of cDNA diluted
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1:100 out of the primary RT-reaction, 0.5µM forward and reverse primer, 12.5µL of
Sybr Green master mix and 2.25µL water. Default PCR conditions of 40 cycles of 15’
seconds annealing at 60◦C and 1 min denaturing at 95◦C were utilized. All primers
were assessed for efficiency using SybrGreen conditions prior to being utilized in qPCR
studies. Gene expression levels were assessed in four biological replicate samples (and 4
technical replicates of each) from each group using the ∆∆CT method and normalization
to Gapdh. Standard deviations were calculated in between the biological replicates of
mock and RML infected cells.
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8.1. In vitro cell culture models of prion infection
In view of the potential impact of the choice of the cell culture model onto the tran-
scriptional response to prion infection, we opted to compare results obtained in three
distinct cell lines. We used N2aPK1, CAD, and GT1 cells, which are all murine and of
neuronal origin. Each of these cell lines can be infected to high rates with the mouse-
adapted scrapie prion strain RML [17]; [96]; [104]; [61];(Mahal, pers. communication).
GT1 cells have been reported to exhibit mild apoptosis and vacuolarization resembling
the pathology in brains of prion infected animals [104]. Instead, prion infection seems
to have no impact on cell viability or morphology in N2a or CAD cells (Mahal, pers.
communication), although N2a cell subclones have been reported to be more sensitive to
caspase-3 /-8 mediated apoptosis [63]. The following measures were taken to avoid the
detection of potential clonal or stochastic artifacts. Firstly, prior to prion infection we
split the respective parental cell line (N2aPK1, CAD, GT1) into eight batches. Four of
these individual batches were infected with RML scrapie prions, and four were exposed
to m¨ock(¨uninfected) brain homogenate. Secondly, we strived to minimize the period
between establishment of prion infection (or mock infection) of cells and harvesting, since
long periods of serial passaging could result in clonal segregation. We opted to use the
cells at the earliest time point at which no residual inoculum is detected, but at which
the cells show a high degree of infection as measured by Western blot for PrPSc (Figure
1a-c) and infection ratio as measured by ELISPOT assay (Figure 1d-f) [61]. After eight
passages we determined that all cell cultures inoculated with RML showed proteinase K
(PK) resistant PrP, whereas this was consistently absent in mock infected control cells
(N2aPK1mock, CADmock and GT1mock). In addition, we determined the prevalence of
infection within the cell cultures that were studied. We reasoned that the infection rate
of the cell cultures would directly impact the sensitivity with which any transcriptional
changes would be detected. Whereas the four investigated Scrapie infected N2aPK1
cultures (N2aPK1RML) showed infection ratios of 65-81% (Figure 1d), the GT1RML and
CADRML cultures showed ratios close to 100% (Figure 1e-f). Numeric values over 100%
represent statistical artifacts: originating from variations in the number of cells seeded in
each well. In summary we generated three murine neuronal cell culture models validated
for prion infection for a comparison of gene expression with mock infected control cells.
Each measurement, therefore, consisted of four true biological replicates for the infected
or mock-infected groups, rather than ’´technical´’ replicates that would result from the
splitting of parental infected or mock infected parental lines at the time of harvesting.
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Figure 8.1.: Immunoblot analysis and quantitative infectivity assessment by
ELISPOT assay
a) Western blot analysis for PrPC and PrPSc of monoclonal anti-PrP (POM1)
probed protein homogenate of four mock infected and four RML infected
biological replicates of N2aPK1 cells are depicted with the respective controls.
Proteinase K (PK) digestion visualizes protease resistant and consecutively
shifted PrPSc. 70 mg of protein were loaded for PK+, 35 mg of protein for
PK- samples.
b) and c) shows equivalent data from mock versus RML infected CAD and
GT1 cells respectively.
d-e) The ratio of infected cells per biological replicate as assessed by ELISPOT
assay. Data are presented as arithmetic means +/- standard deviation.
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8.2. Transcriptional analysis of prion infected N2aPK1 (N2aPK1RML)
versus control mock infected N2aPK1 (N2aPK1mock) cells
For the identification of differentially expressed genes as a response to prion infection, we
compared the expression profiles of N2aPK1mock vs. N2aPK1RML cells. We utilized
the two algorithms, GCRMA and MAS5.0, applying a fold change filter of 2.0 with
an equal-variance t-test significance threshold of p<0.05. Since this did not result in
significant differentially expressed genes, we relaxed the fold change filter conditions and
identified a core set of 84 candidates to be differentially expressed more than 1.5 fold in
at least one of the two algorithms. Although formally significant, a level of differential
expression between 1.5 and 2.2 for 62 out of the 84 candidate genes is indicative of
potentially false positives. 22 candidate genes showed differential expression higher than
2.2 fold in at least one of the two algorithms applied. The strongest downregulation of
gene expression was observed for Gca (grancalcin; 12.7 fold) whereas Asf1 (anti-silencing
function 1 homolog A) was the gene with the strongest upregulation (10.6 fold) as a
response to prion infection (Table 1).
Table 8.1.: Candidate genes found in GCRMA and MAS5 algorithms based on
RNA microarray chip analysis. M = Mock, R=RML.
Affymetrix ID Gene name M/R
GCRMA
Stdev M/R
MAS5
Stdev Gene Id Cand.
iden-
tified
(X)
1415834 at dual specificity phosphatase 6 1.601 0.212 1.737 0.47 X
1416147 at heat shock protein 4 0.665 0.197 0.796 0.291 X
1416196 at laminin receptor 0.983 0.533 1.414 2.586 lamR
1416239 at Argininosuccinate synthetase 1 1.204 0.236 1.402 0.345 ass1
1416516 at Fascin homolog 1 0.656 0.674 0.666 0.656 fscn1 X
1416686 at procollagen lysine, 2-
oxoglutarate 5-dioxygenase
2
0.539 0.207 0.683 0.285 plod1 X
1416759 at NEDD9 interacting protein
with calponin homology and
LIM domains
2.052 0.461 1.431 0.308 X
1416922 a at BCL2/adenovirus E1B 19kDa-
interacting protein 3-like
0.621 0.214 0.671 0.301 X
1417365 a at calmodulin 1 0.989 0.199 1.171 0.28 calm1
1417580 s at Selenium-binding protein 2 0.824 0.497 0.816 0.347 selenbp2
1417835 at murinoglobulin 1 0.987 0.794 7.85 13.518 X
1417976 at adenosine deaminase 1.585 0.267 1.439 0.346 ada X
1418175 at vitamin D receptor 1.634 0.233 1.713 0.388 X
1418539 a at protein tyrosine phosphatase,
receptor type, E
1.86 0.375 1.411 0.337 X
1418626 a at clusterin 1.237 0.229 1.47 0.393 clu
1418709 at cytochrome c oxidase, subunit
VIIa 1
0.543 0.228 0.556 0.29 cox7a X
1418835 at pleckstrin homology-like do-
main, family A, member 1
1.626 0.214 1.735 0.313 X
1419093 at tryptophan 2,3-dioxygenase 0.969 1.463 0.15 0.822 X
1419157 at SRY box containing 4 0.662 0.707 0.645 0.666 sox4 X
1419985 s at DNA segment, Chr 11, ERATO
Doi 461, expressed
1.884 0.383 0.373 0.183 X
1420376 a at histone family 3 B 0.897 0.189 0.906 0.285 hf3B
1420664 s at protein C receptor, endothelial 1.654 0.228 2.178 0.504 X
1420737 at polyamine modulated factor 1
binding protein 1
1.501 0.221 1.291 0.308 X
1420760 s at N-myc downstream regulated 1 0.553 0.208 0.637 0.293 ndrg1 X
1421924 at Solute carrier family 2 0.479 0.526 0.506 0.522 slc2a2 X
1422136 at kinase interacting with
leukemia-associated gene
(stathmin)
0.642 0.216 0.818 0.295 X
1423281 at Stathmin-like 2 1.054 0.202 1.249 0.342 stmn2
1423603 at Zinc finger protein, multitype 1 0.969 0.852 0.941 0.777 zfpm1 X
1423748 at RIKEN cDNA D530020C15
gene
0.472 0.263 0.481 0.301 X
1423946 at PDZ and LIM domain 2 1.714 0.299 1.379 0.294 X
Continued on next page
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Affymetrix ID Gene name M/R
GCRMA
Stdev M/R
MAS5
Stdev Gene Id Cand.
iden-
tified
(X)
1424492 at Transient receptor potential
cation channel,subfamily C,
member 2
1.074 0.191 1.139 0.297 trpc2
1424698 s at grancalcin 0.964 0.639 0.079 1.693 X
1425140 at lactamase, beta 2 0.632 0.19 0.778 0.287 X
1426092 a at tripartite motif protein 34 0.964 0.622 0.098 1.386 X
1426155 a at odd-skipped related 2
(Drosophila)
0.96 0.893 0.125 1.21 X
1427026 at myosin, heavy polypeptide 4,
skeletal muscle
0.953 0.624 7.06 12.24 X
1428517 at WD repeat and FYVE domain
containing 3
1.503 0.215 0.668 0.107 X
1428767 at RIKEN cDNA 1810036L03
gene
1.327 0.209 0.544 0.069 X
1428774 at 12 days embryo male wolf-
fian duct includes surround-
ing region cDNA, RIKEN
full-length enriched library,
clone:6720429C22 prod-
uct:unknown EST, full insert
sequence
1.786 0.443 0.882 0.061 X
1429146 at Adult male testis cDNA,
RIKEN full-length enriched
library, clone:4931406B08
product:unknown EST, full
insert sequence
1.72 0.333 0.682 0.278 X
1430584 s at Carbonic anhydrase 3 0.96 0.276 0.499 0.572 car3 X
1432205 a at RIKEN cDNA C130038G02
gene
1.526 0.299 0.75 0.235 X
1432638 at RIKEN cDNA 2810002N01
gene
0.981 3.143 0.241 0.291 X
1433649 at amine oxidase, flavin contain-
ing 1
1.8 0.296 0.709 0.248 X
1433855 at Transcribed sequence with
strong similarity to protein
ref:NP 065580.1 (M.musculus)
hypothetical protein, I54 (Mus
musculus)
1.642 0.276 2.949 1.238 X
1434099 at RIKEN cDNA A830037N07
gene
0.951 0.451 0.111 3.238 X
1434338 at 18-day embryo whole
body cDNA, RIKEN full-
length enriched library,
clone:1110029E03 prod-
uct:unknown EST, full insert
sequence
1.612 0.284 0.776 0.151 X
1434969 at CDNA clone IMAGE:5683160,
partial cds
1.6 0.246 0.653 0.191 RcDNA X
1435033 at RIKEN cDNA 9330140K16
gene
1.54 0.288 0.906 0.185 X
1435109 at RIKEN cDNA 3010001K23
gene
1.253 0.287 0.188 0.301 X
1435483 x at mitochondrial folate trans-
porter/carrier
1.756 0.352 0.53 0.134 X
1435543 at adenomatosis polyposis coli 1.767 0.34 0.799 0.068 apc X
1435822 at 16 days neonate heart cDNA,
RIKEN full-length enriched li-
brary, clone:D830012I24 prod-
uct:unknown EST, full insert
sequence
1.642 0.327 0.584 0.187 X
1436004 at ubiquitin specific protease 27,
X chromosome
2.219 0.513 0.791 0.107 X
1436195 at cDNA sequence BC046404 1.979 0.44 0.75 0.132 X
1436448 a at prostaglandin-endoperoxide
synthase 1
2.003 0.337 2.386 0.693 ptgs1 X
1436907 at neuron navigator 1 1.558 0.226 0.707 0.149 nav1 X
1437414 at RIKEN cDNA 4933431C08
gene
1.692 0.286 0.63 0.231 X
1437862 at RIKEN cDNA 2610015J01 gene 1.555 0.333 0.827 0.121 X
1438083 at Hedgehog-interacting protein 0.995 0.543 7.458 18.137 X
1438310 at 10 days neonate cerebel-
lum cDNA, RIKEN full-
length enriched library,
clone:B930095L19 prod-
uct:unknown EST, full insert
sequence
1.651 0.356 0.776 0.18 X
Continued on next page
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Affymetrix ID Gene name M/R
GCRMA
Stdev M/R
MAS5
Stdev Gene Id Cand.
iden-
tified
(X)
1438642 at AV278176 RIKEN full-length
enriched, adult male testis
(DH10B) Mus musculus cDNA
clone 4933400E08 3’, mRNA se-
quence.
1.031 0.31 6.987 24.796 X
1438858 x at histocompatibility 2, class II
antigen A, alpha
0.94 0.477 5.011 1.945 X
1440739 at vascular endothelial growth fac-
tor C
1.688 0.334 0.592 0.212 X
1440966 at axotrophin 1.689 0.416 0.653 0.085 axot X
1441894 s at BB071890 RIKEN full-length
enriched, 15 days embryo male
testis Mus musculus cDNA
clone 8030499N14 3’ similar
to AF236099 Mus musculus
GRP1-associated scaffold pro-
tein GRASP mRNA, mRNA se-
quence.
1.694 0.346 0.829 0.197 X
1442146 at H3079F10-3 NIA Mouse 15K
cDNA Clone Set Mus muscu-
lus cDNA clone H3079F10 3’,
mRNA sequence.
1.029 0.32 4.126 1.004 cDNAc X
1446550 at G1 to phase transition 1 1.601 0.254 0.888 0.33 X
1447139 at B-cell CLL/lymphoma 7C 1.195 0.286 0.232 0.126 X
1448364 at cyclin G2 0.592 0.243 0.762 0.324 ccng2 X
1448623 at RIKEN cDNA 2310075C12
gene
0.65 0.185 0.743 0.309 X
1449275 at RIKEN cDNA 2310038H17
gene
0.649 0.228 0.77 0.278 X
1450459 at RIKEN cDNA 2010106G01
gene
0.658 0.219 0.869 0.292 X
1451110 at EGL nine homolog 1 (C. ele-
gans)
0.662 0.224 0.614 0.309 X
1451149 at phosphoglucomutase 2 0.6 0.204 0.714 0.314 X
1451385 at RIKEN cDNA 2310056P07
gene
0.649 0.193 0.74 0.296 X
1451386 at biliverdin reductase B (flavin
reductase (NADPH))
1.549 0.206 1.75 0.416 X
1451461 a at aldolase 3, C isoform 0.527 0.246 0.625 0.349 X
1452444 at N-ethylmaleimide sensitive fu-
sion protein attachment pro-
tein beta
0.583 0.225 0.696 0.287 X
1452565 x at envelope polyprotein; Mouse
endogenous mammary tumor
virus (MMTV) RNA, env gene
and right LTR.
0.953 0.997 0.116 1.103 X
1452670 at myosin, light polypeptide 9,
regulatory
0.403 0.266 0.494 0.304 X
1453465 x at RIKEN cDNA 4930402H24
gene
1.528 0.273 0.415 0.306 X
1455099 at BB414982 RIKEN full-length
enriched, 7 days embryo
Mus musculus cDNA clone
C430040E04 3’, mRNA se-
quence.
1.624 0.214 1.101 0.297 X
1455210 at zinc fingers and homeoboxes
protein 2
1.499 0.268 0.885 0.136 X
1455403 at RIKEN cDNA 4932703L02
gene
1.841 0.386 0.658 0.175 X
1456658 at Actin, alpha 2, smooth muscle,
aorta,
0.957 1.289 1.192 0.649 acta2 X
1456661 at Transcribed sequence with
moderate similarity to protein
pdb:1JZ5 (E. coli) B Chain B,
E. Coli
1.836 0.303 0.515 0.262 X
1456930 at hypothetical protein
9530003A05
1.521 0.239 0.703 0.073 X
1457004 at BB698378 RIKEN full-length
enriched, 2 days neonate sym-
pathetic ganglion Mus muscu-
lus cDNA clone 7120499J15 3’,
mRNA sequence.
0.937 0.325 4.632 0.298 X
1458173 at Transcribed sequence with
moderate similarity to pro-
tein pir:S12207 (M.musculus)
S12207 hypothetical protein
1.011 0.876 8.674 28.737 X
1458232 at dickkopf homolog 1 (Xenopus
laevis)
1.558 0.243 0.581 0.209 X
Continued on next page
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Affymetrix ID Gene name M/R
GCRMA
Stdev M/R
MAS5
Stdev Gene Id Cand.
iden-
tified
(X)
1459882 at ASF1 anti-silencing function 1
homolog A (S. cerevisiae)
1.069 0.323 10.582 14.669 asf1 X
1460214 at Purkinje cell protein 4 0.991 0.206 1.074 0.4 pcp4
19 candidate genes including Gca and Asf1 out of these 22 were not differentially
regulated in the other algorithm. Therefore in a first instance to allow assessment
of all 84 candidates we pooled cDNA from four independent biological replicates of
N2aPK1mock and N2aPK1RML cells. This pooled cDNA was used to assess gene
expression levels by quantitative real time PCR (qPCR) using technical triplicates. 70
of these candidate genes showed no differential expression between N2aPK1mock and
N2aPK1RML. A total of 14 candidates showed statistically significant, but less than 5
fold up- or downregulation in the prescreen qPCR analysis. The expression ratios for
these as determined by the MAS5.0 and GCRMA algorithms are shown in Figures 2a and
2b respectively. The expression levels of these 14 transcripts in N2aPK1RML cells were
analyzed by qPCR, utilizing cDNAs synthesized from RNA obtained from quadruplicate
independent biological replicates and three technical replicates of each were analyzed
(Figure 2c). Of these 14 candidates, we were only able to confirm statistically significant
(p<0.0005) downregulation of the Nav1 transcript of less than 1.8 fold in response to
prion infection in N2aPK1 cells. We were not able to confirm differential expression
of any of the remainder of the potential candidate genes identified in our high-density
oligonucleotide microarrays of N2aPK1mock compared to N2aPK1RML cells.
8.3. Analyses of candidate gene expression in prion infected CAD
(CADRML) cells.
The expression levels of the 14 candidate genes were also assessed in the CAD cell
culture model of prion infection. Again, we could not detect differentially expressed
genes as a response to prion infection (Figure 2d). In particular, we could not observe
downregulation of Nav1 in the CADRML cells. Whilst this may certainly be of biological
significance relevant to N2aPK1 cells, differential expression of this gene is not a feature
common to prion infected neuronal cells in vitro.
8.4. qPCR analyses of candidate differentially expressed genes in
N2aPK1RML and GT1RML cell culture models reported by others.
Statistically significant and profound differential expression of several candidate genes
has been recently reported [42] as a direct result of prion infection in N2aPK1 and
GT1 cell culture models. The expression ratios for nine of those which showed highest
levels of differential expression from that study were chosen for validation in our models.
This is in stark contrast to the expression ratios determined by MAS5.0 and GCRMA
algorithms in our transcriptional profiling analyses of N2aPK1RML and N2aPK1mock
cells (Fig. 3a-b). In the latter study, the genes encoding Selenium binding protein 2
94
8.4. qPCR analysis results reported by others
Figure 8.2.: Gene expression analysis of mock versus RML infected N2aPK1
cells.
a) High-density oligonucleotide chip analysis of mock (white bars) vs. RML
(black bars) infected N2aPK1 cells as analyzed with MAS5.0 or GCRMA data
analysis algorithm. Candidate transcripts originating from one of the two
analysis algorithms were later subjected to quantitative real time PCR-analysis
(qPCR; see also table 1).
b) Verification of microarray data with qPCR in mock (white bars) versus RML
(black bars) infected N2aPK1 cells and expression analysis of candidate genes
in mock versus RML infected CAD cells normalized to Gapdh. The qPCR-
analysis was performed in four biological replicates of each mock and RML
infected cell line and three technical replicates per biological replicate. The
average of four mock biological replicates was set as one. Data are presented
as arithmetic means +/- standard deviation.
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(Selenbp2), Argininosuccinate synthetase 1 (Ass1) and Clusterin (Clu) were reported to
be profoundly over-expressed in prion infected cell lines; in the case of Ass1 up to 40-fold
in N2aPK1RML and GT1RML cells, whereas Histone family 3b (Hf3b), Calmodulin 1
(Calm1 ) and Purkinje cell protein 4 (Pcp4 ) were reported to be downregulated as a
response to prion infection (2-fold, 2-fold, and 5-fold respectively). However, in our own
analyses of prion infected neuronal cells, we were unable to validate these findings, neither
in the MAS5.0 or GCRMA interrogated microarray data (Figure 3a & b) or by qPCR
analyses of our own prion infected N2aPK1RML or GT1RML cell culture models (Figure
3 c & d respectively). Whilst our qPCR studies were performed using Gapdh as the
housekeeping gene for normalization of expression levels, Greenwood et al. used Polr2a
(RNA Polymerase II) and Tbp (TATA box binding protein) for normalization. Whilst
unlikely to account for the discrepancies between these studies, to formally exclude this
possibility we investigated the expression levels of Polr2a and Tbp relative to Gapdh in
mock and prion infected N2aPK1, CAD and GT1 cell culture models (Suppl. Fig. 1). As
expected, the expression levels of these relative to Gapdh are not altered in prion infected
cells, thereby confirming that using these genes as normalization controls in our study
would not alter the conclusions from our data.
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Figure 8.3.: qPCR analysis reported by others
a) High-density oligonucleotide chip analysis of mock (white bars) vs. RML
(black bars) infected N2aPK1 cells as analyzed with MAS5.0 or GCRMA data
analysis algorithm.
b) Results of qPCR analysis of mock (white bars) versus RML (black bars)
infected N2aPK1 or GT1 cells. Relative gene expression levels of published
transcripts in N2aPK1 and N2aPK1RML or GT1 compared to GT1RML cells
normalized to Gapdh. Analysis was performed in four biological replicates
of each mock and RML infected cell line and three technical replicates per
biological replicate. The average of four mock biological replicates was set as
one. Data are presented as arithmetic means and standard deviations.
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Figure 8.4.: House keeping genes to control for relative cDNA abundance
a-c) expression analysis of housekeeping genes in mock (white bars) versus
RML (black bars) infected cells.
The graph shows relative gene expression normalized to Gapdh for a) N2aPK1
cells, b) CAD cells and c) GT1 cells. Analysis was performed in four biological
replicates of each mock and RML infected cell line and three technical replicates
per biological replicate. The average of four mock biological replicates was
defined as one. Data are presented as arithmetic means and standard deviations.
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Prion infection does not induce general changes in RNA profiles of cells in vitro.
Here we have investigated the impact of prion infection on the transcriptome of chronically
infected N2aPK1RML cells, together with targeted assessment of previously reported
differentially expressed candidate genes in three independent neuronal cell culture systems
infected with the mouse adapted scrapie strain RML. Despite high concentrations of
PrPSc as assessed by Western blot and infection ratios of 65 to nearly 100% as confirmed
by colony spot immunochemistry, we were unable to identify differences in gene expression
between prion and mock infected cells that hold true for the three cell lines investigated and
therefore represent global responses to prion infection. The only modest but statistically
significant changes in expression were identified for the Nav1 transcript in response
to prion infection. The neuron navigator 1 protein is a microtubule-associated protein
involved in neuronal migration. However, we could not observe downregulation of Nav1
in the CADRML cells. Therefore we assume, despite a possible biological significance in
N2aPK1 cells, differential expression of Nav1 is not a feature common to prion infected
neuronal cells in vitro. In particular, our investigations of expression levels of previously
reported candidate genes [42] revealed that none of these were differentially expressed in
any of the cell culture models of in vitro prion infection utilized here. This discrepancy
may result from differences in the experimental design of the various studies.
The impact of the cell culture model in studying the transcriptional response of
cells to prion infection
The previous studies on the impact of prion infection on gene expression levels had
compared subclones or separately passaged prion and uninfected control cells. These
cells have been passaged over long periods or subcloning procedures have been performed
prior to eventual biological comparisons. Immortalized cells can exhibit alterations
in chromosomal composition, leading to profound heterogeneity of gene expression
independently of prion infection, with gross differences in morphology or physiology of
the cells [24]; [42]. Whereas this issue of clonal segregation of cells is discussed extensively
by Doh-ura et al., with reference to the candidate gene subset presented in their study,
subsequent publications describing differences in viability, apoptosis, iron regulation or
gene expression profiling appear to have neglected this alternative explanation for their
findings [104]; [82];[47]; [27]; [28]; [42]. The experiments reported here were designed with
the specific goal of avoiding these potential pitfalls. At the beginning of the experiment
we split the respective parental cell line (N2aPK1, CAD, GT1) into eight batches and
independently infected four of these with RML and four with a mock brain homogenate.
This strategy was devised to generate true biological replicates, rather than mere technical
replicates as would be the case when parental cell lines are passaged and then split into
99
9. Discussion
groups for comparison. Furthermore, we opted to use the cells at the earliest time point
possible, the point at which no residual inoculum is detected, but at which the cells
show a high degree of infection as measured by Western blot for PrPSc and infection
ratio as measured by colony spot immunochemistry [61]. This procedure differs from
prior studies in that of utilizing a more appropriate biological control; mock infection
with healthy brain homogenate rather than uninfected cells, and importantly minimizing
the possible clonal segregation of cells of the same parental origin. Our transcriptional
profiling data contradict the study by Greenwood et al. [42]. Possibly those results
obtained with GT1 and N2a cells may be due to clonal differences. It is striking that
the overlap of differentially expressed genes in GT1 and N2a cells as a response to prion
infection in that study is restricted to three genes (Selenbp2, Tmsb4x, H1F0 ), whereas
the expression level of one (H1F0 ) is altered in an opposite manner. Furthermore, curing
of ScN2a cells by pentosan polysulphate in the Greenwood study did not restore gene
expression levels for all differentially expressed transcripts to the level of uninfected cells,
which is a further hint of these results being due to clonal variations rather than to
prion infection. In conclusion Greenwood et al. describe Selenbp2 as the only “true”
differentially expressed gene in N2a and GT1 cells as a response to prion infection. The
reason why we did not identify this candidate in our array study, or were able to confirm
differential expression by qRT-PCR in three independent cell lines, could be due to
the N2a cells used in the Greenwood study. They overexpress 3F4-tagged murine PrP
in addition to endogenous murine wild type PrP and have been generated by stable
selection using Zeocine. We are not able to assess the impact on these varieties to the
observed differences between our and their studies. What evidence do we have to expect
a transcriptional response to prion infection in cells in vitro? By using this experimental
design we did not find any statistically significant and convincing differentially expressed
gene as a response to prion infection in our microarray approach, using a combination of
statistical procedures. Considering previous similar studies by others this was puzzling
and also counterintuitive. But what reasons do we really have to expect changes in gene
expression provoked by prion infection of neuronal cells? There is no evidence for impaired
viability, morphology or physiology in most neuronal cell lines chronically infected with
prions under “normal” cell culture conditions [103]; [17]. Also, more recent studies show
differences between prion infected and uninfected GT1 cells only after challenge with BOS,
a gamma-glutamylcysteine synthetase inhibitor leading to reactive oxygen species induced
stress [82], Lactacystin [63] or “in many but not all experiments” [104]. Furthermore Hetz
et al., report that Caspase-12 and endoplasmatic reticulum stress mediate neurotoxicity
of pathological prion protein [47]. Here again, no differences in viability between ScN2a
and N2a cells are observed under normal cell culture conditions in the absence of stressor.
In conclusion many studies have shown that prion infected and uninfected cells do not
differ in viability under normal culture conditions. It may be surprising to find no
alterations in the transcriptional expression profile of cells after challenge with prions as a
response to misfolded and aggregated protein in the cell. On the other hand it is very well
possible that cells deal with prion infection by post-transcriptional or post-translational
mechanisms which do not lead to differences in gene expression profiles. Similar studies
in yeast also revealed no transcriptional changes after prion infection [102]. Lastly, it
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is conceivable that prion infection in cells in vitro has an entirely benign effect. In
conclusion, we propose that prion infection does not alter the mRNA profile of neuronal
cells in vitro. We conclude therefore that prion agents in cultured neuronal cells infected
at high rates do not induce general or specific changes in the transcriptome. Taking
into account that prions represent a unique form of transmissible pathogen that seems
to consist of endogenous host protein only, it is conceivable that none of the cellular
responses found in virus or bacteria infected cells can be observed in prion infected cells.
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C. Abbreviations
AA amino acid
bp base pair
BM bone marrow
BSA bovine serum albumin
CD cluster of differentation (for surface antigens)
cDNA complementary DNA
CJD Creutzfeldt-Jakob disease
CNS central nervous system
CSF cerebrospinal fluid
CT threshold cycle
Ctrl control
CWD chronic wasting disease
DC dendritic cell
DNA deoxyribonucleic acid
dpi days post inoculation
ECL enhanced chemiluminescence
EDTA ethylendiamintetraacetic acid
FDC follicular dendritic cell
FFI fatal familial insomnia
GALT gut associated lymphoid tissue
GAPDH glyceralaldehyde 3-phospate deghydogenase
GFAP glial acidic fibrilarry protein
GPI glycosylphosphatidylinositol
GSS Gerstmann-Stra¨ussler-Scheinker syndrome
H&E hematoxylin and eosin
HRP horseradish peroxidase
IHC immunohistochemistry
IL interleukin
Il2rg gene ID for “interleukin receptor 2, common gamma chain” (γc)
ip intraperitoneal
kD kilo dalton
LRS lymphoreticular system
M molar
Mb megabases
MRI magnetic resonance imaging
mRNA messenger RNA
NK cell natural killer cell
ORF open reading frame
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PAGE polyacrylamid gel electrophoresis
PBS phosphate-buffered saline
PCR polymerase chain reaction
PK proteinase K
Prnp gene ID for the “mouse prion protein”
PRNP gene ID for the “human prion protein”
PrPC the cellular prion protein (normal isoform)
PrPSc the pathological prion protein (Sc = Scrapie)
Rag gene ID for “recombination activating gene”
RML Rocky mountain laboratory (prion strain)
RNA ribonucleic acid
RT room temperature
RT-PCR reverse transcription PCR
SAF84 antibody used to visualize PrPSc in IHC
SCA scrapie cell assay
sCJD sporadic CJD
SDS sodium dodecyl sulfate
Sirpa gene ID for “signal regulatory protein alpha”
SNP single nucleotide polymorphism
STR short tandem repeat (repetitive non coding DNA)
TSE transmissible spongiform encephalopathies
TF target fraction
NTF nontarget fraction
U unit
vCJD variant CJD
wt wild-type
w/v weight/volume
- negative for
+ positive for
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